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The 2017 Diabetes Poland guidelines  
— remaining on the path of progress
Since 2005, the Diabetes Poland (PTD, Polskie Towarzystwo Diabetologiczne) prepares and publishes annually 
its guidelines on the management of diabetic patients. The idea of guideline development was first suggested in 
2004 by Prof. Jacek Sieradzki who was the president of PTD at that time. The first chairperson of the PTD Guideline 
Writing Group was Prof. Władysław Grzeszczak who acted in this capacity in 2005–2011, followed by the next 
president of PTD, Prof. Leszek Czupryniak, in 2011–2015. 
The guidelines are a product of a team of nearly 50 experts representing numerous medical specialties, co-
vering all aspects of clinical diabetes care. Guideline chapters were prepared by teams coordinated by their leaders.
The goal of this expert teamwork is to improve prevention, diagnosis, and management of diabetes and its 
complications in Poland. The PTD guidelines reflect advances in diabetology, including new clinical and experimen-
tal study findings, epidemiological observations, and registry data. Thus, some modifications and novel aspects 
appear every year. However, as the guidelines have always been based on the principles of evidence-based medi-
cine, only minor changes are required, related to new knowledge from reliable research with major implications 
for clinical practice.
In line with the principles of evidence-based medicine, levels of evidence underlying the recommendations 
have been introduced in some chapters of the 2017 PTD guidelines, similarly to the American Diabetes Association 
(ADA) guidelines.
Summary of the most important changes to the 2017 PTD guidelines
In Chapter 1, the contents has been rearranged and the approach to the diagnosis of hyperglycemia has 
been simplified. If no symptoms of hyperglycemia are present and random venous blood glucose is ≥ 200 mg/dL 
(11.1 mmol/L), fasting venous blood glucose ≥ 126 mg/dL (≥ 7.0 mmol/L) on one and not two occasions is now 
sufficient for the diagnosis of diabetes.
In Chapter 3 on glycemia monitoring, new information has been added regarding flash glucose monito ring (FGM).
In Chapter 4 on the treatment goals, the target HbA1c level in women with prepregnancy diabetes contempla-
ting pregnancy has been set more liberally at < 6.5% (48 mmol/mol), in accordance with the opinion of other 
diabetes societies (ADA, National Institute for Health and Care Excellence — NICE), while HbA1c level < 6.0% 
(42 mmol/mol) remains the goal in the second and third trimester, if it is not associated with an increased rate of 
hypoglycemia. Recommendation on target lipid levels have been expanded based on the available evidence. The 
treatment goal in diabetic subjects at very high cardiovascular risk is low-density lipoprotein cholesterol (LDL-C) 
level < 70 mg/dL (1.9 mmol/L) or reduction by at least 50% if baseline LDL-C level is 70–135 mg/dL (1.9–3.5 
mmol/L), and LDL-C level < 100 mg/dL (2.6 mmol/L) or reduction by at least 50% if baseline LDL-C level is 100–200 
mg/dL (2.6–5.2 mmol/L) in diabetic subjects at high cardiovascular risk. In subjects at low or moderate cardiova-
scular risk, defined as subjects < 40 years of age with diabetes type 1 but without chronic complications and other 
cardiovascular risk factors), the goal LDL-C level is < 115 mg/dL (3.0 mmol/L). A secondary goal for lipid-lowering 
treatment is non-high-density lipoprotein cholesterol (non-HDL-C) level, also set in relation to the overall cardio-
vascular risk at < 100 mg/dL (2.6 mmol/L) in diabetic subjects at very high cardiovascular risk, < 130 mg/dL 
(3.4 mmol/L) in sub jects at high cardiovascular risk, and at < 145 mg/dL (3.7 mmol/L) in subjects at low to mode-
rate cardiovascular risk.
In Chapter 5 on the organization of care for patients with diabetes, recommendations have been added 
regarding care for patients with diabetic foot syndrome. This care should be provided by referral diabetes foot 
clinics (one per voivodship) and basic care clinics (the number depending on the population of given voivodship) 
that cooperate with referral clinics. Personnel requirements were set, as were the principles of multispecialty care, 
equipment requirements, access to laboratory and microbiological testing, and opportunities for hospital care.
In Chapter 6, multiple small editorial changes have been made, and the nomenclature has been improved. 
The need for individualized nutrition care has been highlighted. Recommendations regarding carbohydrate and 
protein intake have been clarified. Carbohydrates should provide about 45% of the total calorie intake; and if they 
are consumed in the form of low glycemic index and high fiber content products, their share in the total calorie 
intake may be even higher (up to 60%). High caloric intake from carbohydrates should also be a feature of the 
diet in subjects who are very active physically. In contrast, a lower carbohydrate share in the total calorie intake 
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(25–45%) may be temporarily recommended in patients with little physical activity if it cannot be significantly 
increased, e.g., due to concomitant conditions. In most diabetic patients, proteins should provide 15–20% of 
the total calorie intake (about 1–1.5 g/kg body weight/day). In patients with diabetes type 2 and excessive body 
weight, a low-calorie diet may contain 20–30% of protein. In patients with chronic kidney disease, protein intake 
should be about 0.8–1 g/kg body weight/day. Salt intake from all sources should not exceed 5 g per day.
In Chapter 8, recommendations regarding education have been updated, reflecting, among others, the techno-
logical progress in blood glucose monitoring.
In Chapter 9 on the management of diabetes type 1, use of insulin analogs for insulin therapy has been pre-
ferred based on the robust available evidence.
In Chapter 10, data from large randomized clinical trials have been included that indicate a reduction of total 
and cardiovascular mortality with the use of GLP-1 agonists and SGLT-2 inhibitors. The algorithm for drug treat-
ment of diabetes type 2 has also been modified, with expanded options of insulin therapy intensification.
In Chapter 11, recommendations on initiating insulin therapy regardless of blood glucose levels have been 
clarified, which apply to all autoimmune-mediated diabetes types regardless of age and not only LADA, and not 
all but only warranted patient wishes. When glycemic control is reevaluated, insulin doses should be gradually 
increased by 2–4 units and not 4–8 units as recommended previously. In patients treated with single basal insulin 
injection, intensification of insulin therapy has been recommended when the basal insulin dose exceeds 30 units 
per day (10 units less compared to the previously recommended threshold). The recommended approaches to 
treatment intensification include adding rapid-acting insulin before meals, with possible stepwise intensification 
using the basal-plus approach, or alternatively initiation of mixed insulin therapy. A recommendation has been 
delated regarding insulin therapy using three or more insulin injections per day if the daily insulin requirement 
exceeds 80 units.
In Chapter 13 on the approach to treatment of dyslipidemia in 2016, the target LDL-C level < 70 mg/dL has 
been set for all patients with diabetes type 2. The target LDL-C level < 100 mg/dL has been only left in young pa-
tients with diabetes type 1 without other cardiovascular risk factors. New clinical trial results and metaanalyses of 
these studies have resulted in updated European Society of Cardiology (ESC) recommendations on the treatment 
of dyslipidemia that have also been adopted by PTD. With the perceived need for more treatment individualization 
in diabetic patients, target LDL-C and non-HDL-C levels set in the 2017 PTD guidelines vary, primarily in relation 
to the 10-year cardiovascular mortality risk. This risk is defined as very high in diabetes with concomitant cardio-
vascular disease (previous myocardial infarction, acute coronary syndrome, coronary revascularization or other 
revascularization procedures, stroke, transient ischemic attack, aortic aneurysm, and peripheral arterial disease) or 
other cardiovascular risk factors, i.e. albuminuria, hypertension, hypercholesterolemia, smoking, or a family history 
of cardiovascular disease. Patients without chronic diabetes complications and other cardiovascular risk factors are 
at high cardiovascular risk. Only in young patients with diabetes type 1 without chronic diabetes complications 
and other cardiovascular risk factors, the risk is moderate or low. Depending on the risk category, target LDL-C 
and non-HDL-C levels in the very high, high, and moderate to low risk groups are < 70 mg/dL and < 100 mg/dL, 
< 100 mg/dL and < 130 mg/dL, and < 115 mg/dL and < 145 mg/dL, respectively. In this way, we hope to increase 
implementation of these guidelines in the clinical practice.
In Chapter 14, it has been highlighted in the section on the management of a prolonged hypoglycemic episode 
that this situation may occur with all diabetes types and not only in diabetes type 2.
In Chapter 15, data have been updated on the mortality due to diabetic ketoacidosis which is now estimated 
at 0.2–2%, and not 5% as indicated previously, and depends on such factors as the expertise of the treating team. 
Recurrent episodes of diabetic ketoacidosis are associated with a much higher mortality risk. Regarding the diag-
nosis of diabetic ketoacidosis, a comment has been added that in patients treated with SGLT-2 inhibitors, blood 
glucose values may be lower than the definition given (> 250 mg/dL). As commercial hypotonic 0.45% saline 
solution is now available, it has again been recommended in the treatment of hyperglycemic-hyperosmolar state.
In Chapter 21 on the organization of care for patients with diabetes foot syndrome, the organizational struc-
ture of referral diabetes foot clinics (previously regional multi-specialty diabetes foot clinics) and basic care clinics 
(previously diabetes foot service in diabetology clinics) has been described, aiming to improve the diagnosis and 
treatment of diabetes foot syndrome in Poland. The recommendation regarding diagnostic tests for osteitis has 
been clarified, and the interval between follow-up foot X-rays has been defined as every 3 to 6 weeks.
Numerous editorial corrections have been made in Chapter 22. Target blood pressure values have been defined 
as < 130/85 mm Hg in those aged 16 years or above, while percentile charts remain in use in younger age groups. 
When discussing insulin therapy, a recommendation has been added that the magnitude of the basal dose and 
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its profile should depend on the age of the child and the type of insulin pump. Recommendations regarding in-
sulin injections with meals have been clarified, and it has been indicated that in the youngest children, in whom 
planning the timing and size of the meal is not possible, dose splitting may be considered by administering half 
of the dose before a meal and the other half during or after a meal. Additions and modifications related to con-
tinuous glucose monitoring have been added to the recommendations regarding blood glucose self-monitoring. 
Important changes have been made to the Table 22.1 on the recommended intervals between serum lipid profile, 
albuminuria, serum creatinine, urinalysis, and thyroid function tests, as performance of these tests is now recom-
mended every 1–2 years at the discretion of the treating physician.
In Chapter 23, significant changes have been made regarding the target 1-hour post-prandial blood glucose 
self-monitoring value which has been relaxed from 120 to 140 mg/dL. The target HbA1c level in the first trimester 
in women with prepregnancy diabetes has been specified at < 6.5% (48 mmol/mol). Nutritional recommendations 
have been amended, including the recommended protein intake of 1.3 g/kg of body weight, and the recommen-
ded saturated fatty acid intake of less than 10% of the total energy value of the diet. Due to the fact that oral 
glucose-lowering agents pass through the placenta and no studies are available regarding their long-term effects 
in the offspring, no recommendation for metformin use during pregnancy has been upheld.
In Chapter 25, recommendations regarding glucose, insulin, and potassium infusion in adult diabetic patients 
in the perioperative period have been unified and simplified, and a section on differences regarding the mana-
gement of children has been added.
A new Chapter 30 has been added to the 2017 PTD guidelines, with brief recommendations regarding selected 
special situations in diabetic patients, including shift work, time zone change, and glucocorticosteroid therapy.
In Appendix 4, errors regarding the management of diabetes type 1 in relation to the TPOAb titer have been 
corrected.
In Appendix 6 which includes recommendations regarding the principles of personal insulin pump therapy 
reimbursed by the National Health Fund in children, adolescents, and young adults below 26 years of age, the 
requirements for centers contracting this service have been clarified, which include patient education regarding 
continuous subcutaneous insulin infusion, providing the patient with an insulin pump, and offering consultation 
services. In case of insulin pumps with continuous glucose monitoring option, alarm presetting is recommended, 
taking into account the current level of metabolic control and patient capabilities. Patient knowledge should be 
verified using a diabetes knowledge test developed by PTD. The HbA1c level criterion for insulin pump therapy 
reimbursement has been changed from > 9.0% to ≥ 9.0%.
By making the above changes, in part suggested by the users of these recommendations, the 2017 PTD Guide-
line Writing Group hopes that these guidelines will serve as an even better signpost leading to improved medical 
care for diabetic patients in our country.
We sincerely thank everybody who has contributed to the development of the new edition of PTD guidelines!
 Prof. Dorota Zozulińska-Ziółkiewicz Prof. Maciej Małecki 
 Deputy President of the Diabetes Poland President of the Diabetes Poland
 Plenipotentiary of the Board  
 of the Diabetes Poland for Clinical Guidelines
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Table 1. American Diabetes Association evidence-grading system for “Standards of Medical Care in Diabetes”
Level of evidence Description
A Clear evidence from well-conducted, generalizable randomized controlled trials that are adequately  
powered, including:
• Evidence from a well-conducted multicentre trial
• Evidence from a meta-analysis that incorporated quality ratings in the analysis
Compelling nonexperimental evidence, i.e., “all or none” rule developed by the Centre for Evidence-
-Based Medicine at the University of Oxford
Supportive evidence from well-conducted randomized controlled trials that are adequately powered, 
including:
• Evidence from a well-conducted trial at one or more institutions
• Evidence from a meta-analysis that incorporated quality ratings in the analysis
B Supportive evidence from well-conducted cohort studies
• Evidence from a well-conducted prospective cohort study or registry
• Evidence from a meta-analysis of cohort studies
Supportive evidence from well-conducted case-control study
C Supportive evidence from poorly or incontrolled studies
• Evidence from randomized clinical trials with one or more major or three or more minor  
methodological flaws that could invalidate the results
• Evidence from observational studies with high potential for bias (such as case series with comparison 
with historical controls)
• Evidence from case series or case reports
Conflicting evidence with the weight of evidence supporting the recommendation
E Expert consensus or clinical experience
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Table 1.1. Diagnostic criteria for dysglycemia
Random blood glucose — measured in 
a blood sample collected at any time 
of the day, regardless of the timing of 
the last meal
Fasting blood glucose — measured in 
a blood sample collected 8–14 hours 
after the last meal
Blood glucose at 120 minutes during 
an oral glucose tolerance test (OGTT) 
according to WHO 
Venous plasma glucose level
≥ 200 mg/dL (≥ 11.1 mmol/L) Æ diabetes* 
(if symptoms of hyperglycemia are present, 
such as increased thirst, polyuria, fatigue)
70–99 mg/dL (3.9–5.5 mmol/L) Æ normal 
glucose tolerance (NGT)
100–125 mg/dL (5.6–6.9 mmol/L) Æ im-
paired fasting glucose (IFG)
≥ 126 mg/dL (≥ 7.0 mmol/L) Æ diabetes*
< 140 mg/dL (7.8 mmol/L) Æ normal glu-
cose tolerance (NGT)
140–199 mg/dL (7.8–11.0 mmol/L) Æ im-
paired glucose tolerance (IGT)
≥ 200 mg/dL (≥ 11.1 mmol/L) Æ diabetes*
WHO — World Health Organization
*Diagnosis of diabetes requires one abnormal reading except for fasting blood glucose which requires two abnormal readings. A potential effect of factors 
not related to testing itself should be taken into account when measuring blood glucose (timing of the last meal, exercise, time of the day)
1. Diagnostic criteria for dysglycemia
Diabetes mellitus is a group of metabolic diseases 
characterized by hyperglycemia due to defective se-
cretion and/or action of insulin. Chronic hypergly-
cemia is associated with damage, dysfunction, and 
failure of various organs, in particular eyes, kidneys, 
nerves, heart, and blood vessels.
 I. Symptoms suggesting the presence of diabetes:
— Body weight reduction;
— Increased thirst;
— Polyuria;
— Fatigue and somnolence;
— Presence of purulent skin lesions and inflamma-
tory conditions of the genitourinary tract. 
In case of the onset of symptoms random venous 
plasma glucose level should be measured (table 1.1).
II.  Diagnostic criteria for dysglycemia (table 1.1): 
— Random venous plasma glucose level measurement 
at the time when symptoms of hyperglycemia are 
identified — values ≥ 200 mg/dL (≥ 11.1 mmol/L) 
are consistent with the diagnosis of diabetes;
— If no symptoms are present or when symptoms are 
present and random blood glucose is < 200 mg/dL 
(< 11.1 mmol/L), fasting blood glucose should be 
measured twice on separate days — diabetes is 
diagnosed if fasting blood glucose on both these 
occasions is ≥ 126 mg/dL (≥ 7.0 mmol/L);
— If no symptoms of hyperglycemia are pre-
sent and random blood glucose is ≥ 200 mg/dL 
(≥  11.1  mmol/L), fasting blood glucose should 
be measured and diabetes is diagnosed if fasting 
blood glucose is ≥ 126 mg/dL (≥ 7.0 mmol/L);
— An oral glucose tolerance test (OGTT) should be 
performed if fasting blood glucose on one or two 
occasions is 100–125 mg/dL (5.6–6.9 mmol/L), or 
impaired glucose tolerance (IGT) or diabetes may 
be reasonably suspected with fasting blood glu-
cose < 100 mg/dL (< 5.6 mmol/L);
— An OGTT should be performed without prior limi-
tations of carbohydrate intake in a fasting, rest-
ed subject after an overnight sleep; the subject 
should remain resting at the site of testing for the 
2-hour period before ingestion of 75 g glucose so-
lution and blood sampling, with all blood glucose 
level measurements performed in venous blood 
plasma in a laboratory;
— If OGTT is to be performed in a subject with pre-
diabetes treated with metformin for that reason, 
the drug should be withdrawn at least one week 
before OGGT;
— OGTT is the preferred method to diagnose IGT. 
Glucose meter measurements should not be used 
for diagnostic purposes.
Currently, PTD does not recommend measuring hae-
moglobin A1c (HbA1c) level to diagnose diabetes.
III.  Nomenclature of hyperglycemic states according 
to the World Health Organization (WHO):
— Normal fasting blood glucose: 70–99 mg/dL (3.9– 
–5.5 mmol/L);
— Impaired fasting glucose (IFG): 100–125 mg/dL 
(5.6–6.9 mmol/L);
— Impaired glucose tolerance (IGT): 120-minute blood 
glucose at 120 minutes of OGTT 140–199 mg/dL 
(7.8–11 mmol/L);
— Prediabetes: IFG and/or IGT;
— Diabetes — one of the following criteria:
1. Symptoms of hyperglycemia and random blood 
glucose level ≥ 200 mg/dL (≥ 11.1 mmol/L);
2. Fasting blood glucose ≥ 126 mg/dL (≥ 7.0 
mmol/L) on two occasions;
3. Blood glucose at 120 minutes of OGTT ≥ 200 
mg/dL (≥ 11.1 mmol/L).
IV.  Subjects at risk require screening for diabetes, as 
symptoms of hyperglycemia are absent in more 
than half of them. Testing for diabetes should be 
performed every three years in all subjects > 45 
 years of age. In addition, the following risk groups 
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should be tested annually regardless of age:
— Overweight or obese subjects [body mass index 
(BMI) ≥ 25 kg/m2 and/or waist circumference > 80 cm 
(women) or > 94 cm (men)];
— Subjects with a family history of diabetes (in par-
ents or siblings);
— Physically inactive subjects;
— Members of community or ethnic groups charac-
terized by increased rates of diabetes;
— Those with prediabetes identified during previous 
testing;
— Women with a history of gestational diabetes;
— Women who gave birth to an infant with a birth 
weight > 4 kg;
— Subjects with hypertension (≥ 140/90 mm Hg);
— Subjects with dyslipidemia [high-density lipopro-
tein (HDL) cholesterol < 40 mg/dL (< 1.0 mmol/L) 
and/or triglycerides > 150 mg/dL (> 1.7 mmol/L)];
— Women with polycystic ovary syndrome;
— Subjects with cardiovascular disease.
V.	 	 Etiologic	 classification	of	diabetes	 according	 to	
WHO:
1. Diabetes type 1
— Autoimmune;
— Idiopathic.
2. Diabetes type 2
3.	Other	specific	forms	of	diabetes
— Genetic defects of beta cell function;
— Genetic defects of insulin function;
— Exocrine pancreatic diseases;
— Endocrinopathies;
— Drugs and chemicals;
— Infections;
— Rare immunologic forms of diabetes;
— Other genetic syndromes associated with diabetes.
4. Gestational diabetes
Latent autoimmune diabetes in adults (LADA)
The category of autoimmune diabetes type 1 in-
cludes slowly progressing diabetes caused by autoag-
gression. Latent autoimmune diabetes in adults (LADA) 
is a late manifesting autoimmune form of diabetes in 
adults, most commonly diagnosed in patients above 
35 years of age, characterized by clinical insulin inde-
pendence in the first months after the diagnosis, with 
the presence of serum antibodies against glutamic 
acid decarboxylase (anti-GAD65) and/or other anti-islet 
antibodies and a low serum peptide C level. LADA is 
a form of diabetes type 1 with slowly progressive auto-
immune-mediated destruction of beta cells. This diabetes 
subtype is present in 5–10% of subjects with diabe-
tes diagnosed after 35 years of age and categorized as 
diabetes type 2. Clinical manifestations of LADA do not 
always allow a definite diagnosis, presenting diagnostic 
challenges when differentiating with diabetes type 2.
A definite diagnosis of LADA requires identification 
of autoantibodies typical for diabetes type 1, mostly anti-
GAD65, and/or a low serum peptide C level.
Monogenic diabetes
Monogenic diabetes amounts to 1–2% of all diabe-
tes cases. It is caused by single gene mutations. Most 
forms are associated with a defect of insulin secretion, 
and the most common ones are maturity-onset diabe-
tes of the young (MODY), mitochondrial diabetes, and 
neonatal diabetes. Taking into account the monogenic 
forms in the differential diagnosis of diabetes may con-
tribute to treatment optimization and proper evaluation 
of prognosis in the patient and his family members. 
A definite diagnosis of monogenic diabetes is a result of 
genetic testing. Patient selection for genetic testing for 
monogenic diabetes and any therapeutic decisions re-
sulting from such a diagnosis should be made in centers 
with a large experience in this area.
Neonatal diabetes is defined as the disease onset 
before 9 months of age. Genetic testing should be per-
formed in all patients with persistent neonatal diabetes. 
This should include testing for mutations in the KCNJ11 
gene which codes for Kir6.2 protein. Mutations in this 
gene are the most common cause of persistent neonatal 
diabetes. Regardless of age, most patients with KCNJ11 
gene mutations may be treated with sulphonylureas 
which are effective and safe in this group and thus may 
be used as an alternative to insulin. Further targets for 
genetic testing include mutation in the insulin genes, the 
ABCC8 gene coding for SUR1 protein, ad the glucokinase 
gene. If a mutation in the ABCC8 gene is identified, 
sulphonylurea treatment may be attempted. Carriers of 
mutations in the insulin gene and a double mutation in 
the glucokinase gene need to be treated with insulin. 
Decisions regarding search for mutations in other genes 
should be made individually by diabetes specialists (dia-
betologists) with an appropriate experience in the genet-
ics of diabetes.
In families with an autosomal dominant early-onset 
diabetes caused by impaired insulin secretion, in most cases 
without obesity, the differential diagnosis should include 
MODY and mutations in the responsible genes should be 
searched for. The most common form of MODY is associ-
ated with HNF1A and glucokinase gene mutations.
Typical clinical presentation of MODY due to a HNF1A 
gene mutation includes:
 1. Early onset of diabetes (typically before 25 years of 
age);
 2. No insulin dependence and ketoacidosis, low insulin 
requirement, detectable peptide C levels despite the 
disease being present for several years or even longer;
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 3. Family history of diabetes over at least 2 generations, 
with an early-onset diabetes in at least two family 
members. OGTT performed at an early stage of dia-
betes usually shows high postprandial glucose level 
elevation with often normal fasting blood glucose;
 4. Absence of autoantibodies typical for diabetes type 1;
 5. Glycosuria higher than expected based on blood glu-
cose levels.
Chronic complications of diabetes develop in a large 
proportion of patients with MODY due to a HNF1A gene 
mutation, and thus optimal disease control should be 
actively pursued early after the disease onset. Sulphonyl-
ureas are the drugs of choice (except for pregnancy or 
the presence of typical contraindications to these drugs). 
If these are not effective, combined therapy with insulin, 
metformin or dipeptidyl peptidase-4 (DPP-4) inhibitors, 
or insulin monotherapy should be considered.
Testing for glucokinase gene mutations is indicated in 
the following situations:
 1. Persistently elevated fasting blood glucose in the 
range of 99–144 mg/dL (5.5–8.0 mmol/L);
 2. An increase in blood glucose during OGTT lower than 
83 mg/dL (4.6 mmol/L);
 3. A family history of diabetes in one of the parents, but 
negative family history does not exclude this form of 
diabetes.
Healthy nutrition with elimination of simple sugars 
is the treatment of choice in glucokinase defects due 
to a single gene mutation; drugs are usually ineffective. 
HbA1c value characteristic for glucokinase defect is not 
higher than 7.5%.
Decisions regarding testing for mutations in other 
genes associated with MODY should be made individu-
ally in centers experienced in such testing.
The most common cause of mitochondrial diabetes is 
the A3243G mutation of the gene coding for leucine tRNA. 
Testing for this mutation should be performed in case of 
maternal transmission of an early-onset diabetes associated 
with deafness in some family members. The therapeutic 
approach in mitochondrial diabetes may include diet and 
treatment with sulphonylureas or insulin depending on the 
degree of defective insulin secretion. Metformin use should 
be avoided in mitochondrial diabetes.
Cystic	fibrosis-related	diabetes	(CFRD)
Diabetes is present in about 20% of adolescents and 40– 
–50% adults with cystic fibrosis, Diabetes associated with 
cystic fibrosis is classified as other specific type of diabetes 
associated with exocrine pancreatic disease, characterized 
by a slow progression and usually remains asymptomatic 
for many years. Diabetic ketoacidosis occurs rarely, most 
likely due to preserved endogenous insulin secretion or 
concomitant impairment of glucagon secretion. Initially, 
hyperglycemia is usually seen in circumstances that ex-
acerbate insulin resistance, such as acute and chronic 
infections, glucocorticoid therapy, and ingestion of large 
amounts of carbohydrates (intake by oral or intravenous 
route, gastric tube or percutaneous gastrostomy).
Insulin therapy is the treatment of choice.
Routine annual testing for diabetes should be per-
formed in generally healthy subjects with cystic fibrosis 
aged ≥ 10 years.
2. Preventing and delaying development of diabetes
Diabetes type 1
Currently, no effective and clinically useful methods 
exist to prevent diabetes type 1 both in the general popu-
lations and in subjects at risk.
Diabetes type 2
Screening should be undertaken with fasting blood 
glucose measurements or OGTT using 75 g of glucose 
(see Chapter 1). It is also possible to use HbA1c level mea-
surements to screen for dysglycemia.
I.  Risk factors for diabetes type 2 (see Chapter 1).
II.  Overview of recommendations regarding preven-
tion and delaying development of diabetes:
— Subjects at a high risk of developing diabetes type 2 
should receive appropriate education regarding 
healthy lifestyle (health benefits related to moder-
ate weight reduction and regular physical activity);
— Indications for screening (see Chapter 1);
— Patients with prediabetes (IFG or IGT) should be 
advised to reduce weight and increase physical 
activity. Pharmacological prevention of diabetes 
by using metformin should be considered in sub-
jects at a high risk of developing diabetes type 2, 
particularly if IFG or IGT is present;
— Repeated advice regarding lifestyle changes is of 
paramount importance for the effectiveness of 
prevention;
— It is recommended to monitor patients for other 
cardiovascular disease risk factors (e.g., tobacco 
smoking, hypertension, dyslipidemia) and their 
treatment;
— Use of diabetogenic drugs should be avoided.
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Table 3.1. Recommended frequency of blood glucose self-monitoring
Treatment regimen Frequency of blood glucose self-monitoring
Multiple (i.e., at least 3 times daily) insulin injections
Intensive insulin therapy, regardless of the diabetes type
Multiple (i.e., at least 4 times daily) readings during the day  
according to the treatment regimen and patient needs
Diet treatment only 4-point blood glucose profile (fasting and 2 hours post main 
meals) once a month, once a week at various times of the day
Oral hypoglycemic drugs and/or GLP analogs 4-point blood glucose profile (fasting and 2 hours post main 
meals) once a week, once daily at various times of the day
Diabetes type 2 treated with fixed insulin doses 1–2 readings daily plus 4-point blood glucose profile (fasting and 
2 hours post main meals) once a week plus 7-point blood  glucose 
profile once a month
All patients Additional immediate readings in case of feeling unwell, sudden 
illness etc.
GLP — glucagon-like peptide
Current monitoring and retrospective evaluation of 
blood glucose levels are integral parts of adequate diabe-
tes treatment. Appropriate blood glucose self-monitoring 
(BGSM) requires regular patient education in this regard, 
including evaluation of the ability to use glucose meter 
and interpret BGSM results, i.e. using them for day-to-
day modification of nutrition, exercise, and medication 
doses. Regular HbA1c level measurements are another 
necessary component of diabetes treatment monitoring.
I. Blood glucose self-monitoring
Blood glucose self-monitoring is an integral part of 
diabetes treatment.
Patients treated with multiple daily insulin injections 
or continuous subcutaneous insulin infusion (CSII) should 
perform a daily blood glucose profile that includes read-
ings at morning fast, before and 60–120 minutes after 
each main meal, and before bedtime. Frequency and 
timing of additional measurements should be set indi-
vidually.
Use of blood glucose monitoring systems including 
continuous glucose monitoring (CGM) and flash glucose 
monitoring (FGM) to supplement blood glucose self-
monitoring is particularly indicated in patients with labile 
diabetes type 1 with frequent hypoglycemia episodes 
and hypoglycemia unawareness, as it improves treatment 
safety and effectiveness.
Blood glucose self-monitoring is also indicated to 
reach therapeutic targets in patients treated with single 
insulin injections, oral antidiabetic agents, diet, and pre-
scribed physical exercise (Table 3.1).
Proper BGSM requires patient education regarding 
glucose meter use, interpretation of readings, and fur-
ther management steps. For BGSM, it is recommended 
to use glucose meters that display plasma glucose level 
with the declared margin of error of up to 15% for glu-
cose levels ≥ 100 mg/dL (5.6 mmol/L) and 15 mg/dL (0.8 
mmol/l) for glucose levels < 100 mg/dL (5.6 mmol/L). 
Analysis of glucose readings using a computer software 
may be useful in patients performing ≥ 4 measurements 
daily. Glucose meters and the technique of their use by 
the patients should be checked in case of suspected mea-
surement errors and at least once a year at the facility 
where the patient receives outpatient treatment.
II. Hemoglobin A1c (HbA1c)
Hemoglobin A1c level reflects average blood glucose 
levels during the period of approximately 3 last months, 
with about 50% of HbA1c currently present in blood being 
formed during the last month before the measurement.
Hemoglobin A1c level measurements should be per-
formed annually in patients with stable disease in whom 
the therapeutic targets have been met. In those in whom 
the therapeutic targets have not been met or the treat-
ment has been modified, HbA1c level should be measured 
at least every 3 months.
Hemoglobin A1c level measurements should be per-
formed using analytic methods certified by the Nation-
al Glycohemoglobin Standardization Program (NGSP) 
(http://www.ngsp.org). Point-of-care testing for HbA1c is 
also possible when using methods and analyzers certified 
by NGSP.
It has been suggested that diagnostic laboratories 
report HbA1c levels in SI units (mmol/mol) in addition to 
traditional units.
When interpreting HbA1c levels, interfering factors 
should be taken into account, such as changes in the 
erythrocyte survival time, hemoglobinopathies, and 
chemical hemoglobin modifications which may render 
use of these measurements difficult or impossible.
3. Blood glucose monitoring
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I. General considerations
 1. Therapeutic targets in diabetes include target blood 
glucose levels, blood pressure values, lipid profile, 
and body weight.
 2. In older patients and those with comorbidities, who 
are expected to survive for less than 10 years, thera-
peutic targets should be relaxed so as to not compro-
mise patient’s quality of life.
 3. Generally, therapeutic targets and treatment intensifi-
cation should be largely individualized. In all diabetic 
patients, and particularly those with diabetes type 2, 
the following factors should be taken into account 
when setting therapeutic targets: patient’s attitude 
towards treatment and the expected engagement 
in the treatment process (including that of patient’s 
family members, caretakers etc.), the risk of hypogly-
cemia and its possible consequences (more severe in 
the elderly, and in those with preexisting cardiovascu-
lar or nervous system damage), duration of diabetes, 
expected survival, presence of major vascular diabetic 
complications and significant comorbidities, the de-
gree of patient’s education, and the risk-to-benefit 
ratio associated with specific therapeutic targets. In 
some circumstances (e.g., in those with advanced 
complications and in the elderly), the therapeutic 
targets should be attained gradually, within several 
(2 to 6) months.
II.   Criteria of adequate blood glucose control (ta-
king into account the above considerations)
A general target:
HbA1c ≤ 7% (≤ 53 mmol/mol)
Individual targets:
a) HbA1c ≤ 6.5% (≤ 48 mmol/mol)
— Diabetes type 1 [fasting and preprandial  blood 
glucose, including BGSM: 80–110 mg/dL (4.4– 
–6.1 mmol/L); 2-hour post-prandial BGSM < 
140 mg/dL (7.8 mmol/L)];
— Diabetes type 2 of a short duration;
— In children and adolescents, regardless of the 
diabetes type. When evaluating blood glucose 
profile in relation to target HbA1c, values gi-
ven in Table 4.1 should be consulted, showing 
mean daily blood glucose values and blood 
glucose ranges corresponding to specific HbA1c 
levels.
b) HbA1c ≤ 8.0% (≤ 64 mmol/mol)
— In patients at an advanced age and/or in dia-
betics with macroangiopathic complications 
Table 4.1. Relation between HbA1c levels and average plasma glucose levels
HbA1c Average plasma  
glucose levels
Average fasting 
blood glucose
Average preprandial  
blood glucose
Average postprandial  
blood glucose
[mg/dL] [mmol/L] [mg/dL] [mg/dL] [mg/dL]
6 126 7.0
< 6.5 122 118 144
6.5–6.99 142 139 164
7 154 8.6
7.0–7.49 152 152 176
7.5–7.99 167 155 189
8 183 10.2
8–8.5 178 179 206
9 212 11.8
10 240 13.4
11 269 14.9
12 298 16.5
Correlation between HbA1c and average plasma glucose levels 0.92 (according to Diabetes Care 2015; 28: 35)
4. Setting therapeutic targets in diabetes
Most important recommendations
•  In diabetic patients, the overall goal of diabetes control is HbA1c level ≤ 7.0% (53 mmol/mol). [A] 
•  In all patients with diabetes type 1 and increased urinary albumin secretion and/or renal dysfunction, a statin is 
recommended to reduce LDL-C level by at least 50% regardless of the baseline LDL-C level. [C] 
• In patients with diabetes type 2 and cardiovascular disease or chronic kidney disease, and those > 40 years of 
age without overt cardiovascular disease but with ≥ 1 risk factor or target organ damage, lipid-lowering therapy 
is recommended to reach the goal LDL-C level of < 70 mg/dL (1.8 mmol/L). [B] 
•  In patients with diabetes type 2 without target organ damage and risk factors, the goal LDL-C level is < 100 mg/dL 
(2.6 mmol/L). [B] 
•  The recommended blood pressure goal is < 140/90 mm Hg. [A]
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(previous myocardial infarction and/or stroke) 
and/or multiple comorbidities;
c) HbA1c level < 6.5% (48 mmol/mol) in women with 
prepregnancy diabetes contemplating pregnancy, 
< 6.0 % (42 mmol/mol) in the second and third 
trimester, if it is not associated with an increased 
rate of hypoglycemia.
If a diabetic patient aged > 65 years is expected to 
survive for more than 10 years, gradual attainment of 
general therapeutic targets should be aimed for, with 
target HbA1c level ≤ 7%.
Correlation between HbA1c and average plasma 
glucose levels 0.92 (according to Diabetes Care 2015; 
28: 35)
III.	Criteria	of	adequate	lipid	profile	control:
— LDL-C level < 70 mg/dL (1.9 mmol/L) or reduction 
by at least 50% if baseline LDL-C level is 70–135 
mg/dL (1.9–3.5 mmol/L) in diabetic subjects at very 
high cardiovascular risk;
— LDL-C level < 100 mg/dL (2.6 mmol/L) or reduction 
by at least 50% if baseline LDL-C level is 100–200 
Comprehensive diabetes care requires input of ade-
quately competent physicians, nurses or educators enga-
ged in diabetic education, and dietitians. Care should be 
patient-centered, taking into account individual patient 
situation, needs, and preferences. Due to multidiscipli-
nary nature of late diabetic complications and conco-
mitant conditions, cooperation with other specialists is 
also necessary.
Children and adolescents and pregnant women — 
see relevant chapters.
I. Outpatient care
Modern diabetes treatment requires competencies 
regarding treatment, monitoring, and patient educa-
tion to convey appropriate knowledge and motivation to 
comply with treatment recommendations. Cooperation 
between primary care physicians and specialists is also 
required.
II. Goals of primary care
 1.  Promoting healthy lifestyle to prevent development 
of dysglycemia.
 2.  Identification of risk factors for diabetes.
 3.  Investigating diabetes and prediabetes.
 4.  Evaluation of the risk of long-term complications.
 5.  Investigating early stages of long-term complications.
 6.  Managing patients with diabetes type 2 treated with li-
festyle changes (diet, physical activity), and oral agents.
mg/dL (2.6–5.2 mmol/L) in diabetic subjects at 
high cardiovascular risk;
— LDL-C level < 115 mg/dl (3.0 mmol/L) in subjects at 
low or moderate cardiovascular risk (subjects < 40 
years of age with diabetes type 1 but without chronic 
complications and other cardiovascular risk factors);
— Non-HDL cholesterol level < 100 mg/dL (2.6 mmol/L) 
in diabetic subjects at very high cardiovascular risk;
— Non-HDL cholesterol level < 130 mg/dL (3.4 mmol/L) 
in diabetic subjects at high cardiovascular risk;
— Non-HDL cholesterol level < 145 mg/dL (3.7 
mmol/L) in subjects < 40 years of age with diabe-
tes type 1 but without vascular complications or 
other cardiovascular risk factors;
— Triglyceride level < 150 mg/dL (< 1.7 mmol/L);
— HDL cholesterol > 40 mg/dL (> 1.0 mmol/L) [in 
women, higher by 10 mg/dL (0.275 mmol/L)].
IV. Criteria of adequate blood pressure control:
— Systolic blood pressure < 140 mm Hg;
— Diastolic blood pressure < 90 mm Hg.
Details — see Chapter 12.
5. Organization of care for adult patients with diabetes
 7.  Initiation and continuation of insulin therapy combi-
ned with oral agents in patients with diabetes type 2.
 8.  Referring treated patients (at least once a year) for 
specialist consultations to:
— Evaluate metabolic control;
— Evaluate the severity of long-term complications 
and initiate specific treatment if needed;
— Provide education regarding lifestyle changes;
— Set therapeutic targets and treatment plans.
III. Goals of specialist care (Table 5.1)
 1. Evaluation of treatment effects and setting therapeu-
tic targets during annual specialist check-ups in dia-
betic patients managed by primary care physicians.
 2. Managing patients with diabetes type 1 and other ty-
pes of diabetes treated with injected agents [insulin, 
glucagon-like peptide 1 (GLP-1) receptor agonists].
 3. Performing specialist investigations and the differen-
tial diagnosis of diabetes types, including diagnosis 
and treatment of monogenic diabetes and diabetes 
combined with other diseases.
 4. Investigating, monitoring, and preventing progres-
sion of long-term complications.
 5. Diabetes education.
 6. Investigating and managing diabetes in pregnant 
women (in collaboration with obstetricians).
 7. Managing patients with clinically overt complications.
 8. Investigating concomitant conditions.
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Table 5.1. Recommendations regarding monitoring in adult diabetic patients
Parameter Comments
Nutritional and therapeutic education At each visit
HbA1c Once a year, more frequently if doubts regarding maintenance of 
normoglycemia or need to verify treatment effectiveness following 
its modifications
Serum total cholesterol, HDL cholesterol, LDL cholesterol, 
 triglycerides
Once a year, more frequently if dyslipidemia
Albuminuria Once a year in patients not receiving an angiotensin-converting 
enzyme inhibitor or an angiotensin receptor blocker
Urinalysis (with urine sediment) Once a year
Serum creatinine + estimation of eGFR Once a year (beginning at 5 years after the diagnosis in diabetes 
type 1)
Serum creatinine, Na+, K+, Ca2+, PO4
3– Every six months in patients with elevated serum creatinine
Fundoscopy (with mydriasis) At 5 years after the diagnosis in diabetes type 1, at the time of the 
diagnosis in diabetes type 2 (details see Chapter 19)
eGFR — estimated glomerular filtration rate; HbA1c — hemoglobin A1c; HDL — high-density lipoprotein; LDL — low-density lipoprotein
IV. Goals of specialist inpatient care
 1. Cases of newly detected diabetes type 1 and diabetes 
type 2 with symptomatic hyperglycemia.
 2. Acute diabetic complications (hypo- and hyperglyce-
mia, diabetic ketosis and coma).
 3. Exacerbation of chronic complications.
 4. Performance of minor procedures.
 5. Modifications of the treatment regimen in patients 
in whom therapeutic targets cannot be met during 
outpatient therapy.
 6. Initiation of intensive insulin therapy using a personal 
insulin pump and/or continuous glucose monitoring 
system (cgms).
 7. Initiation of insulin therapy in gestational diabetes 
and preexisting diabetes previously not treated with 
insulin.
 8. Difficulties with obtaining normoglycemia in pre-
gnant patients with preexisting diabetes.
V. Organizational requirements
Specialist diabetes hospital units
A.  Physician personnel — two full-time diabetologists 
(in pediatric units, two diabetologists or pediatric 
endocrinologists and diabetologists), alternatively, in 
addition to a diabetologist, an internist (pediatri-
cian in pediatric units) or endocrinologist with an 
experience in diabetology confirmed by the diabetes 
voivodship consultant.
B.  Nursing staff — two nurses with an experience in 
education, with duties limited to education and 
care for diabetic patients, a diabetes educator if 
possible.
C.  Dietician — with duties limited to diabetes care (at 
least half-time).
D.  Access to specialist consultations (as in diabetes 
clinics, including psychologist consultations).
Recommended	therapeutic	team	staffing	for	eve-
ry 15–20 adult diabetes beds: 2–3 physicians, 2 nurses 
experienced in care for diabetic patients, a dietician, 
a psychologist (employed or available as a consul-
tant), and a social worker.
E. Equipment:
— At least one intensive metabolic care bed per 10 
regular diabetes beds;
— Space and necessary teaching equipment for edu-
cation (education room);
— Required equipment: medical scales, blood pres-
sure monitors, intravenous infusion pumps, glucose 
meters, food scales, neurological hammers, 128 Hz 
tuning forks, monofilaments, and continuous ac-
cess to cardiac [exercise testing, electrocardiograp-
hy (ECG), ECG Holter monitoring, ambulatory blood 
pressure monitoring, coronary angiography] and 
vascular (Doppler ultrasonography) investigations.
— Recommended (optional) equipment: continuo-
us subcutaneous glucose monitoring system, op-
hthalmoscope, pedobarography, neurothesiome-
ter, Doppler cine-loop.
Specialist diabetes clinics
A.  Physician personnel — a diabetologist (in pedia-
tric diabetology clinic, a diabetologist or pediatric 
endocrinologist and diabetologist) and another phy-
sician: an internist, pediatrician, or endocrinologist 
with an experience in diabetology confirmed by the 
diabetes voivodship consultant.
B. Nursing staff — a nurse with at least one year pro-
fessional experience in diabetes nursing, with formal 
duties limited to care for diabetic patients, a diabetes 
educator if possible.
C.  Dietician — with duties limited to diabetes care (at 
least half-time).
D.  Psychologist — employed or available as a consultant.
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E.   Access to specialist consultations, including servi-
ces of a(n):
— Ophthalmologist;
— Nephrologist;
— Neurologist;
— Vascular surgeon or angiology specialist;
— Cardiologist;
— Orthopedic surgeon.
F.   Social worker
A therapeutic team that includes one physician, one 
nurse experienced in diabetic nursing, one dietician (part-
-time) and a psychologist may provide care to 800 adult 
diabetic patients.
Children and adolescents, pregnant women — see 
relevant chapters.
G.  Equipment in specialist diabetes clinics:
— Required: medical scales, blood pressure monitors, 
glucose meters, 128 Hz tuning forks, monofila-
ments, food scales;
— Recommended (optional): continuous subcutaneo-
us glucose monitoring system, ambulatory blood 
pressure monitoring system, ophthalmoscope, neu-
rothesiometer, computers with printers to retrieve 
and print glucose meter, personal insulin pump, and 
continuous glucose monitoring system data. Howe-
ver, computer equipment that allows data retrieval 
from insulin pumps and continuous glucose moni-
toring systems is necessary for the proper manage-
ment of patients with diabetes type 1 treated with 
a personal insulin pump.
VI. Organization of care for patients with diabetic 
foot syndrome
A.  Referral diabetes foot outpatients clinics
 1.  Personnel requirements:
  Physicians: equivalent of at least 2 full-time positions 
— diabetes specialist with at least one year of docu-
mented experience in the management of patients 
with diabetic foot syndrome;
  Nurses: equivalent of at least 2 full-time positions 
— at least one year of documented experience in the 
management and care of patients with diabetic foot 
syndrome or chronic wounds.
 2. An established organizational pathway allowing pa-
tient hospitalizations in a unit within the same facility 
(medical center) that has a contract for diabetology or 
internal medicine services signed with the Polish Na-
tional Health Fund (NFZ, Narodowy Fundusz Zdrowia).
 3. Access to multidisciplinary care, including surgeon, 
vascular surgeon, or angiology specialist consulta-
tions.
 4. Ability to provide intravenous antibiotic therapy.
 5. Access to basic imaging modalities, e.g. X-ray, ultra-
sound (including Doppler studies) and CT and/or MRI.
 6. Access to laboratory and microbiologic testing perfor-
med in a medical diagnostic laboratory listed in the re-
gister of the National Chamber of Laboratory Diagnosti-
cians (KRDL, Krajowa Rada Diagnostów Laboratoryjnych).
B. Basic care outpatients clinics
 1.  The responsibility of these clinics should include the 
diagnosis and management of diabetes foot syndro-
me along with prevention of ulcerations, infections, 
and Charcot neuro-osteoarthropathy complicating 
diabetes foot syndrome. These clinics should coope-
rate with referral clinics where more severe cases are 
consulted and offered further treatment.
6. Behavioral therapy (lifestyle changes)
Most important recommendations
• All diabetic patients should be offered education regarding the general principles of proper diabetes nutrition by 
appropriately trained personnel (physician, dietician, diabetes nurse, diabetes educator) and using various methods 
and techniques, including telemedicine. Detailed nutritional recommendations should be tailored to the needs and 
capabilities of the patient. [A]
• The major macronutrient determining periprandial insulin requirement are carbohydrates. Instruction how to 
estimate carbohydrate content of a meal to optimize insulin dosing should be a key component of dietary educa-
tion in patients with diabetes type 1. [A]
• There is no single universal diet that would be appropriate for all diabetic patients. The optimal proportions of 
macronutrients for a given patient should be determined individually, taking into account patient’s age, physical 
activity, presence of diabetes complications, and concomitant conditions. [E]
• Due to its pleotropic benefits, physical exercise is an integral part of proper comprehensive diabetes management. 
For optimal effects, exercise should be regular, undertaken at least every 2–3 days but preferably daily. [A]
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Behavioral therapy is an indispensable element of 
all patients of all ages diagnosed with diabetes treat-
ment (both type 1 and type 2). Proper nutrition and 
physical activity are important in improving the overall 
patients’ health and in the prevention and treatment of 
chronic complications of diabetes. All patients should 
be educated on the general principles of proper nutri-
tion in diabetes by authorized persons (doctor, dietician, 
diabetes nurse , diabetes educator) by using different 
methods and techniques, including telemedicine. Patient 
management should include therapeutic lifestyle chan-
ges encompassing balanced diet, regular physical activity, 
avoidance of tobacco smoking and alcohol use, optimal 
sleep duration, and avoidance of stress. Education for 
therapeutic lifestyle, adapted to the needs and possibili-
ties of the patient, allows to achieve intended therapeutic 
target and reduces the costs related to the treatment 
caused by diabetic complications.
Dietary recommendations
I. General recommendations
The goals of dietary treatment in diabetic patients are 
to obtain and to maintain:
— Normal (near normal) blood glucose level to pre-
vent diabetic complications;
— Optimal serum lipid and lipoprotein levels;
— Optimal blood pressure values to reduce the risk of 
vascular disease; and
— Desired body weight.
Dietary treatment includes advice on:
— Individually determined energy value of the diet;
— Calorie distribution over individual meals during 
the day;
— Food sources that will provide necessary calories, 
vitamins, minerals, and phytochemicals.
— Products that should be limited.
When planning diet, individual patient nutritional and 
cultural preferences, age, gender, the level of physical acti-
vity, and the economic status should be taken into account.
Nutritional strategy in diabetic patients should in-
clude:
— Evaluation of usual dietary intake;
— Nutritional diagnosis;
— Determination of the goal and plan of the dietary 
intervention;
— Nutritional intervention (individual or group coun-
seling);
— Monitoring of nutrition and evaluation of its ef-
fects;
— Correction of the dietary plan if the therapeutic 
goal has not been reached.
Diabetic patients should be encouraged to adhere to 
the recommendations on healthy nutrition addressed to 
healthy subjects, and additionally to: 
— Controlling the size of usually consumed portions;
— Monitor carbohydrate intake overall and in indivi-
dual meals;
— Limit intake of foods containing simple absorbable 
carbohydrates, including added sugar;
— Consume frequent, regular meals.
There is no single universal diet that would be appro-
priate for all diabetic patients.
Patients with diabetes type 1 without overweight 
and obesity should avoid consuming easily absorbable 
simple carbohydrates and adhere to an appropriately 
balanced diet. In all cases, the dietary plan and insulin 
regimen should be individually tailored. Insulin therapy 
should be adjusted to the patient’s dietary habits, meal 
composition (carbohydrate, protein, and fat content), 
lifestyle, and physical activity. When planning diet, 
a priority should be given to estimation of absorbable 
carbohydrate content of the meal, e.g. using the carbo-
hydrate exchange system. Glycemic index and glycemic 
load values may also be useful when making dietary 
choices.
In diabetic patients in the oldest age groups, dietary 
education should be particularly careful and individuali-
zed to provide appropriate protein intake.
Although carbohydrates are the major macronutrient 
determining periprandial insulin requirement, patients 
with diabetes type 1 should also be educated regarding 
the glycemic effect of protein and fat.
In diabetes type 2, the major goals are not only to 
maintain good metabolic control of the disease but also 
reduce excess body weight and maintain the desired 
body weight. Thus, in addition to the above recommen-
dations, a factor of major importance is the total calorie 
content of the diet which should be adjusted to the pa-
tient’s age, actual body weight, and the level of physical 
activity, allowing gradual but systematic body weight 
reduction. A reduction in the total calorie intake (by 
500–1000 kcal/day) should allow gradual but systematic 
body weight reduction (by about 0.5–1 kg/week). 
Body weight reduction may be achieved by using 
a low-calorie diet with various proportions of macro-
nutrients (protein, fat, carbohydrates). Depending on 
individual patient preferences, the following diets may 
be recommended for the prevention and treatment of 
diabetes: a Mediterranean-type diet, the Dietary Appro-
aches to Stop Hypertension (DASH), portfolio, vegeta-
rian or vegan, low-fat or low-carbohydrate diet. Fasting 
to reduce body weight is not recommended. Despite 
various views on the ideal macronutrient proportions, 
a low-carbohydrate diet remains the gold standard in 
the management of diabetes in patients who require 
body weight reduction. Body weight reduction may be 
achieved by using both a reduced carbohydrate diet and 
a low-fat diet.
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II.	Specific	recommendations
Diet composition
1. Carbohydrates:
— No sufficient scientific evidence is available to de-
termine single optimal carbohydrate content in 
the diet of diabetic patients; 
— Carbohydrates should provide about 45% of the 
total calorie intake; and if they are consumed in 
the form of low glycemic index and high fiber 
content products, their share in the total calorie 
intake may be even higher (up to 60%). High 
caloric intake from carbohydrates should also be 
a feature of the diet in subjects who are very active 
physically. In contrast, a lower carbohydrate share 
in the total calorie intake (25–45%) may be tempo-
rarily recommended in patients with little physical 
activity if it cannot be significantly increased, e.g., 
due to concomitant conditions;
— The main source of carbohydrates should be who-
le grain cereal products, especially with low glyce-
mic index (< 55 IG);
— The major limitation should apply to the intake of 
simple carbohydrates which should be reduced to 
the minimum;
— Artificial sweeteners may be used in doses recom-
mended by the manufacturers;
— Daily fructose intake should not exceed 50 g. Fru-
ctose use as a replacement for sugar is not recom-
mended;
— Due to a beneficial effect of dietary fiber on 
postprandial glycemia, dietary fiber content sho-
uld be about 25–50 g/day or 15–25 g/1000 kcal. 
Intake of soluble fibers (pectins, beta-glucans) is 
particularly recommended.
2. Fats:
— Fats should provide 30–35% of the total calorie 
intake in the most patients;
— Saturated fats should provide less than 10% of the 
total calorie intake, and less than 7% of the total 
calorie intake in patients with serum LDL choleste-
rol level ≥ 100 mg/dL (≥ 2.6 mmol/L);
— Monounsaturated fats should provide 10–15% of 
the total calorie intake;
— Polyunsaturated should provide about 6–10% of 
the total calorie intake;
— Cholesterol intake should be limited to ≤ 300 mg/ 
/day, and < 200 mg/dL in patients with serum LDL 
cholesterol level ≥ 100 mg/dL (≥ 2.6 mmol/L);
— To reduce serum LDL cholesterol level, low glyce-
mic index carbohydrates and/or monounsaturated 
fats should be substituted for saturated fats. It 
may be beneficial to supplement diet with functio-
nal foods containing plant sterols/stanols;
— Intake of trans fatty acids should be limited to the 
minimum.
3. Proteins:
— In most diabetic patients, similarly to the general 
population, proteins should provide 15–20% of 
the total calorie intake (about 1–1.5 g/kg body 
weight/day). In patients with diabetes type 2 and 
excessive body weight, a low-calorie diet may con-
tain 20–30% of protein. In patients with chronic 
kidney disease, protein intake should be about 
0.8–1 g/kg body weight/day;
— There is no need to limit animal protein intake, 
although substituting plant protein (e.g., soy pro-
tein) for animal protein may be beneficial in some 
patients.
4. Vitamins and microelements:
— Vitamin or microelement supplementation is not 
recommended unless their deficiencies have been 
identified;
— The exceptions are vitamin D3 (supplementation 
according to the recommendations for the general 
population) and folic acid (supplementation at the 
dose of 400 µg in pregnant women).
5. Alcohol:
— Alcohol intake is not recommended in diabetic 
patients;
— Patients should be informed that alcohol inhibits 
hepatic glucose release and thus its intake (parti-
cularly without food) may predispose to hypogly-
cemia;
— Acceptable levels of alcohol intake are ≤ 20 g/day 
of ethanol in women and ≤ 30 g/day in men.
Alcohol should not be consumed by patients with 
dyslipidemia (hypertriglyceridemia), neuropathy, or a his-
tory or pancreatitis.
6. Salt:
— Salt intake from all sources should not exceed 5 g 
per day; 
— If reasonable, patients with hypertension may be 
advised more strict salt intake limitations accor-
ding to the DASH diet principles.
Dietary recommendations for special patient popula-
tions (e.g., pregnant women, children and adolescents, 
patients with established nephropathy etc.) are provided 
in the relevant chapters.
Physical exercise
Due to its pleotropic benefits, physical exercise is an 
integral part of comprehensive diabetes management. 
Physical exercise has a beneficial effect on insulin sens-
itivity, blood glucose control, and lipid profile, promotes 
body weight reduction, and exerts a beneficial effect on 
mood, even with subjects with depression.
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I.   General recommendations regarding physical 
exercise:
— Initially, moderate physical activity should be re-
commended, depending on the patient’s ability to 
exercise;
— For optimal effects, exercise should be regular, un-
dertaken at least every 2–3 days, preferably daily;
— Intensive physical activity should be preceded by 
a 5- to 10-minute warm-up and concluded with 
cool-down exercises;
— Physical exercise may increase the risk of acute or 
delayed hypoglycemia;
— Alcohol may increase the risk of hypoglycemia 
after exercise;
— Dehydration should be prevented when exercising 
in high ambient temperatures;
— The risk of foot damage during exercise (particu-
larly with coexisting peripheral neuropathy and 
a reduced pain perception) and the need for 
appropriate foot care and comfortable shoes sho-
uld be taken into account.
II.  Exercise intensity is determined by the physician 
based on the full clinical picture
The most appropriate form of exercise in patients 
with diabetes type 2 aged > 65 years and/or overweight 
is brisk walking (until panting) 3–5 times a week (approx. 
150 minutes/week).
Nordic walking is an appropriate form of exercise in 
overweight/obese subjects at any age.
Those without significant contraindications, espe-
cially in the younger age groups, should be encouraged 
to increased  physical activity , including sports. Such 
patients require additional education in the effect of 
glycemic induced by different types of physical activity 
(e.g. aerobic exercise, effort resistance, interval).
III.  Risks of physical exercise in diabetic patients
 1.  Hypoglycemia:
— Blood glucose level should be measured before, 
during, and after exercise;
— Before planned exercise, reduction of rapid/short-
-acting insulin dose by 30–50% (depending on 
individual response) should be considered if peak 
action of the drug would coincide with the exerci-
se or occur shortly afterwards;
— During treatment with insulin pump, it is recom-
mended to reduce basal insulin rate by 20–80%, 
depending on the intensity and duration of exer-
cise, preferably 2 hours before exercise;
— Before unplanned exercise, an additional portion 
of simple carbohydrates should be consumed (20–
–30 g per 10 minutes of exercise), and a reduction 
of post-exercise insulin dose should be considered;
— Insulin injections into the limbs about to exercise 
should be avoided if exercise commences within 
30–60 minutes after the injection.
 2.  Metabolic decompensation:
— Very intensive, short-lasting exercise (> 90% 
VO2max) and exercise in hypoxic conditions (e.g., 
high-altitude climbing) may lead to hypoglycemia 
and acidosis;
— If blood glucose level exceeds 250 mg/dL (13.9 
mmol/L), urine testing for ketone bodies is indica-
ted in patients with diabetes type 1, and exercise 
should be avoided if ketonuria is found;
— Patients with diabetes type 2 should consider a si- 
milar limitation if blood glucose level exceeds 300 
mg/dL (16.7 mmol/L);
 3.  In some circumstances, strenuous exercise may have 
a negative effect on the general health status of the 
patient:
— Diabetic proliferative retinopathy — risk of  vitreous 
body bleeding and retinal detachment;
— Diabetic nephropathy — increase in albuminuria/ 
/proteinuria;
— Autonomic neuropathy — risk of orthostatic hypo-
tension;
— Risk of myocardial ischemia.
Tobacco control
 1.  In all current or former smokers, determine:
— Age at which the patient began smoking;
— Duration of smoking;
— Number of cigarettes smoked;
— Any attempts to quit smoking and duration of 
abstinence;
— Duration of current abstinence.
 2.  Counselling:
— Explanation of the risks associated with smoking 
to non-smokers;
— Advice to quit smoking;
— Patient support in the decision to quit smoking;
— Psychological and pharmacological support if 
needed;
— Discussion regarding smoking during each visit;
— If the patient refuses to quit smoking, this should 
be documented in the medical records.
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The mental state of the patient affects nearly all 
aspects of the management. Non-compliance to treat-
ment is commonly associated with psychological prob-
lems which require identification and appropriate psy-
chotherapeutic interventions. For this reason, education 
limited to providing the patient with information regar-
ding prescribed therapy and other therapeutic recom-
mendations is not very effective. The mental state of the 
patient should be evaluated at the treatment initiation 
and during every visit. Use of appropriate questionnaires 
and tests is recommended.
 1.  Psychological support should include:
— Adequate communication with the patient;
— Continuous evaluation (monitoring) of the mental 
state and compliance to treatment, along with 
psychological interventions.
 2.  The goals of individualized approach to the patient 
include:
— Consideration of the patient’s psychosocial status 
and planning treatment which in the patient’s 
opinion may be realistically undertaken in his or 
her life situation (which is of major importance 
for setting the therapeutic plan that will be both 
optimal and realistic);
— Developing motivation to engage in optimal ma-
nagement;
— Avoidance of frightening the patient with adverse 
consequences of non-compliance to therapeutic 
recommendations which is ineffective and harmful 
in most cases;
— Implementation of effective education based on 
the psychological diagnosis.
3. Evaluation of the psychological/mental state (psycho-
logical diagnosis) in diabetic patients includes the 
following aspects:
I. Social and psychological situation.
II. Patient’s quality of life.
III. Attitudes, beliefs, concerns, and duties related to 
diabetes (unjustified worries and concerns may 
reduce the ability to cope with the disease). Ask 
the following question:
 To what degree do you worry about the future 
and the possibility that severe complications will 
develop: (0) It is not an issue at all; (1) It is a minor 
issue; (2) It is a moderately important issue; (3) It is 
quite an important issue; (4) It is a very important 
issue. A score of 3 or more indicates a high risk of 
developing psychosocial problems.
IV. Sense of control over the disease. Lacking sen-
se of control over the disease results in choo-
sing approaches to cope with the disease-
-related stress that are characterized by avo-
idance of thoughts about the disease and/ 
/or reducing emotions provoked by the disease.
V. Evaluation of the ability to cope with the disease 
(a trend to reduce search for the optimal coping 
strategy and focus on solving disease-related 
problems is seen).
VI. Evaluation of depressive symptoms (depression 
often coexists and increases the risk of diabetic 
complications).
A.  Use tools available freely online to screen for depres-
sion: the Well-being index WHO-5, www.who-5.org 
(score < 13 indicates the need to investigate for de-
pression, and score ≤ 7 indicates a high risk of depres-
sion) or the Patient Health Questionnaire PHQ-9, www.
phqscreeeners.com/overview/aspx (score < 5 is normal, 
5–9 indicates mild depression, 10–14 indicates mo-
derate depression, 15–19 indicates moderately severe 
depression, and 20–27 indicates severe depression).
OR
B.  Ask two questions:
Did you often feel depressed or hopeless during the 
last month?
Did you often lack an interest in undertaking various 
activities or a feeling of pleasure during these activities?
A positive answer to one of these questions has 
a sensitivity of 97% and a specificity	of	67% for the 
diagnosis of depression. In these circumstances, the pa-
tient should be referred to a psychiatrist.
VII. Evaluation of anxiety symptoms, addictions, eat-
ing disorders, reduced cognition (these may signi-
ficantly impair adaptation to diabetes).
 4.  Psychological interventions in diabetic patients include:
— Developing the sense of control over the disease 
by:
7. Psychological management in diabetes
Most important recommendations
•  The mental condition of the patient should be evaluated at the initiation of diabetes treatment and during each 
subsequent visit. [B] 
•  Depression often coexists with diabetes and significantly increases the risk of diabetes complications. [B]
•  Diabetic patients should be evaluated for anxiety symptoms, addictions, eating disorders, and cognitive dysfunc-
tion. These conditions may significantly impair their adaptation to the disease. [B]
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• Providing the patient with comprehensible infor-
mation regarding the disease and its treatment,
• Collaborative development of therapeutic goals 
and plans which are realistic from the patient’s 
perspective,
• Gradual achievement of therapeutic goals 
(small steps strategy),
• Offering help in case of treatment failures (so 
the patient knows that the physician will help 
him determine the cause of failure without any 
negative attitude);
— Developing and maintaining diabetes coping skills 
focused on solving disease-related problems.
representing various medical professions, should also 
participate in education. Both educational programs 
for subjects with newly diagnosed diabetes and rein-
forcement programs for patients with long-standing 
diabetes are needed. It is necessary to offer education 
to patients’ family members and caretakers of chil-
dren and elderly with diabetes.
 3. Modern technologies (DVD, Internet) should be used 
for educational purposes.
 4. Education should focus on setting individual diabetes 
management goals, taking into account problems 
specific for a given person. The educational program 
should include developing skills to influence the co-
urse of the disease, as the knowledge itself is not 
sufficient for optimal diabetes management.
 5.  Diabetes education in children and adolescents sho-
uld be tailored to their intellectual capabilities, age, 
and needs.
 III.  Framework educational program should include 
the following components:
 1. Support regarding disease acceptance, increasing 
appropriate motivation for treatment, and increasing 
patient empowerment.
 2. Setting and evaluating individual therapeutic goals 
based on the disease course, prognosis, recommen-
ded treatment, and personal situation of the patient.
 3. Basic information about the disease and its treat-
ment (causes, clinical characteristics, course and pro-
gnosis, etc.)
 4. Teaching the techniques of systematic self-monitoring 
of blood glucose, ketone bodies, blood pressure etc., 
and how to manage situations when an intervention 
is necessary.
 5. Teaching the techniques of insulin administration 
(factors affecting the rate of insulin absorption, sites 
of insulin administration, appropriate needle length, 
prevention of insulin-induced lipodystrophy).
 5.  Clinically severe depression (depressive episode, dys-
thymia) and other mental health problems require 
psychiatric consultation. In case of maladaptation 
to the disease, psychotherapeutic intervention may 
be undertaken by a primary care physician or a spe-
cialist. Help of a clinical psychologist is necessary in 
more complex cases.
 6.  Teamwork
Cooperation of the whole therapeutic team is an 
important prerequisite of treatment success. Effective 
communication between team members is required. In 
diabetes clinics, a psychologist is a necessary member of 
the specialist therapeutic team.
8. Education
 I. Education is targeted at subjects at an increased 
risk of diabetes, subjects with prediabetes, and tho-
se treated for diabetes, and their carers and family 
members. Education is a constant, integral, and 
necessary component of diabetes management du-
ring each visit. In addition, it should be undertaken 
in a structured way, including education at the time 
of treatment initiation, followed be reinforcements 
based on regular evaluation of the patient’s educa-
tional needs or if requested by the patient.
 1. The educational program should be developed in 
cooperation with the patient and the treating physi-
cian and be closely associated and coordinated with 
the recommended treatment approach. The patient 
is an active member of the therapeutic team.
 2. The goal of patient education is to support self-mana-
gement and lifestyle modifications based on the re-
commended diet and physical activity. Management 
of obesity is a particularly important issue in diabetes 
type 2.
 II. Effectiveness of self-management programs has 
been documented. They actively engage partici-
pants in the learning process, adjusting the con-
tent and form to the individual situation and per-
sonal experiences of the participants, and motivate 
them to set personal behavioral treatment targets, 
developed in cooperation with the physician.
 1. Strategies to integrate diabetes self-management 
with everyday life activities are recommended. Their 
goals are to increase patients’ empowerment by di-
scovering and using their natural and acquired abili-
ties to take responsibility for their own life.
 2. It is recommended to provide individualized educa-
tion along with group educational programs. Educa-
tion should be provided by an appropriately trained 
personnel (physicians, diabetes educators, nurses, 
dieticians). Other members of the therapeutic team, 
A18
Clinical Diabetology 2017, Vol. 6, Suppl. A
 6. For patients treated with a personal insulin pump: 
advantages and disadvantages of and indications and 
contraindications to insulin pump therapy, principles 
of programming and modifying basal infusion rate, 
temporary changes of the basal infusion rate, use 
of single, delayed, and combination boluses, use of 
a bolus calculator, setting an infusion system (how 
to choose the injection site), use of CGM and pro-
per interpretation of glucose level readings, what 
to do in case of an insulin pump failure — return to 
treatment using insulin pens, management of initial 
symptoms of ketoacidosis, principles of withholding 
insulin infusion in special situations (e.g., sport), 
technical aspects of insulin pump use, calculation of 
carbohydrate and protein-fat exchanges, achieving 
appropriately balanced meal composition, maintain-
ing an electronic self-control diary.
 7. Information about the appropriate use of indepen-
dent and integrated insulin pump intergrated with 
continuous glucose monitoring (CGM) system — the 
backward and in real time, about their functions, set-
ting alarms for hypo- and hyperglycemia, dynamics of 
trend changes, and interpretation of CGM results for 
the current therapy.
 8. Information about diagnosing and treating compli-
cations, both acute (hypoglycemia, infections, my-
ocardial infarction, stroke, etc.) and chronic (nephro-
pathy, retinopathy, neuropathy, erectile dysfunction, 
diabetic foot), along with their risk factors (hyperlipi-
demia, hypertension, smoking, etc.) and approaches 
to prevent complications and diseases related to dia-
betes.
 9. Information about healthy nutrition and its role in the 
management (including practical information about 
carbohydrate content in foods and creating a nutri-
tional plan based on individual habits, needs, and 
therapeutic strategies, etc.).
 10. Information about the effect of physical exercise on 
the regulation of blood glucose (hypo- and hypergly-
cemia, etc.).
 11. Information about managing special situations (tra-
vel, contraception, pregnancy).
 12. Information about social rights of diabetic patients 
(work, driving license, insurance, etc.).
 13. Principles of healthcare utilization (visit frequency, 
follow-up evaluations), optimal compliance to treat-
ment recommendations.
 14. Discussion of the importance of psychological prob-
lems in the management of diabetes and opportuni-
ties for specialist care.
 IV.  Duration of the initial education should be at least 
5 hours in diabetic patients treated with diet or 
diet and oral antidiabetic agents, about 9 hours 
in patients treated with insulin, and 9–15 hours in 
patients treated with a personal insulin pump, de-
pending on the settings of care (outpatient or in-
patients), patient situation, and facility resources. 
Diabetes education should be initiated in each 
patient as early as possible after the diagnosis is 
made and continued during further follow-up, for 
a total of 5–9 hours in patients with diabetes type 
1 and at least 7–14 hours in patients with diabe-
tes type 2. During subsequent years, duration of 
education must depend on the knowledge alrea-
dy absorbed by the patient, number of previous 
errors, and the type of developing complications 
and concomitant disorders.
 V.  It is recommended to introduce new educational 
programs	of	proven	efficacy,	confirmed	by	study	
findings.
 VI.  Education delivered by physicians, nurses, diabetes 
educators, and dieticians should be undertaken in 
parallel to drug treatment, taking into the account 
the above mentioned time constraints, which requi-
res separate funding within specifically defined and 
contracted services.
VII. Every education program should be based on the 
principle of professional diabetologist-patient com-
munication. Its goal is to achieve trust, empathy, 
and motivation for strict compliance with therapeutic 
recommendations.
VIII. Standard requirements for an education center:
 1. Documentation of the educational activities inclu-
ding: framework educational program and training 
sessions undertaken with each patient, identification 
of the local education coordinator, and education-
-related duties of the healthcare personnel and indi-
vidual patient education charts.
 2. Periodic (at least once a year) evaluation of the 
patient’s self-management of diabetes.
 3. Providing patients with an opportunity for periodic 
(at least once a year) evaluation of the quality of 
education delivered in a given center.
 4. Improving skills of the personnel delivering education 
(participation in education courses, providing up-to-
-date knowledge).
 5. Consideration of patient evaluation of the quality of 
the education delivered.
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9. General principles of the management of diabetes type 1
Management of diabetes type 1
—  Insulin therapy is absolutely required in patients with 
diabetes type 1. Insulin therapy should be continued 
even in the remission phase.
—  The recommended treatment approach is in-
tensive insulin therapy using multiple subcuta-
neous insulin doses or CSII using a personal insu-
lin pump. A prerequisite for effective treatment 
is appropriate education (as outlined in Chap-
ter 8), allowing self-adjustments of insulin doses 
by the patient based on systematic BGSM using 
a glucose meter (as outlined in Chapter 3).
—  In patients with diabetes type 1, use of insulin ana-
logs is preferred due to a lower risk of hypoglycemia 
and better quality of life.
—  Optimization of insulin dose is important in insulin 
therapy for diabetes type 1. Long-term use of supra-
physiological amounts of insulin without attempts to 
identify causes of high insulin requirement and treat 
the underlying problem — except for specific situations 
(acute illness, medications increasing insulin require-
ment, stress) — may lead to adverse metabolic conse-
quences including excessive body weight increase.
—  A key element of therapy for diabetes type 1 is the 
patient’s ability to modify insulin doses based on 
meal calorie content (based on calculating carbohy-
drate and protein-fat exchanges) and planned intens-
ity of physical activity.
—  Use of CGM is indicated with recurrent episodes of 
severe hypoglycemia or large circadian variation of 
blood glucose levels.
—  Systematic physical exercise should be an integral 
part of the management of diabetes type 1.
Organization of care for patients with diabetes type 1
—  Patients with diabetes type 1 should be cared for 
by a diabetes specialist since the very diagnosis of 
diabetes type 1 and afterwards. Such a management 
approach allows continuous collaboration with an 
education team (as outlined in Chapter 5) and access 
to necessary consultations.
—  New diabetes type 1 cases and difficult-to-treat acute 
diabetes complications require admission to the ho-
spital at diabetes care unit.
Goals of diabetes type 1 management
The goal of diabetes type 1 management is to achieve 
good metabolic control with blood glucose levels as close 
to normal values as possible and HbA1c ≤ 6.5% unless 
associated with episodes of hypoglycemia or reduced 
patient quality of life. In other cases, the therapeutic goal 
should be HbA1c ≤ 7.0%.
Only such a management approach may prevent acu-
te and chronic complications and allow patient to enga-
ge in normal, active family, professional, and social life.
Early diagnosis of chronic diabetes complications
—  Early diagnosis of diabetes complications is possible 
with screening for nephropathy, retinopathy, and neu-
ropathy. Screening for these complications in patients 
with diabetes type 1 is outlined in Chapters 18–20.
—  In patients with long-lasting diabetes type 1, dia-
betic macroangiopathy manifesting as ischemic he-
art disease, cerebrovascular disease, or peripheral 
arterial disease may develop earlier compared to the 
general population. Principles of diagnosing and tre-
ating ischemic heart disease are discussed in Chapter 
16, and management of stroke and acute coronary 
syndrome is outlined in Chapters 17 and 16.1, re-
spectively.
Diagnosis and management of acute complications
—  An adequately educated patient with diabetes type 
1 must know how to treat acute mild to moderate 
hyper- and hypoglycemia and should be able to ma-
nage these conditions independently. More severe 
conditions require medical intervention as outlined 
in Chapters 14 and 15.
Special situations in subjects with diabetes type 1
—  Patients with diabetes type 1 and good metabolic 
control, treated with intensive insulin therapy, may 
Most important recommendations
• The recommended treatment approach is intensive insulin therapy using multiple subcutaneous insulin doses or 
continuous subcutaneous insulin infusion (CSII) using a personal insulin pump. [A]
• A key element of therapy for diabetes type 1 is the patient’s ability to modify insulin doses based on carbohydrate 
meal content, baseline blood glucose level, and planned physical activity. Knowledge of the effect of protein and 
fat on blood glucose level is also important for optimization of insulin dosage. [E]
• In patients with diabetes type 1, use of insulin analogs is preferred due to a lower risk of hypoglycemia and better 
quality of life. [A]
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be subjected to one-day surgery (minor surgical pro-
cedures). Other principles of perioperative manage-
ment in patients with diabetes type 1 are outlined in 
Chapter 25.
—  Compared to the general population, diabetes type 1 
is more commonly accompanied by endocrino-
pathies, in particular autoimmune disease of the thy-
roid (Hashimoto disease, Graves disease) and adrenal 
cortex (Addison disease), celiac disease, vitamin B12 
deficiency anemia (Addison-Biermer anemia), and 
connective tissue disease. These comorbidities may 
significantly worsen the course of diabetes type 1. 
Development of diseases that complicate the meta-
bolic derangements of diabetes requires admission 
to a specialist unit.
—  Obesity with concomitant insulin resistance may be 
present in subjects with diabetes type 1, resulting in 
an increased insulin requirement and worsened me-
tabolic control. Diagnosis and management require 
specialist investigations and therapy.
—  Eating disorders including bulimia and anorexia are 
increasingly common in young patients with diabetes 
type 1. Diagnosis and management of these condi-
tions require specialist psychiatric treatment in close 
collaboration with a diabetes specialist.
A well-educated patient with diabetes type 1, tre-
ated with intensive insulin therapy with good meta-
bolic control, is able to engage in the same physical 
activity and achieve similar professional goals as non-
-diabetic subjects of similar age.
10. Oral antidiabetic agents and GLP-1 receptor agonists  
in the management of diabetes type 2
Lowering hyperglycemia by comprehensive manage-
ment of diabetes type 2 (in addition to treating hyper-
tension and dyslipidemia, lifestyle changes, antiplatelet 
treatment etc.) is of key importance for preventing and 
delaying progression of chronic complications of diabe-
tes (both macro- and microvascular).
I.   Lowering hyperglycemia occurs by correcting 
both pathogenetic mechanisms of diabetes type 
2, i.e. insulin resistance and impaired insulin se-
cretion. Treatment of diabetes type 2 must be 
gradual and adapted to the progressive nature of 
the disease. If the therapy used at a given stage is 
no longer effective, i.e., target HbA1c level cannot 
be reached, treatment should proceed to the next 
step after 3–6 months.
II.   Management of diabetes type 2
  Step 1. Monotherapy:
— Lifestyle modification (body weight reduction, 
increasing physical activity to 30–45 minutes/day), 
reduction of meal calorie content in combination 
with treatment with metformin;
— To minimize the risk of adverse effects of metformin, 
mostly gastrointestinal complaints, therapy should 
be started with small doses which are then gradual-
ly increased to the maximum tolerated dose;
— If metformin is not tolerated or contraindicated, 
therapeutic options included sulphonylureas or 
DPP-4 inhibitors (using drugs that have been 
approved for monotherapy), sodium-glucose 
transport protein 2 (SGLT-2) inhibitors, and pe-
roxisome proliferator activated receptor gamma 
(PPAR-g) agonists (pioglitazone); in such cases, 
DPP-4 inhibitors and SGLT-2 inhibitors should be 
preferred in obese subjects and those at a high risk 
Most important recommendations
• Metformin should be the first choice drug when initiating drug therapy of diabetes type 2 unless it is contraindi-
cated or poorly tolerated. [A]
• If monotherapy using maximum recommended or tolerated doses becomes insufficient to achieve or maintain target 
HbA1c level, another oral agent, GLP-1 agonist, or basal insulin should be added. This decision should not be postponed 
by more than 3–6 months. [A]
• The choice of further drugs should be individualized, taking into account their effectiveness, side effects, the effect 
on body weight, risk of hypoglycemia, cost, and patient preferences. [E]
• In patients with cardiovascular disease, particularly previous myocardial infarction, drugs with an established 
beneficial effect on the cardiovascular risk should be considered first. In addition to metformin, such effect was 
shown for some GLP-1 agonists and one SGLT-2 inhibitor. Lack of drug cost reimbursement may be a barrier for 
using these drugs in Poland. [A]
• Due to progressive nature of diabetes type 2, insulin therapy is indicated in many patients when the treatment is 
gradually intensified. [B]
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of hypoglycemia, and a PPAR-g agonist should not 
be used in patients with heart failure;
— Therapeutic effectiveness of the oral therapy used 
may be assessed only after several weeks of treat-
ment.
  Step 2. Combined oral therapy:
— Option 2a: Lifestyle modification and adding sulp-
honylurea, incretin-based therapy (DPP-4 inhibitor 
or GLP-1 receptor agonist), a SGLT-2 inhibitor, or 
a PPAR-g agonist to metformin;
— Option 2b: Lifestyle modification and three-drug the-
rapy including metformin (in all cases) and two other 
agents with different mechanisms of action from the 
following classes: sulphonylureas, a-glucosidase in-
hibitors (acarbose), DPP-4 inhibitors, GLP-1 receptor 
agonists, SGLT-2 inhibitors, and PPAR-g agonist.
It also possible to add basal insulin to metformin, 
i.e. switching from Step 1 directly to Step 3 treatment, 
bypassing Steps 2a and 2b.
  Step 3. Lifestyle modification and simple insulin the-
rapy [mostly with basal insulin (NPH insulin, long-
-acting insulin analog); various regimens — see Chap - 
ter 11], possibly with continuation of metformin the-
rapy, particularly with continuing overweight.
  Step 4. Lifestyle modification and complex insulin 
therapy, possibly with continuation of metformin 
therapy, particularly with continuing overweight (see 
Chapter 11).
If lifestyle modification and complex insulin thera-
py combined with metformin therapy does not allow 
achieving the desired degree of metabolic control, incre-
tin-based therapy (DPP-4 inhibitor or GLP-1 receptor 
agonist), a SGLT-2 inhibitor, or a PPAR-g agonist may be 
added.
 III.  Agents used for the treatment of diabetes type 2 
are listed in Table 10.1. Their effect on non-glycemic 
parameters (i.e., cardiovascular risk, body weight, 
risk of hypoglycemia, lipid parameters, etc.) should 
be taken into account when selecting and combi-
ning drugs, with due attention paid to treatment 
individualization (see Chapter 4.I.3). Data from large 
randomized clinical trials indicate a reduction of total 
and cardiovascular mortality with the use of GLP-1 
agonists and SGLT-2 inhibitors.
IV.  Practical algorithm of drug treatment for diabetes 
type 2 is shown in Figure 10.1.
Figure 10.1. A practical management algorithm for diabetes type 2
SU — sulphonylurea; SGLT-2 — sodium-glucose transport protein 2
alifestyle modification recommended at each step
bif metformin not tolerated or contraindicated
cglucagon-like peptide 1 (GLP-1) receptor agonist or gliptin
din addition to metformin, other oral drugs may also be combined with insulin if licensed for such treatment
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Insulin therapy in patients with diabetes type 1
In patients with diabetes type 1, insulin therapy is the 
only treatment approach. Intensive insulin therapy with 
multiple injections or CSII is recommended, using insulin 
pens or personal insulin pump. In patients with diabetes 
type 1, insulin analogs are preferred due to a lower risk 
of hypoglycemia.
Insulin therapy in patients with diabetes type 2
Diabetes type 2 is a progressive disease. Increasing 
underlying pathophysiologic disturbances, particularly 
the beta cell defect, result in a need for gradual treat-
ment intensification, including initiation of insulin ther-
apy (see Chapter 10). Insulin therapy is often needed to 
achieve normoglycemia.
I.   Criteria of initiating insulin therapy in diabetes 
type 2:
— Newly diagnosed diabetes (with an option to re-
turn to the typical treatment algorithm):
• Blood glucose ≥ 300 mg/dL (16.7 mmol/L) with 
concomitant clinical symptoms of hyperglyce-
mia;
— Treatment ineffectiveness without use of insulin 
(HbA1c > 7% despite intensified behavioral therapy)
II.   Indications for switching from previous glu-
cose-lowering therapy (using oral  antidiabetic 
agents, in some cases in combination with 
a GLP-1 receptor agonist) to combined therapy 
including insulin if blood glucose remains un-
controlled:
— Continuing hyperglycemia as confirmed on several 
occasions;
And
— Unsuccessful attempts to eliminate potentially cor-
rectable causes of hyperglycemia, such as:
• Dietary errors;
• Too low physical activity;
• Irregular intake of oral antidiabetic agents 
(poor compliance);
• Infections;
• Inadequate doses of oral agents.
III.   Indications for initiating insulin therapy regard-
less of blood glucose levels:
— Pregnancy;
— Autoimmune-mediated diabetes in adults (type 1/ 
/LADA);
— Diabetes associated with cystic fibrosis;
— Reasonable patient’s request.
In overweight or obese patients with LADA, metfor-
min use combined with insulin therapy is beneficial.
IV.   Indications for temporary insulin therapy:
— Diabetes decompensation due to transient causes 
(infection, trauma, glucocorticoid therapy, etc.);
— Surgical procedure (see Chapter 25);
— Stroke (see Chapter 17);
— Percutaneous coronary intervention (PCI);
— Acute coronary syndrome;
— Other acute illness requiring admission to an in-
tensive care unit.
V.   Insulin therapy algorithm
 1.  Long-acting insulin (isophane — NPH or long-acting 
insulin analog) in one daily injection:
— With morning hyperglycemia — in the evening; 
use of long acting analogues reduces the risk of 
nocturnal and severe hypoglycemia;
— With fasting and daytime hyperglycemia — in the 
morning (consider multiple injections of a short/ 
/rapid-acting insulin if postprandial hyperglycemia 
is noticed).
In selected cases, when initiation of insulin therapy 
was long overdue, resulting in severe hyperglycemia and 
HbA1c levels much above the therapeutic target, initia-
tion of mixed insulin therapy or intensive insulin therapy 
should be considered as the initial treatment option, 
particularly in relatively young patients with long life 
expectancy. Currently, no convincing evidence exists for 
better effectiveness or safety of mixed human insulins or 
insulin analogs. The choice of a particular insulin prepara-
tion should be made individually, taking into account pa-
tient’s preferences regarding the number of daily meals.
 2.  Initial dose is 0.1–0.2 unit/kg or 10 units.
 3.  Oral agents and incretin-based therapies may be used 
according to the registration in subjects treated with 
insulin:
— In case of concomitant obesity, combined therapy 
including insulin and metformin or a-glucosidase 
inhibitors, or an incretin-based therapy, or a SGLT-2 
inhibitor.
— With normal body weight, combination with a sul-
phonylurea may be considered.
 4.  Blood glucose control should be evaluated within 
4–5 days, with gradual dose increments by 2–4 units 
based on SBGM readings until adequate control.
 5.  If daily basal insulin requirement is > 30 units and gly-
cemia is poorly controlled, treatment intensification 
may be considered using mixed insulin or biphasic 
insulin analog; it may also be considered to supple-
11. Insulin therapy
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ment long-acting insulin (administered once or twice 
daily) with a short-acting insulin/rapid-acting insulin 
analog administered at 1–3 meals (basal-plus insulin 
regimen, intensive insulin therapy). Discontinuation of 
insulin secretagogues should be considered.
 6.  If large daily insulin doses are used (> 100 units), in-
dicating insulin resistance, causes of the latter should 
be considered and the possibility of adverse effects 
should be taken into account.
An attempt to reduce the degree of insulin resistance 
by a 72- to 96-hour continuous subcutaneous or intrave-
nous insulin infusion is recommended.
Intensive insulin therapy
Intensive insulin therapy is undertaken based on 
similar principles in all types of diabetes, using multiple 
daily insulin injections, or by CSII using a personal insulin 
pump.
I. Principles of intensive insulin therapy:
— Daily SBGM;
— Self-adjustment of insulin doses or administering 
additional insulin doses depending on blood glu-
cose readings, energy requirement, and physical 
activity;
— Precise definition of target blood glucose levels;
— Appropriate therapeutic and nutritional education 
and patient motivation;
— Possibility of a rapid patient contact with the ther-
apeutic team;
— In diabetes type 2, CSII using a personal insulin 
pump is not a routine treatment approach.
II. Algorithms of multiple insulin injections:
— Short-acting insulin or rapid-acting insulin analog 
before meals; and
— Isophane insulin (NPH) or long-acting insulin ana-
log to provide constant basal insulin levels admin-
istered before bedtime and/or in the morning.
In some cases of diabetes type 2 with normal fasting 
blood glucose levels, short-acting insulin injections or 
insulin analog at mealtimes may be sufficient.
III. Personal insulin pump treatment algorithm
Therapy with personal insulin pumps should be un-
dertaken in centers experienced in such treatment. This 
approach is used in diabetes type 1 and some other spe-
cific diabetes types (e.g. diabetes associated with cystic 
fibrosis).
 1.  Indications:
— Need for small insulin doses (e.g., in children);
— Recurrent, unpredictable hypoglycemia episodes;
— Hypoglycemia unawareness;
— Irregular lifestyle and meals;
— Early-morning hyperglycemia;
— Pregestational diabetes mellitus which is difficult 
to control with multiple insulin injections;
— Patient preference if costs incurred by this treat-
ment approach are accepted.
 2.  Contraindications:
— Low intellectual or educational level of the patient;
— Lack of patient compliance;
— No contact with a specialist clinic.
12. Treatment of hypertension in diabetic patients
Most important recommendations
• The aim for blood pressure in patients with diabetes is < 140/90 mm Hg. [A]
• The drug of first choice in the treatment of hypertension in patients with diabetes are drugs blocking of the re-
nin–angiotensin–aldosterone system. [A]
• Pharmacological treatment of hypertension should be continued without interruption, because it is the only way 
to reduc cardiovascular risk. [A]
• In the treatment of hypertension patients with diabetes should strive not only to achieve the target blood pressure, 
but also to maintain or restore normal diurnal variation in blood pressure assessed by 24-hour monitoring. [B]
In patients with diabetes, initiation of drug treat-
ment is recommended if blood pressure is above 
140/90 mm Hg. The goal of treatment is to reduce the 
global cardiovascular event risk by lowering systolic 
blood pressure below 140 mm Hg, while the optimal 
diastolic blood pressure is 90 mm Hg.
I. Principles of blood pressure measurement
Blood pressure should be measured during each visit, 
also in the standing position to evaluate orthostatic blood 
pressure falls. Home blood pressure measurements are 
recommended in all patients with the diagnosis of hy-
pertension. In patients with systolic blood pressure ≥ 
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140 mm  Hg or diastolic blood pressure ≥ 90 mm Hg, 
measurement should be repeated on another day, and 
out-of-office blood pressure measurements should be rec-
ommended. Systolic blood pressure ≥ 140 mm Hg or dia-
stolic blood pressure ≥ 90 mm Hg during repeated mea-
surements confirms the diagnosis of hypertension. In case 
of diagnostic uncertainties, 24-hour ambulatory blood 
pressure measurement (including evaluation of night-time 
blood pressure values) is useful, along with home blood 
pressure measurements performed by the patient.
II. Principles of antihypertensive therapy:
— Drug treatment should be combined with lifestyle 
changes in all patients with hypertension;
— Drug treatment should be started with lowest 
doses available to minimize adverse effects;
— If the target blood pressure has not been reached, 
the dose of a single drug may be increased to 
a medium dose; if the treatment is still unsuccess-
ful, a second drug from another class should be 
added; maximum drug doses should not be used;
— The presence of proteinuria does not change pre-
defined blood pressure goal;
— In stage 2 and 3 hypertension, treatment is initiated 
with two drugs, with an option to increase the dose 
of one or two drugs to the maximum dose, particu-
larly if the systolic/diastolic blood pressure exceeds 
the recommended target value by ≥ 20/10 mm Hg;
— Effective combined therapy should include drugs 
of different classes with different mechanisms of 
action to achieve an additive blood pressure-low-
ering effect; preferred combinations: an angioten-
sin-converting enzyme inhibitor (ACEI) + calcium 
antagonist (a metabolically neutral combination); 
ACEI + thiazide/thiazide-like diuretic, angiotensin 
receptor blocker (ARB) + thiazide/thiazide-like di-
uretic, ARB + calcium antagonist (a metabolically 
neutral combination);
— A combination of an ACEI and a beta-blocker is 
commonly used in patients with hypertension and 
cardiac disease (ischemic heart disease, heart fail-
ure);
— Combinations of drugs with similar mechanisms 
of action are of little value, as the blood pres-
sure-lowering effect is less than additive or an 
increased risk of adverse effects exists;
— If a given drug if not effective or not tolerated by 
the patient, substitution with a drug from another 
class is recommended before the dose is increased 
or another drug is added;
— Use of fixed-dose combinations increases compli-
ance;
— A drug from another class should be added if tar-
get blood pressure has not been reached despite 
two-drug treatment (one of the drugs used should 
be a diuretic);
— In case of a non-dipping nocturnal blood pressure 
pattern or a morning blood pressure surge, modi-
fication of the timing of antihypertensive drug 
administration should be considered;
— Long-acting antihypertensive drugs which allow 
24-hour blood pressure control with once daily 
dosing should be preferred;
— Serum creatinine, potassium, and glomerular fil-
tration rate (GFR) should be monitored during 
treatment with ACEI, ARB, renin inhibitors, and 
diuretics;
— In patients aged > 65 years, blood pressure should 
be lowered gradually to avoid treatment complica-
tions.
III. Choice of blood-pressure lowering drugs
An effective treatment resulting in normalization 
of blood pressure is more important for the preven-
tion of cardiovascular complications than the choice 
of drugs:
— Drug treatment may be initiated with an ACEI, 
ARB, diuretic, beta-blocker (vasodilating beta- 
-blockers are preferred if no compelling indica-
tions are present that would suggest otherwise), 
or a cal cium channel blocker;
— Renin-angiotensin-aldosterone (RAA) system in-
hibitors should be preferred if albuminuria/pro-
teinuria is present;
— Combined treatment with ACEI and ARB is contra-
indicated;
— Combined treatment may include drugs from the 
above listed and other drug classes, taking into 
account the principles of combining antihyperten-
sive drugs;
— Drug treatment of hypertension in patients with 
concomitant renal dysfunction — see Chapter 18;
— In patients aged > 55 years with concomitant 
cardiovascular risk factors, treatment with ACEI 
should be considered to reduce the cardiovascular 
risk regardless of blood pressure values;
— ACEI or ARB is recommended in normotensive sub-
jects with urinary albumin-to-creatinine ratio ≥ 30 
mg/g to prevent and delay progression of diabetic 
kidney disease;
— In patients with ischemic heart disease, previous 
myocardial infarction, or heart failure, beta-block-
ers and ACEI are reasonable as first-choice drugs 
to reduce mortality risk;
— Use of nonselective beta-blockers should be avoid-
ed with concomitant peripheral arterial disease;
— In case of coexistence of peripheral arterial disease, 
taking non-selective b-bleckers should be avoided;
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— Thiazide/thiazide-like diuretics should be used 
in patents with GFR ≥ 30 mL/min/1.73 m2, while 
a loop diuretic should be used if GFR is < 30 mL/ 
/min/1.73 m2.
Clinical studies indicate that use of at least two dif-
ferent antihypertensive drugs is necessary to reach thera-
peutic goals in more than 70–75% patients, and > 90% 
of the elderly patients. Often, this requires use of other 
drug classes in addition to those listed above (including 
alpha-blockers, centrally-acting drugs, and vasodilators).
Resistant hypertension, which requires multiple drug 
therapy, is common in diabetes. Testing for obstructive 
sleep apnea should be considered in diabetic patients 
with resistant hypertension.
Principles of diabetes management in children and 
adolescents, pregnant women and those contemplating 
pregnancy, and patients above 65 years of age — see 
Chapters on respective subjects. 
IV. Management of hypertension in pregnant women
The goal blood pressure is < 140/90 mm Hg but 
diabetic nephropathy in pregnant women is an abso-
lute indication to lower blood pressure below 130/80 
mm Hg.
In pregnant women with non-severe hypertension, 
oral drugs of choice are (in the order given) methydopa, 
labetalol, and calcium antagonists. In life-threatening 
situations, the preferred drugs are labetalol and nitro-
glycerin (administered parenterally). If these are not avail-
able, parenteral hydralazine may be used, although an 
increase in the rate of adverse effects in the perinatal 
period has been reported.
13. Treatment of dyslipidemia
The main goal is to reduce LDL cholesterol level, while 
non-HDL cholesterol level is a secondary therapeutic tar-
get. Complete normalization of the atherogenic lipid 
profile after achieving target LDL cholesterol level, i.e. in-
creasing HDL cholesterol level and decreasing triglyceride 
level, may be associated with beneficial effects.
Diabetic patients with vascular complications (previ-
ous myocardial infarction, acute coronary syndrome, cor-
onary revascularization or other revascularization proce-
dures, stroke, transient ischemic attack, aortic aneurysm, 
and peripheral arterial disease) or other cardiovascular 
risk factors, i.e. albuminuria, hypertension, hypercholes-
terolemia, smoking, or a family history of cardiovascular 
disease should be considered at very high cardiovascu-
lar risk. Patients without chronic diabetes complications 
and other cardiovascular risk factors are at high car-
diovascular risk. Only in young patients with diabetes 
type 1 without chronic diabetes complications and other 
cardiovascular risk factors, the risk is moderate or low.
I. Diagnosis of lipid disorders
History should include:
— Assessment of nutrition and alcohol intake;
— Assessment of physical activity — type and dura-
tion of activity;
— Presence of cardiovascular disease: ischemic heart 
disease, cerebrovascular disease, and peripheral 
arterial disease;
— Evaluation for thyroid, liver, and kidney disease to 
exclude secondary hyperlipidemia;
— Family history of lipid disorders, cardiovascular 
disease, hypertension, and diabetes in first-degree 
relatives;
— Use of drugs that may increase lipid levels.
Desirable levels of lipid parameters:
— LDL-C level < 70 mg/dL (1.9 mmol/L) or reduction 
by at least 50% if baseline LDL-C level is 70–135 
mg/dL (1.9–3.5 mmol/L) in diabetic subjects at very 
high cardiovascular risk;
— LDL-C level < 100 mg/dL (2.6 mmol/L) or reduction 
by at least 50% if baseline LDL-C level is 100–200 
mg/dL (2.6–5.2 mmol/L) in diabetic subjects at 
high cardiovascular risk;
— LDL-C level < 115 mg/dL (3.0 mmol/L) in subje-
cts at low or moderate cardiovascular risk (sub-
jects < 40 years of age with diabetes type 1 but 
Most important recommendations
• In all patients with diabetes type 1 and increased urinary albumin excretion and/or renal dysfunction, statin treat-
ment to reduce LDL-C level by at least 50% is recommended regardless of baseline LDL-C level. [C] 
• In patients with diabetes type 2 and cardiovascular disease or chronic kidney disease, or patients > 40 years of 
age without overt cardiovascular disease but with ≥ 1 cardiovascular risk factor or target organ damage, target 
LDL-C level during treatment is < 70 mg/dL. [B]
• In patients with diabetes type 2 without target organ damage and other cardiovascular risk factors, target LDL-C 
level is < 100 mg/dL. [B]
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without chronic complications and other cardiova-
scular risk factors);
— Non-HDL-C level < 100 mg/dL (2.6 mmol/L) in dia-
betic subjects at very high cardiovascular risk;
— Non-HDL-C level < 130 mg/dL (3.4 mmol/L) in dia-
betic subjects at high cardiovascular risk;
— Non-HDL-C level < 145 mg/dL (3.7 mmol/L) in 
subjects < 40 years of age with diabetes type 1 
but without chronic complications and other car-
diovascular risk factors;
— HDL-C: no target level but values > 1.0 mmol/L (> 
40 mg/dL) in men and > 1.2 mmol/L (> 45 mg/dL) 
in women indicate a lower risk.
Triglycerides: 
— No target level but values < 1.7 mmol/L (< 150 
mg/dL) indicate a lower risk.
LDL cholesterol level may be estimated using the 
Friedewald formula if triglyceride level is < 400 mg/dL 
(< 4.5 mmol/L) and LDL cholesterol level cannot be di-
rectly measured:
— LDL cholesterol [mmol/L] = total cholesterol 
[mmol/L] – HDL cholesterol [mmol/L] – triglycer-
ides/2.2 [mmol/L]
II. Lipid level monitoring
 1.  Diabetes type 2
— Lipid parameters should be measured at the time 
of the diagnosis of diabetes, with follow-up mea-
surements annually or more frequently, depending 
on the measured levels;
— If lipid parameters are above the normal values, 
these should be re-checked every 8–12 weeks af-
ter treatment initiation until the desired levels are 
reached;
— If lipid parameters are within the desired range, 
follow-up measurements should be performed an-
nually;
 2.  Diabetes type 1 (see also the respective chapter on 
diabetes type 1):
— If lipid levels indicate low risk, lipid parameters 
should be re-checked every 2–5 years, depending 
on the presence of other risk factors for cardiovas-
cular disease.
III. Treatment of dyslipidemia in diabetic patients
 1.  Lifestyle changes:
— Increase in physical activity;
— Body weight reduction in overweight and obese 
subjects;
— Cessation of tobacco smoking;
— Diet with a reduction of saturated fat intake to 
< 10% of the total calorie intake, reduced cho-
lesterol (< 300 mg/day or < 200 mg/day with 
increased LDL cholesterol levels), and maximum 
reduction of trans fat intake; intake of n-6 polyun-
saturated fatty acids should be 4–8% of the total 
calorie intake, and intake of n-3 polyunsaturated 
fatty acids should be 2 g of linolenic acid and 200 
mg/day of very long-chain fatty acids;
— In hypertriglyceridemia, reduction of obesity, 
reduced alcohol intake, reduced mono- and di-
saccharide intake (reduction of fructose intake), 
reduced saturated fat intake, adding monounsatu-
rated fats to diet, and reduction of carbohydrate 
intake are all of major importance.
 2.  Tight glycemic control
Tight glycemic control is of major importance for con-
trolling dyslipidemia, in particular hypertriglyceridemia.
 3.  Drug treatment
— Statins are first-line drugs in the treatment of dia-
betic dyslipidemia. They are recommended in all 
patients with diabetes type 2 or diabetes type 1 at 
the age of > 40 years. They may also be considered 
in subjects < 40 years of age if the risk is significan-
tly elevated due to the presence of microvascular 
complications or other cardiovascular risk factors. 
Drug treatment, mostly with statins, is used in:
— In diabetic patients with concomitant cardiovascu-
lar diseases;
— In diabetic patients with chronic kidney disease;
— In diabetic patients > 40 years of age without 
concomitant cardiovascular disease but with ≥ 1 
cardiovascular risk factor or markers of target or-
gan damage.
 Statin therapy should be considered in patients 
with diabetes type 1 or 2 aged 18–39 years wit-
hout concomitant cardiovascular disease in whom 
LDL-C level is > 100 mg/dL (> 2.6 mmol/L) or car-
diovascular risk in increased due to the presence 
of other risk factors (such as diabetic nephropathy, 
retinopathy, poor glycemic control, hypertension, 
positive family history of premature vascular 
disease) or long duration of diabetes.
— In diabetic patients with concomitant hypertriglyc-
eridemia ≥ 2.3 mmol/L (≥ 200 mg/dL) persisting 
despite attainment of the target LDL cholesterol 
level using a statin, an increase in statin dose 
should be considered to reduce non-HDL choles-
terol level which is a secondary therapeutic target. 
Combination treatment with a fibrate should be 
considered in selected cases;
— Statin treatment is contraindicated during preg-
nancy and breastfeeding.
 4.  Combined therapy
— In statin-treated patients with diabetes type 2 in 
whom triglyceride level is > 2.3 mmol/L (> 200 
mg/dL) and HDL cholesterol level is < 0.88 mmol/L 
(< 34 mg/dL), adding a fibrate to a statin is associ-
ated with an additional reduction of cardiovascu-
lar events;
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Figure 13.1. An algorithm for managing dyslipidemia in diabetes. TG — triglycerides; HDL-C — high-density lipoprotein chole-
sterol; LDL-C — low-density lipoprotein cholesterol
Table	13.1.	Indications	for	specific	intensities	of	statin	treatment	in	diabetic	patients
Age Risk factors Recommended statin dose
< 40 years No Not recommended
IHD risk factors* Moderate or high
IHD present** High
40–75 years No Moderate
IHD risk factors* High
IHD present** High
> 75 years No Moderate
IHD risk factors* Moderate or high
IHD present** High
IHD — ischemic heart disease
*IHD risk factors: low-density lipoprotein cholesterol ≥ 100 mg/dL (2.6 mmol/L), hypertension, smoking, overweight or obesity. **History of a cardiovascular 
event or current acute coronary syndrome
— Combined statin and ezetimibe treatment was as-
sociated with further LDL cholesterol level lower-
ing and a reduction in the cardiovascular event 
rate compared to statin monotherapy. Ezetimibe 
may thus be of use in patients in whom recom-
mended LDL cholesterol lowering has not been 
attained using a maximum tolerated statin dose 
or statin treatment is not tolerated.
Combined treatment with statins and other lipid-
lowering drugs (fibrates, ezetimibe, PCK9 inhibitors) me 
be useful to achieve target lipid parameters in diabetic 
patients but no large clinical trials have been conducted 
to confirm efficacy and safety of such treatment.
Combined therapy (mostly with statin + fenofibrate) 
is associated with an increased risk of abnormal liver 
function tests, myositis, and rhabdomyolysis, particularly 
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with concomitant chronic kidney disease and use of high 
drug doses.
 5.  Management of severe hypertriglyceridemia
A clinically significant risk of acute pancreatitis oc-
curs with triglyceride levels > 10 mmol/L (> 880 mg/dL). 
Hypertriglyceridemia underlies about 10% of acute pan-
creatitis cases, but pancreatitis may develop already with 
triglyceride levels > 5 mmol/L (> 440 mg/dL).
 Recommended management includes:
— Hospital admission in case of acute pancreatitis;
— Strict control of triglyceride levels:
• Reduction of the total calorie intake and fat 
intake (to 10–15% of the total calorie intake),
• Complete abstinence from alcohol,
• Therapy with fibrates.
In diabetic patients who are not treated with insulin, 
insulin therapy should be started to achieve optimal 
blood glucose control, most commonly using intravenous 
insulin pump. This approach allows reduction of triglyc-
eride levels within 2–5 days.
Principles of diabetes management in children and 
adolescents, pregnant women and those contemplating 
pregnancy, and patients above 65 years of age — see 
Chapters on respective subjects.
14. Hypoglycemia
I.		 	 Definition	of	hypoglycemia.	Hypoglycemia	is	di-
agnosed when blood glucose level falls below 70 
mg/dL (3.9 mmol/L) regardless of clinical symp-
toms which may occur only with lower blood 
glucose levels in some patients, particularly those 
with long-standing diabetes type 1 present for 
many years. Symptoms of hypoglycemia may also 
develop with higher blood glucose levels (> 100 
mg/dL) if a rapid decrease in blood glucose has 
occurred. So called hypoglycemia unawareness, 
defined	 as	 unawareness	 of	 pathologically	 low	 
(< 70 mg/dL, i.e. < 3.9 mmol/L) blood glucose 
levels,	 is	 a	 significant	 complication	 of	 frequent	
hypoglycemia episodes. Hypoglycemia unaware-
ness may also be due to autonomic neuropathy.
Blood glucose levels < 70 mg/dL (3.9 mmol/L) require 
counteracting further blood glucose lowering regardless 
of the presence or absence of clinical symptoms. This 
justifies setting the threshold for imminent hypoglycemia 
at 70 mg/dL.
Severe hypoglycemia is an episode requiring help of 
another person to administer carbohydrates, glucagon, 
or initiate other measures. Exact blood glucose values 
during the episode may be not available but resolution 
of symptoms following normalization of blood glucose is 
considered a sufficient proof that the episode was caused 
by low blood glucose levels.
Recurrent severe hypoglycemia: two or more epi-
sodes of severe hypoglycemia during last 12 months.
II. General considerations
 1.  Diabetic subjects should not be automatically consid-
ered at risk of hypoglycemia and thus handicapped in 
terms of employment and the social status.
 2.  Risk of hypoglycemia is increased in the following 
situations:
— Insulin use as monotherapy or in combination 
with other antidiabetic agents;
— Sulphonylurea use as monotherapy or in combina-
tion with other antidiabetic agents;
— Inappropriate dosing of the above mentioned 
agents in the settings of increased physical activ-
ity, reduced calorie intake or alcohol consumption;
— Aiming for rapid HbA1c level normalization.
 3.  Hypoglycemia may be directly life-threatening in 
some situations (the elderly, patients with ischemic 
heart disease)
III. Management of hypoglycemia unawareness:
— Patient and family member education regarding 
identification of subtle and atypical prodromes of 
hypoglycemia;
— Consideration of this problem during professional 
activities and driving;
— Treatment modifications leading to a significant 
reduction of hypoglycemia episodes as the only 
approach to improve hypoglycemia awareness;
— Frequent BGSM, consideration of CGM.
IV. Management of recurrent hypoglycemia episodes 
includes thorough evaluation of patient’s habits and 
current treatment of diabetes and other conditions, 
and modification of diabetes therapy to minimize 
the risk of hypoglycemia (e.g., by reducing insulin 
dose before anticipated physical exercise, switching 
to another insulin type, etc.).
V. Acute management of hypoglycemia
 1.  In a conscious patient:
— Depending on the degree of hypoglycemia, ad-
minister orally 10–20 g of glucose (glucose tablets 
or gel) or a sweetened beverage;
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— A dose of 10–20 g of glucose will raise blood 
glucose level after about 10–20 minutes. To avoid 
recurrent hypoglycemia, complex carbohydrates 
should be consumed and blood glucose level 
should be re-evaluated after 60 minutes;
— Blood glucose should be monitored;
— Consider subcutaneous or intramuscular glucagon 
administration, educate patient’s relatives how to 
administer glucagon;
 2.  In an unconscious patient or a person with impaired 
consciousness and unable to swallow:
— Intravenous administration of 20% dextrose solu-
tion (0.2 g dextrose/kg body weight) followed by 
infusion of 10% dextrose;
— If intravenous access is difficult, administer 1 mg 
of glucagon intramuscularly or intravenously 
(0.5 mg in children < 6 years of age);
— Upon return of consciousness, administer carbo-
hydrates orally until complete resolution of the 
risk of recurrent hypoglycemia;
— In patients with diabetes treated with insulin or 
sulphonylureas, prolonged hypoglycemia may oc-
cur that sometimes requires prolonged glucose 
infusion;
— If severe hypoglycemia occurs, hospital admission 
should be considered due to a life-threatening 
condition associated with a risk of irreversible le-
sions in the central nervous system.
 3.  In patients receiving intensive insulin therapy using 
insulin analogs or a personal insulin pump, manage-
ment of hypoglycemia usually includes only admin-
istration of 15 g of glucose orally and rechecking 
blood glucose level after 15 minutes. If blood glu-
cose level continues to be low, glucose should be re-
administered and blood glucose level rechecked after 
further 15 minutes (the 15/15 rule). If oral intake of 
simple carbohydrates is not possible during personal 
insulin pump treatment, interruption of basal insulin 
infusion and repeated blood glucose measurements 
are indicated.
 4.  In patients treated with long-acting insulins (human 
or insulin analogs) a possibility of delayed recur-
rent hypoglycemia after initial successful treatment 
should be taken into consideration.
15. Management of acute diabetes complications due to hyperglycemia
I.	Classification
 1.  Diabetic ketoacidosis (mortality: 0.2–2%; mortality 
risk is increased in patients with recurrent episodes 
of diabetic ketoacidosis).
 2.  Hyperglycemic hyperosmolar state (mortality — 
about 15%).
 3.  Lactic acidosis (mortality — about 50% according to 
the historical data but depends to a large degree on 
the experience of the treating center, the severity of 
the underlying disease, and concomitant conditions).
II. Ketoacidosis
 1.  Causes of diabetic ketoacidosis and ketoacidotic 
coma:
— Interruption or errors of insulin therapy;
— Too late diagnosis of diabetes type 1;
— Alcohol abuse;
— Acute inflammation (e.g., bacterial, viral, and fun-
gal infections);
— Pregnancy;
— Other.
 2.  Diagnosis:
Laboratory criteria of diabetic ketoacidosis:
— Blood glucose usually > 250 mg/dL (> 13.9 
mmol/L), blood glucose values may be lower in 
patients treated with SGLT-2 inhibitors;
— Blood pH < 7.3;
— Serum bicarbonate level < 15 mmol/L;
— Presence of ketone bodies in urine or serum;
— Anion gap: Na+ (mmol/L) – [Cl– (mmol/L) + HCO3
– 
(mmol/L)] > 12 (measured and not corrected so-
dium level is used in this formula).
 3.  Differential diagnosis:
— Fasting ketosis;
— Alcohol-induced ketoacidosis [blood glucose level 
rarely > 250 mg/dL (13.9 mmol/L), serum bicar-
bonate level usually ≥ 18 mmol/L];
— Metabolic acidosis with anion gap > 20 mEq/L 
(ethylene glycol, methanol, paraldehyde, or salicy-
late poisoning);
— Lactic acidosis (blood lactate level may also in-
crease in ketoacidosis);
— Other comatose conditions leading to hyperglyce-
mia and ketosis, or the latter accompanied by e.g., 
stroke or uremic coma.
 4.  Monitoring of ketoacidosis:
— Evaluation of blood pressure, heart rate, breathing 
rate, and the degree of consciousness: every 1–2 
hours;
— Fluid balance: every 1–2 hours;
— Body temperature measurements: every 8 hours;
— Blood glucose measurements: every hour;
— Serum sodium and potassium measurements: ev-
ery 4 hours [corrected serum sodium level should 
be calculated using the formula: measured se-
rum Na+ + 2.0 mmol/L per each 100 mg/dL (5.6 
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mmol/L) of blood glucose level above 100 mg/dL 
(5.6 mmol/L)];
— If serum potassium > 5.5 mmol/L when potassium 
is not supplemented: serum potassium measure-
ment after 2 hours, and after normalization — 
 every 4 hours;
— Blood gases: every 4 hours;
— Baseline blood and/or urine ketones.
 5.  Management:
 A.  Patient hydration:
— Water deficit (on average 100 mL/kg body weight) 
should be corrected intravenously within 24–48 
hours with monitoring of the patient’s cardiovas-
cular status:
• 1000 mL 0.9% saline within first hour,
Followed by:
• 500 mL/h 0.9% saline for 4–6 hours,
Followed by:
• 250 mL/h 0.9% saline until normalization of 
acid-base balance,
• When blood glucose is reduced below 250 mg/dL 
(13.9 mmol/L), add 5% dextrose infusion at 
100 mL/h; if dextrose infusion is added after 
24 hours of fluid therapy, decrease the rate of 
0.9% saline infusion to 150 mL/h,
• In situations associated with increased energy 
requirement (e.g., ketoacidosis associated with 
infection, hyperthyroidism, pregnancy), it is 
recommended to substitute 10% dextrose for 
5% dextrose, administered at the rate of 70 mL/ 
/hour;
 B.  Correcting hyperglycemia:
— Intravenous insulin therapy:
• Initial insulin bolus 0.1 unit/kg body weight,
• Followed by intravenous insulin infusion at 0.1 
unit/kg body weight/hour with blood glucose 
monitoring,
• The rate of infusion should be adjusted de-
pending on current blood glucose level, mea-
sured every hour,
• Hourly blood glucose level reduction should be 
not higher than 100 mg/dL (5.6 mmol/L),
• If plasma glucose level does not fall by 50–70 
mg/dL (2.8–3.9 mmol/L) from the baseline value 
during the first hour, increase (usually double) 
the rate of intravenous insulin infusion until 
constant blood glucose level reduction by 50– 
–70 mg/dL (2.8–3.9 mmol/L) per hour is 
reached.
 C.  Correction of electrolyte disturbances:
— Potassium deficit in a person with ketoacidosis is 
3–5 mmol/kg body weight;
— Potassium supplementation according to the fol-
lowing principles:
Serum potassium level:
• K+ > 5.5 mmol/L Æ do not administer KCl;
• K+ 5.0–5.5 mmol/L Æ 5–10 mmol KCl per hour;
• K+ 4–5 mmol/L Æ 10–15 mmol KCl per hour;
• K+ 3–4 mmol/L Æ 15–20 mmol KCl per hour;
• K+ < 3 mmol/L Æ stop insulin infusion and 
administer 25 mmol KCl per hour.
Potassium supplementation > 15 mmol/h should 
be administered via a central venous line or to two 
peripheral veins.
 D.  Bicarbonate administration — consider only if arte-
rial blood pH < 6.9 (in small doses, not more than 
1 mmol/kg body weight); increased lactate level in 
ketoacidosis (which is often associated with mild 
lactate level elevation due to tissue ischemia) is not 
an indication for bicarbonate administration.
 6.  Treatment adverse effects:
— Hypokalemia related to insulin administration 
and correction of acidosis with bicarbonates;
— Hypernatremia, mostly related to inappropri-
ate administration of sodium bicarbonate (np. 
pulmonary edema, cerebral edema; intravenous 
mannitol infusion at 1–2 g/kg body weight dur-
ing 20 minutes is recommended in case of cere-
bral edema;
— Hyperglycemia caused by interruption of intra-
venous insulin administration following initial 
improvement, without early initiation of subcu-
taneous insulin treatment;
— Hypoglycemia due to overly intensive insulin ther-
apy;
— Hyperchloremia due to administration of exces-
sive amounts of saline.
 7.  Complication of diabetic ketoacidosis:
— Hypovolemic shock;
— Acute renal failure
— Cerebral edema, more commonly in children.
 8.  Management of acute ketoacidosis in children — see 
Figure 22.1.
III. Hyperglycemic hyperosmolar state
 1.  Causes:
— Most commonly due to a delayed diagnosis or in-
adequate treatment of diabetes type 2, stroke, or 
myocardial infarction, following consumption of 
large amounts of alcohol, use of some diuretics, 
in patients with chronic kidney disease, mental 
health problems, and evidence of infection.
 2.  Diagnosis
Laboratory diagnostic criteria of a hyperglycemic 
hyper osmolar state:
— Blood glucose > 600 mg/dL (> 33.3 mmol/L);
— pH > 7.30;
— Serum bicarbonate level > 15.0 mmol/L;
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— Hypernatremia: corrected serum sodium level (cal-
culated using the formula given above) ≥ 150 
mmol/L;
— Serum ketone bodies: absent/trace;
— Effective plasma osmolality > 320 mOsm/kg H2O.
Effective plasma osmolality (mOsm/kg H2O) =  
2 [Na+ (mmol/L)] + blood glucose (mmol/L)  
{2 [measured Na (mEq/L)] + [blood glucose  
(mg/dL)]/18}
Normal plasma osmolality is 280–300 mOsm/kg H2O.
 3.  Differential diagnosis:
— Ketoacidotic coma;
— Comatose states due to central nervous system 
disease;
— Uremic coma;
— Coma due to poisoning.
 4.  Management
The approach to management is similar to the man-
agement of diabetic ketoacidosis, except for bicarbonate 
administration:
— Blood glucose lowering (similar insulin doses as in 
the management of diabetic ketoacidosis);
— Normalization of plasma osmolality (with gradual 
reduction by no more than 3 mOsm/kg H2O per 
hour);
— Subcutaneous administration of a low molecular 
weight heparin;
— Correction of water and electrolyte deficits:
• Water deficit is much larger than in patients 
with diabetic ketoacidosis;
— Use of a hypotonic multi-electrolyte solution 
(0.45% saline or hypotonic multi-electrolyte so-
lution), followed by normal saline when plasma 
osmolality has been normalized, with monitoring 
of the patient’s cardiovascular status.
• The rate of saline infusion is determined based 
on serum sodium level and plasma osmolality;
— Blood glucose and electrolyte monitoring.
IV. Lactic acidosis
 1.  Causes:
— Type A is due to cardiogenic shock, massive bleed-
ing, septic shock, acute or chronic respiratory fail-
ure (it is not characteristic for diabetes) but three 
fourths of diabetic patients die due to cardio-
vascular causes; this condition may also occur in 
diabetic patients.
— Type B is due to causes other than hypoxemia. It 
develops in patients with diabetes, liver disease, 
malignancies, and following ingestion of ethanol, 
biguanides, salicylates, and methanol.
 2.  Laboratory diagnostic criteria:
— Moderately elevated blood glucose (but may also 
be normal);
— Reduced blood pH (< 7.30), bicarbonate level < 
10 mmol/L, anion gap > 16 mmol/L;
— Lactate level > 5 mmol/L;
— Normal serum sodium level (may be reduced in 
alcohol abuse);
— Usually increased serum potassium level.
 3.  Management:
— Includes the following measures:
• Preventing and counteracting shock (correction 
of hypovolemia, vasoconstrictors in moderate 
doses),
• Counteracting hypoxemia and hypoxia,
• Reducing excessive lactate production (glucose 
and insulin infusion with blood glucose moni-
toring),
• Alkalinization by administration of sodium bi-
carbonate (requirement: base excess × 0.3 × 
body mass in kg),
• In some cases, renal replacement therapy may 
be required (biochemical and/or clinical indica-
tions).
16. Diagnosis and management of ischemic heart disease  
 in diabetic patients
Ischemic heart disease (IHD) is the major cause of 
mortality among diabetic patients. Diagnosis and man-
agement of IHD and heart failure in this patient popula-
tion are the same as in subjects without dysglycemia.
I.   Differences in the clinical course of IHD in dia-
betic patients indicate the need for follow-up 
assessment of risk factors in this population at 
least once a year.
II.   Indications for diagnostic, functional, and ana-
tomic investigations to diagnose IHD and stratify 
risk in diabetic patients (a cardiology consulta-
tion) (Figure 16.1):
 1.  Presence of typical or atypical cardiovascular symp-
toms or signs.
 2.  Abnormal resting ECG.
 3.  Concomitant atherosclerotic lesions in carotid or pe-
ripheral arteries.
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 4.  Planned intensive physical exercise in subjects > 35 
years of age who previously lived a sedentary lifestyle.
 5.  Diabetes type 1 for > 15 years.
 6.  Presence of at least two risk factors for IHD in addi-
tion to diabetes:
— Dyslipidemia (see Chapter 4);
— Hypertension;
— Smoking;
— Family history of premature atherosclerosis;
— Albuminuria;
— Autonomic neuropathy.
III.  Management of stable IHD in diabetic patients
 1.  Initiation of a healthy lifestyle (see Chapter 6).
 2.  Lipid-lowering therapy to achieve therapeutic targets 
(see Chapter 4).
 3.  Reduction or elimination of risk factors for IHD:
— Blood pressure normalization (see Chapter 12);
— Treatment of dyslipidemia (see Chapter 13).
 4.  Drug therapy for IHD in diabetes
Antiplatelet therapy:
— Acetylsalicylic acid should be also used in patients 
> 40 years of age with diabetes type 1 or 2 and 
an increased cardiovascular event risk (IHD risk 
> 5% during 10 years). Effectiveness of acetyl-
salicylic acid in the primary prevention in diabetic 
patients has not been established.
• The recommended acetylsalicylic acid dose is 
75–100 mg/day,
• If acetylsalicylic acid is contraindicated, clopi-
dogrel 75 mg/day may be beneficial although 
new antiplatelet agents (i.e., prasugrel and ti-
cagrelor) are currently preferred due to their 
higher effectiveness; if these are unavailable, 
clopidogrel is recommended,
• Dual antiplatelet therapy (acetylsalicylic acid 
75–100 mg/day, clopidogrel 75 mg/day) is rec-
ommended in patients after a percutaneous 
coronary intervention (PCI). Duration of dual 
antiplatelet therapy depends on the presen-
tation of IHD and the type of the implant-
ed stent. Recommended treatment duration 
is one month after the procedure in stable 
IHD treated with a bare metal stent (BMS), 
and 6–12 months after implantation of 
a drug-eluting stent (DES). In all patients after 
an acute coronary syndrome, dual antiplatelet 
therapy for 12 months is recommended;
— Cardioselective beta-blockers or combined alpha1- 
and beta-adrenergic blockers:
Figure 16.1. An algorithm for the diagnosis of and risk stratification in ischemic heart disease (IHD) in diabetic patients. ECG 
— electrocardiogram; MET — metabolic equivalent
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• RAA system inhibitors;
— Additional therapy:
• Omega-3 fatty acids: a beneficial effect on the 
development and progression of IHD has been 
suggested.
If drug treatment is not successful, coronary revascu-
larization should be considered.
Exercise testing and other functional (stress) tests 
are used to confirm the diagnosis, document ischemia, 
stratify risk, and guide selection of treatment modalities 
and evaluate their effectiveness. Exercise ECG is still most 
easily available and thus most commonly performed but 
its sensitivity and specificity for diagnosing ischemia is 
limited, particularly in women. Other functional (stress) 
tests include stress echocardiography, myocardial perfu-
sion scintigraphy, magnetic resonance imaging (MRI), 
and positron emission tomography (PET). Among ana-
tomical methods, invasive coronary angiography remains 
the gold standard, although multidetector computed to-
mography (MDCT) may also be useful. Diabetic patients 
are usually at moderate to high coronary artery disease 
risk. Functional tests are recommended as first-choice 
modalities in moderate-risk patients, while coronary an-
giography is the major first-choice modality in high-risk 
patients. An advantage of MDCT is its high negative 
predictive value and thus this modality is mostly useful 
to exclude significant coronary artery disease. However, 
it s not recommended in high-risk patients, as it results 
in unnecessary contrast agent and radiation exposure.
16.1. Management of acute coronary syndromes in diabetic patients  
 — glucose-lowering therapy
In acute coronary syndromes, normalization of blood 
glucose levels using intravenous insulin infusion is recom-
mended in somewhat vague states of relative hypergly-
cemia, which should be defined as blood glucose level 
above 140 mg/dL (7.8 mmol/L) in subjects with estab-
lished diabetes and above 180 mg/dL (10.0 mmol/L) in 
subjects without a previous diagnosis of diabetes. Intra-
venous insulin administration is the only approach that 
allows rapid normalization of blood glucose levels and 
improvement of outcomes following an acute coronary 
syndrome. If possible, a diabetologist should be involved 
in the management of IHD in patients with dysglycemia.
I.		 The	first	day	of	an	acute	coronary	syndrome
 1.  Stop oral antidiabetic agents.
 2.  Measure blood glucose on admission in all patients 
with an acute coronary syndrome.
 3.  If blood glucose is above 140 mg/dL (7.8 mmol/L) 
in subjects with established diabetes or above 180 
mg/dL (10.0 mmol/L) in subjects without a previ-
ous diagnosis of diabetes, initiate intravenous insulin 
infusion at the rate shown in Table 16.1.1. Recom-
mended frequencies of blood glucose measurements 
during daytime: every 1 hour, followed by every 2 
hours when blood glucose levels become stabilized. 
Blood glucose level should be kept at 100–180 mg/dL 
(5.6–10 mmol/L) by adjusting appropriately the rate 
of insulin infusion.
 4.  Serum potassium level should be monitored during 
insulin infusion.
If blood glucose increases above 180 mg/dL (10 
mmol/L), temporarily stop intravenous glucose infusion, 
restarting it when blood glucose falls to 180 mg/dL (10 
mmol/L), and at the same time increase the rate of intra-
venous insulin infusion.
 5.  If meals are consumed by the patient, add intrave-
nous boluses of a short-acting insulin.
 6.  If diabetic ketoacidosis is present, treat accordingly 
(Chapter 15).
II.  From the second day of an acute coronary syn-
drome until discharge
 1.  Target blood glucose values during glucose-lower-
ing therapy are 100–180 mg/dL (5.6–10.0 mmol/L) 
Table 16.1.1. Approximate insulin infusion rate in relation to blood glucose level
Blood glucose 10% dextrose [ml/hour] Insulin [unit/hour]
<100 mg/dL (< 5.5 mmol/L) 50 Stop infusion for 15–30 minutes
100–140 mg/dL (5.5–7.8 mmol/L) 50 0.5–1.0
140–180 mg/dL (6.7–10.0 mmol/L) 50 1.0–2.0
180–250 mg/dL (10.0–13.9 mmol/L) Stop infusion until blood glucose < 180 mg/dL 
(10.0 mmol/L) then 50
2.0–4.0
250–300 mg/dL (13.9–17.4 mmol/L) Stop infusion until blood glucose < 180 mg/dL 
(10.0 mmol/L) then 50
4.0–6.0
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throughout 24 hours. Thus, treatment must be in-
dividualized, preferably in cooperation with a diabe-
tologist.
 2.  In patients without evidence of acidosis, with dysgly-
cemia diagnosed on the first day of an acute coro-
nary syndrome or with previous successful metformin 
treatment, appropriate diet may allow adequate met-
abolic control of diabetes in this period (Chapter 6). 
In the remaining cases, initiate insulin therapy with 
multiple injections as described earlier (Chapter 11).
 3.  In overweight or obese patients with diabetes type 2, 
metformin may be started before discharge, even as 
early as on the third day after the coronary interven-
tion, if not contraindicated. A reduction in insulin 
dose may be possible after 2–3 days of metformin 
therapy.
III. Following discharge
Metformin should be started in all patients with dia-
betes type 2 after an acute coronary syndrome, unless 
contraindicated or not tolerated.
In patients with diabetes type 2 in whom good meta-
bolic control (see II.1 in this chapter) was achieved at the 
time of discharge and daily insulin requirement does not 
exceed 30 units, it is possible to return to previous glu-
cose-lowering treatment that was used before the acute 
coronary syndrome. In overweight or obese patients with 
diabetes diagnosed during the hospital stay and good 
metabolic control (see II.1) achieved at the time of dis-
charge, with daily insulin requirement not exceeding 30 
units, oral metformin therapy may be used, combined 
with other agents if needed. If good metabolic control 
cannot be achieved or daily insulin requirement exceeds 
30 units, insulin therapy should be continued. Following 
an acute coronary syndrome, each patient with dysglyce-
mia should be urgently referred to a diabetologist.
Note 1: In all patients with an acute coronary syn-
drome, except for those with previously established dia-
betes, oral glucose tolerance test (see Chapter 1, III, 
Table 16.1.1.) should be performed before discharge. It 
glucose intolerance or diabetes is diagnosed, a diabetolo-
gist should be consulted.
Note 2: Metformin should be withdrawn at least 48 
hours before elective diagnostic or therapeutic cardiac 
catheterization/coronary angiography. The drug may be 
resumed 24 hours after coronary angiography.
17. Stroke in diabetic patients
Diabetes is a strong risk factor for stroke, both isch-
emic and hemorrhagic.
Elevated blood glucose is seen in as many as 60% of 
patients hospitalized due to an acute stroke. In about 
20% of cases, hyperglycemia occurs in subjects with 
established diabetes, in 16–24% of cases in patients with-
out previous diagnosis of diabetes, and in the remaining 
cases it is intermittent hyperglycemia (stress hypergly-
cemia).
Hyperglycemia in the acute phase of stroke is an 
adverse prognostic factor both in diabetic patients and 
in those without diabetes. Its presence is associated with 
a risk of a larger ischemic area and its hemorrhagic trans-
formation, a more severe course of the condition, and 
a worse prognosis (lower degree of patients’ indepen-
dence and increased early and late mortality). Hyper-
glycemia found on admission often tends to decrease 
gradually and spontaneously within first several hours to 
days after the stroke onset.
Target blood glucose levels in patients with acute 
stroke are similar to that in other severely ill patients 
with hyperglycemia. Insulin therapy should be initiat-
ed if blood glucose is ≥ 180 mg/dL (10 mmol/L), and 
blood glucose should be kept at 140–180 mg/dL (7.8–10 
mmol/L), preferably close to 140 mg/dL (7.8 mmol/L). 
Blood glucose levels below 110 mg/dL (6.1 mmol/L) 
should be avoided to the risk of hypoglycemia.
Insulin should be given intravenously in 0.9% saline 
using a syringe pump, with strict monitoring of blood 
glucose levels. The rate of insulin infusion should be 
modified depending on blood glucose levels measured 
every 1 hour, and every 2 hours after stable blood glucose 
values are obtained. A general algorithm for modifying 
the rate of intravenous insulin infusion depending on 
blood glucose levels is shown in Table 16.1.1. Serum po-
tassium level should be checked 2–3 times a day during 
insulin infusion.
It is not recommended to administer insulin as glu-
cose-insulin-potassium (GIK) infusion. Insulin should not 
be administered subcutaneously during the first two days 
of stroke or longer in unconscious patients.
Physicians and nursing personnel in the acute stroke 
care unit should be trained in the treatment of hyper-
glycemia using a specified intravenous insulin dosing 
algorithm, with adjustments of the insulin infusion rate 
in relation to blood glucose levels.
When the patient’s condition improves and meals be-
gin to be given orally, intravenous insulin infusion should 
be stopped and subcutaneous insulin dosing should be 
initiated. Withdrawal of intravenous insulin should be 
preceded by subcutaneous administration of a short- 
-acting insulin or rapid-acting insulin analog by about 1 
hour before the planned cessation of intravenous insulin 
infusion. The recommended treatment regimen includes 
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a short-acting insulin or rapid-acting insulin analog be-
fore meals and long-acting insulin once or twice daily. In 
some cases, it is sufficient to give a short-acting insulin or 
rapid-acting insulin analog before meals. Insulin should 
be given before food, with dosing based on blood glu-
cose readings immediately before meals.
Due to a high likelihood of diabetes in patients with 
an acute stroke and no previous diagnosis of diabetes, 
investigations for diabetes are needed after the patient’s 
condition has stabilized.
Recommendations regarding management of hyper-
tension and other aspects of care for patients with an 
ischemic stroke are the same as in non-diabetic patients, 
as no evidence is available to indicate benefits from any 
different or specific management of diabetic patients.
Secondary prevention after stroke should be insti-
tuted according to the general recommendations in this 
regard.
18. Prevention, diagnosis, and treatment of diabetic kidney disease
I.   In diabetic patients, urinary albumin excretion, 
serum creatinine, and estimated GFR should be 
determined to detect and evaluate the severity 
of diabetic nephropathy. Albuminuria and esti-
mated GFR are independent predictors of cardio-
vascular and renal risk in diabetic patients.
II.   Screening for albuminuria should be performed 
according to the following principles:
— Testing should be performed annually, beginning 
at 5 years after the diagnosis of diabetes type 1 
and at the time of the diagnosis of diabetes type 
2;
— Urinalysis should be performed first to detect/ex-
clude overt proteinuria or a urinary tract infection; 
if overt proteinuria is found, there is no need to 
investigate albumin excretion;
To evaluate albuminuria:
— An albumin/creatinine (ACR) ratio should be deter-
mined in a single (spot) urine sample (preferably 
morning urine sample) — for interpretation of the 
results see Table 18.1; or
— Albumin excretion rate (AER) should be measured 
in a 24-hour urine collection or a single morn-
ing urine collection. Albuminuria determined in 
a 24-hour urine collection may be considered an 
equivalent of albuminuria expressed in mg per 1 g 
of creatinine (i.e., ACR). For interpretation of the 
results see Table 18.1.
If a positive AER result is obtained, investigations 
should be repeated twice during 3 months. Albuminuria 
may be diagnosed based on 2 positive results out of 
3 AER measurements. Urinary albumin excretion is in-
creased by physical exertion during preceding 24 hours, 
infection, hyperglycemia, heart failure, and high blood 
pressure.
III.		 Abnormal	urinary	albumin	excretion	is	defined	in	
Table 18.1.
IV.  Serum creatinine level in diabetic patients should 
be measured at least annually regardless of urinary 
albumin excretion and used for estimation of GFR.
V.			 Glomerular	 filtration	 rate	 should	 be	 estimated	
using the following formulas:
MDRD formula
— For serum creatinine (SCr) in mg/dL:
Estimated GFR (mL/min/1.73 m2) = 186 ×  
[SCr]–1.154 × (age)–0.203 × 0.742 (in women)
Estimated GFR (mL/min/1.73 m2) = 186 ×  
[SCr]–1.154 × (age)–0.203 (in men)
— For serum creatinine (SCr) in µmol/L:
Estimated GFR (mL/min/1.73 m2) = 186 × 
[SCr/88.4]–1.154 × (age)–0.203 × 0.742 (in women)
Estimated GFR (mL/min/1.73 m2) = 186 × 
[SCr/88.4]–1.154 × (age)–0.203 (in men)
or
Table	18.1.	Definitions	of	abnormal	urinary	albumin	excretion*
Category AER [mg/day] ACR (spot urine sample)  
[mg/day	or	mg/g	creatinine]*
Albumin excretion  
[µg/min] in urine collection
A1 normal to slightly increased albuminuria < 30 < 30 < 20
A2 moderately increased albuminuria 30–300 30–300 20–200
A3 overt proteinuria > 300 > 300 ≥ 200
AER — albumin excretion rate; ACR — albumin/creatinine ratio
*As the amount of albumin excreted with urine per 1 g of creatinine is approximately equal to 24-hour urinary albumin excretion, this approach allows avo-
iding errors of 24-hour urine collection
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CKD-EPI formula
GFR = 141 × min (SCr/k, 1)a × max (SCr/k, 1)–1.209 × 
0.993Age × 1.018 (for women)
Where
SCr — serum creatinine
k = 0.7 for women and 0.9 for men
a = –0.329 for women and –0.411 for men
min = the minimum of SCr/k or 1
max = the maximum of SCr/k or 1
VI.		 Stages	of	chronic	kidney	disease	are	defined	 in	
Table 18.2.
VII.  It is recommended to perform annual evaluation of 
albuminuria in patients with established increased 
urinary albumin excretion (if the patient does not 
receive an optimal therapy with ACEI or ARB).
VIII. If estimated GFR decreases below 60 m mL/min/ 
/1.73 m2 or treatment of hypertension becomes 
difficult,	 a	 nephrology	 consultation	 should	 be	
considered. If estimated GFR decreases below 
30 mL/min/1.73 m2, a nephrology consultation is 
mandatory.
Nephrological work-up for proteinuria should be con-
sidered in patients with short duration of diabetes type 2 
and no changes in fundoscopy.
IX.  Recommendations for prevention
 1.  Blood glucose, blood pressure, and lipid control 
should be optimized to reduce the risk of nephro-
pathy or delay its progression.
 2.  Tobacco smoking is an independent risk factor for 
development and progression of nephropathy in pa-
tients with diabetes type 2.
 3.  Yearly screening for albuminuria and determination 
of serum creatinine level is indicated in patients with 
diabetes type 1 beginning at 5 years after the diagno-
sis, and in all patients with diabetes type 2 beginning 
at the time of the diagnosis.
X. Management
 1.  Therapeutic targets for blood glucose, lipid parameters, 
and blood pressure as described in Chapter 4 should be 
aimed for to delay progression of diabetic nephropathy.
 2.  If albuminuria is found, therapy with ACEI or ARB 
should be initiated (unless contraindicated) as these 
drugs reduce the risk of progression of nephropathy.
 3.  In patients with diabetes type 1 with concomitant hy-
pertension and albuminuria, ACEI delay progression 
of nephropathy at any stage.
 4.  In patients with diabetes type 2 with concomitant 
hypertension and albuminuria, both ACEI and ARB 
delay progression of nephropathy.
 5.  In patients with diabetes type 2 with concomitant hy-
pertension, albuminuria, and in the category G3a or 
higher chronic kidney disease (estimated GFR < 60 mL/ 
/mL/1.73 m2), ARB delay progression of nephropathy.
 6.  Serum creatinine and potassium should be monitored 
during treatment with ACEI, ARB, and/or a diuretic.
 7.  In albuminuric patients receiving optimal treatment 
with ACEI or ARB, the importance of annual evalua-
tion of urinary albumin excretion is questionable.
 8.  Combining ACEI with ARB is not recommended. 
When evaluating potential benefits of other possible 
combinations of RAA system inhibitors (e.g., more 
effective reduction of progression of renal or heart 
failure), the risk of significant adverse effects should 
always be considered.
 9.  Daily dietary protein intake should be reduced to 
0.8–1.0 g/kg body weight in patients with diabetes 
complicated with chronic kidney disease in the cat-
egory G1–G2. In the category G3–G5 and in patients 
with overt proteinuria, daily dietary protein intake 
should be reduced to ≤ 0.8 g/kg body weight (about 
10% of the daily calorie intake).
 10. In patients in whom therapeutic targets are not met 
during ACEI or ARB therapy, addition of calcium 
channel blockers, beta-blockers or diuretics should 
be considered.
11. Use of a thiazide/thiazide-like diuretic may be conside-
red (thiazide-like diuretics are preferred) with estimated 
GFR ≥ 30 mL/min/1.73 m2, while a loop diuretic should 
be used with estimated GFR < 30 mL/min/1.73 m2.
12. Use of aldosterone antagonists may decrease the 
rate of GFR reduction in some patients, provided that 
serum potassium level is monitored.
13. Use of metformin in diabetic patients with estimated 
GFR < 60 mL/min/1.73 m2 is summarized in Table 18.3.
It should be noted that none of the metformin 
preparations available in Poland has been licensed 
to use in patients with estimated GFR < 60 mL/ 
/min/1.73 m2.
14. Management of diabetic patients with chronic kidney 
disease is summarized in Table 18.4.
Table 18.2. Stages of chronic kidney disease
Category Description eGFR [mL/ 
/min/1.73 m2]
G1 Kidney damage* with  
normal or high eGFR
≥ 90
G2 Kidney damage* with mildly 
decreased eGFR
60–89
G3a Moderately decreased eGFR 45–59
G3b Moderately to severely  
decreased eGFR
30–44
G4 Severely decreased eGFR 15–29
G5 End-stage renal failure < 15
eGFR — estimated glomerular filtration rate
*Kidney damage is defined as urinalysis and/or urine sediment abnormalities 
and/or abnormalities in blood markers of kidney damage and/or imaging stu-
dies of the kidneys or urinary tracts persisting for more than 3 months
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Table 18.3. Recommendations for metformin use based on the severity of renal failure (according to Lipska et al.,  
Diabetes Care 2011; 34: 1431–1437)
eGFR [mL/min per 1.73 m2] Action
≥ 60 No contraindication to metformin
Monitor renal function annually
45–49 Metformin may be continued
Monitor renal function every 3–6 months
30–44 Exercise particular caution when using metformin
Metformin may be continued in a decreased (by 50%) dose
Monitor renal function every 3 months
Do not start new patients on metformin
< 30 Do not use metformin
eGFR — estimated glomerular filtration rate
Table 18.4. Management of diabetic patients with chronic kidney disease
eGFR [mL/min per 1.73 m2] Action
All diabetic patients Measure albuminuria and serum creatinine and potassium annually*
45–60 Refer the patient to a nephrologist
Adjust drug doses
Monitor renal function every 6 months
Monitor sodium, potassium*, and hemoglobin levels annually
Deliver nutritional education
30–44 Monitor renal function every 3 months
Monitor sodium, potassium*, and hemoglobin levels every 6 months
Adjust drug doses
< 30 Refer for nephrological treatment
eGFR — estimated glomerular filtration rate
*Serum potassium levels should be particularly carefully monitored in patients treated with angiotensin-converting enzyme inhibitors/angiotensin receptor 
blockers/mineralocorticoid receptor antagonists, especially following significant drug dose increases
19. Diabetic eye disease
Diabetic complications involve nearly all anatom-
ic structures of the visual system. The most com-
mon and most severe complication, with a threat 
of vision loss, is diabetic retinopathy and related 
diabetic macular edema. Among extraretinal dia-
betic complications, clinically the most important 
are diabetic cataract and secondary (hemorrhagic) 
glaucoma. The recommendations given below take 
into	account	the	new	classification	of	diabetic	reti-
nopathy.
Prevention, diagnosis, and management of diabetic 
retinopathy
I.		 	 Natural	history	and	classification	of	diabetic	reti-
nopathy
 1.  No evidence of diabetic retinopathy.
 2.  Mild non-proliferative diabetic retinopathy (NPDR) — 
presence of microaneurysms only.
 3.  Moderate non-proliferative diabetic retinopathy — 
more advanced changes than in a mild form but less 
advanced than in a severe form.
 4.  Severe non-proliferative diabetic retinopathy:
—  Microhemorrhages (> 20) in 4 retinal quadrants; 
and/or
—  Venous beading in least 2 quadrants; and/or
— Intraretinal microvascular abnormalities in at least 
1 quadrant. 
 5.  Proliferative diabetic retinopathy (PDR) (retinal neo-
vascularization and connective tissue growth) leading 
to vision loss in the mechanisms of:
—  Recurrent bleeding to the vitreous body from the 
retinal neovessels;
—  Retinal detachment due to traction by proliferative 
membranes;
—  Development of glaucoma.
II.	 		Natural	history	and	classification	of	diabetic	mac-
ular edema
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 1.  No evidence of diabetic macular edema.
 2.  Mild diabetic macular edema — lesions away from 
the macular center. 
 3.  Moderate diabetic macular edema — lesions close to 
the macular center. 
 4.  Severe diabetic macular edema — lesions involving 
the macular center. 
III.  Risk factors for the development and progression 
of diabetic retinopathy
 1.  Duration of diabetes — the strongest prognostic fac-
tor for the development and progression of diabetic 
retinopathy
 2.  Poor metabolic control of diabetes:
— Intensive treatment reduces the risk of the devel-
opment and progression of retinopathy in patients 
with diabetes type 1;
— Intensive treatment of diabetes type 2 reduces 
the rate of microangiopathic complications and 
reduction of HbA1c level by 1% is associated with 
a significantly reduced risk of the development of 
microangiopathy.
 3.  Hypertension
 4.  Lipid disorders
 5.  Diabetic nephropathy
 6.  Pregnancy in diabetic women
 7.  Period of adolescence
 8.  Surgery for cataract
 9.  Following kidney and pancreas or kidney transplantation
IV.  Diagnosis of diabetic retinopathy
 1.  Assessment of visual acuity
 2.  Assessment of color identification
 3.  Fundoscopy (using an ophthalmoscope, always with 
mydriasis)
 4.  Digital color photographs of the eye fundus used 
mostly for screening (they do not replace complete 
ophthalmologic examination)
 5.  Fluorescein angiography of the eye fundus
— Indications:
• Identification of moderate and severe preprolif-
erative retinopathy,
• Identification of early neovascularization foci in 
proliferative retinopathy,
• Evaluation of the effectiveness of laser photo-
coagulation,
• Investigation of unexplained decrease in visual 
acuity.
 6.  Wide-angle scanning laser ophthalmoscopy
 7.  Optical coherent tomography — major method for 
the diagnosis and monitoring of macular edema.
 8.  Ultrasound — particularly in patients with vitreous 
body hemorrhage.
 9.  Confocal microscopy (evaluation of corneal lesions as 
an early indicator of neuropathy)
V.   Indications for ophthalmologic examination in 
diabetic patients
 1.  Initial examination
— In diabetes type 1 — should be performed within 
5 years after the diagnosis;
— In diabetes type 2 — should be performed at the 
time of the diagnosis or shortly after the diagnosis.
 2.  Follow-up examinations and management:
—  Indicated due to an initially asymptomatic nature 
of retinopathy.
—  Frequency should depend on the degree of sever-
ity of diabetic retinopathy:
• No retinopathy at baseline — once a year,
• Early non-proliferative retinopathy — every 6 
months,
• More severe non-proliferative retinopathy — 
every 3 months,
• Severe non-proliferative retinopathy — urgent 
laser therapy,
• Proliferative retinopathy — urgent laser therapy 
or consideration of other ophthalmologic pro-
cedures (e.g. vitrectomy),
• Diabetic macular edema — urgent laser therapy 
in extrafoveal disease; intravitreal anti-VEGF injec-
tions and possibly laser therapy in foveal disease,
• Following retinal laser treatment — one month 
after the procedure,
• Following vitrectomy — individualized follow-up 
depending on the condition of the eye fundus,
• In pregnant diabetic women — every 1–3 
months throughout the pregnancy depending 
on the condition of the eye fundus,
• In women contemplating pregnancy — before 
conception, with retinal laser treatment at that 
time if needed.
 3.  Urgent indications for ophthalmologic examination:
—  Risk of vision loss:
• Presence of proliferative retinopathy,
• Presence of advanced eye complications (retinal 
neovascularization, vitreous body hemorrhage, 
acute retinal detachment);
—  Presence of changes potentially associated with 
a risk of vision loss:
• Severe non-proliferative retinopathy,
• Non-proliferative retinopathy with diabetic 
macular edema,
• Other difficult-to-interpret abnormalities in the 
eye fundus or unexplained decrease in visual 
acuity,
• Pregnancy.
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Table 19.1. Recommended frequency of ophthalmologic examinations in various patient groups
Initial examination
Diabetes type 1 Diabetes type 2
Initial 5 years after the diagnosis  
(when diagnosed during puberty — shortly after the diagnosis)
At the time of the diagnosis
Follow-up examinations and treatment
Severity of retinopathy Frequency of examinations and treatment
No retinopathy
Early non-proliferative
Preproliferative
Proliferative
Diabetic macular edema:
     extrafoveal
     intrafoveal
Annually
Every 6–12 months
At least every 3–6 months
Urgent laser therapy
Urgent laser therapy
Intravitreal anti-VEGF injections + laser therapy
Follow-up after ophthalmologic procedures in special situations
After laser treatment
After vitrectomy
Pregnant women
Women planning pregnancy
Uncontrolled diabetes, hypertension or proteinuria
Depending on the condition of the eye fundus
Depending on the condition of the eye fundus
Every 1–3 months depending on the condition of the eye fundus
Before conception; laser therapy at that time
Every 1–6 months regardless of fundoscopy findings
The recommended frequency of ophthalmologic ex-
amination in specific patient groups is summarized in 
Table 19.1. Following these primarily screening recom-
mendations can reduce even several times the risk of 
blindness caused by diabetes.
VI. Management of diabetic retinopathy
 1.  Treatment intensification in patients with poor met-
abolic control of diabetes, intensive treatment of 
hypertension, primarily using ACEI and ARB, and 
treatment of dyslipidemia (fenofibrate, statins). Ace-
tylsalicylic acid used for cardioprotection is not con-
traindicated in patients with retinopathy and does 
not pose a risk of retinal hemorrhage.
 2.  Retinal laser photocoagulation (possible if the optical 
system of the eye is clear):
— Early retinal laser photocoagulation reduces pro-
gression of diabetic retinopathy;
— Types of retinal laser photocoagulation:
• Focal — recommended in early retinopathy and 
extrafoveal diabetic macular edema,
• Grid-type — in diffuse diabetic macular edema,
• Panphotocoagulation — recommended in severe 
non-proliferative and proliferative retinopathy.
 3.  Vitrectomy
—  Indications:
• Vitreous hemorrhages unresponsive to other 
therapies; in such cases, early vitrectomy is in-
dicated (the earlier is the procedure, the better 
are its outcomes),
• Advanced complicated proliferative retinopa-
thy.
 4.  In severe diabetic macular edema, intravitreal injec-
tions of anti-VEGF agents aflibercept, ranibizumab, 
and bevacizumab, optionally in combination with 
retinal laser therapy. Bevacizumab is used off-label 
for this purpose. Intravitreal anti-VEGF agent injec-
tions are recommended as the first-line therapy of 
any diabetic macular edema with foveal involve-
ment.
 5.  Intravitreal or periocular injections of steroids ex-
erting an antiangiogenic and antiedematous effect, 
e.g. triamcinolone, long-acting dexamethasone, or 
extended-release fluocinolone acetonide. 
 6.  In irreversible vision loss, a low vision and blindness 
specialist should be consulted and the patient should 
be referred for blind rehabilitation services.
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I.   Diabetic neuropathy causes severe complaints, 
significantly	 reduces	 the	 quality	 of	 life,	 and	 is	
an established risk factor forthe development of 
diabetic foot syndrome and sudden deaths.
II.			 Clinical	classification	of	neuropathy:
—  Generalized symmetrical polyneuropathy:
• Chronic sensorimotor,
• Autonomic,
• Acute sensory;
—  Focal and multifocal neuropathies:
• Involving cranial nerves,
• Involving spinal nerves (thoracic and lumbar),
• Focal limb neuropathies, including compression 
syndromes,
• Proximal motor neuropathy (amyotrophy).
III. Approach to testing for neuropathy:
—  Testing frequency:
• Diabetes type 1 — at 5 years after the diagno-
sis, unless symptoms suggesting neuropathy 
develop earlier,
• Diabetes type 2 — at the time of the diagnosis,
• Evaluation for evidence of diabetic neuropathy 
— at least once a year.
—  Other, non-diabetic etiologies of the peripheral 
nervous system damage should be excluded (fol-
lowing a neurological consultation).
— In doubtful cases neurologist consultation is in-
dicated.
IV. Diagnostic criteria of diabetic neuropathy
Somatic peripheral polyneuropathy
 A.  Diagnostic methods:
—  Pressure sensation using a 10 g monofilament 
(Semes-Weinstein 5.07);
—  Vibration sensation using a biothesiometer or 128 Hz 
tuning forks;
—  Pain sensation using a sterile needle;
—  Temperature sensation using a rod with two differ-
ent (metal and plastic) ends;
—  Electroneurographic examination.
 B.  Diagnostic principles:
— Symptoms: abnormal sensation, numbness, burn-
ing, tingling, spontaneous pain, muscle jerks and 
cramps, mostly involving feet and calves, persist-
ing for several months (worsened or occurring 
mostly during the night; exercise does not cause 
or worsen symptoms);
— Signs: reduced muscle power, reduced or absent 
tendon reflexes (knee, ankle), reduced or absent 
vibration, pressure, pain and temperature sensa-
tion;
— Peripheral diabetic neuropathy is considered most 
likely based on the presence of 2 out of the fol-
lowing 3 components of the clinical examinations: 
symptoms, reduced or absent sensation (touch, 
vibration, pain, and/or temperature) and/or absent 
tendon reflexes;
— Nerve conduction studies (electroneurography) 
may be also necessary to make a definite diagnosis 
of neuropathy in selected patients;
— Evaluation of corneal nerve fiber density by confo-
cal microscopy may also used for the diagnosis of 
thin fiber neuropathy.
Autonomic neuropathy
Autonomic nervous system function is evaluated indi-
rectly based on the analysis of effector organ function in 
response to specific stimuli. Due to a non-specific nature 
of clinical symptoms and signs, the diagnosis should be 
supported by specific tests. It is necessary to exclude 
other disease of the effector organ, take into account 
other organic and functional abnormalities, and exclude 
an effect of the treatment used.
 1.  Cardiovascular system:
Autonomic neuropathy may be suspected when the 
results of two of the tests listed below are positive, and 
it may be diagnosed when the results of three tests are 
positive:
—  Tests evaluating the parasympathetic nervous sys-
tem:
• Heart rate change during deep breathing,
• Heart rate change in response to the upright 
posture,
• Heart rate change in response to the Valsalva 
manoeuver;
—  Tests evaluating the sympathetic nervous system:
• Systolic blood pressure change in response to 
the upright posture,
• Diastolic blood pressure change;
—  Other tests:
• Evaluation of heart rate variability during 
a 5-min ute resting ECG recording or 24-hour 
Holter monitoring.
 2.  Gastrointestinal system:
—  Gastric dysfunction — barium radiography, ra-
dioisotope scanning, electrogastrography (EGG), 
insulin challenge test, manometry;
—  Small intestine dysfunction — no specific diagnos-
tic tests, manometry to identify abnormal intesti-
nal motility;
20. Prevention, diagnosis, and management of diabetic neuropathy
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—  Large intestine dysfunction — barium follow-
-through, manometry;
—  Gall bladder dysfunction — functional ultrasound.
 3.  Genitourinary system
—  Bladder dysfunction — cystometry (evaluation 
of bladder volume before and after micturition); 
bladder sphincter electromyography, uroflow-
metry and urethral pressure profile;
—  Erectile dysfunction — questionnaires [Interna-
tional Index of Erectile Function (IIEF) and its ab-
breviated 5-item version (IIEF-5)], vascular studies 
(Doppler ultrasound), cavernosography, functional 
testing (nocturnal penile tumescence tests).
 4.  Dysfunctional sudomotor function — simple perspi-
ration tests, testing using sophisticated equipment 
(evaluation of sudomotor function using Sudoscan).
 5.  Pupil dysfunction — pupillometry.
V. Management
 1.  Causal treatment of diabetic neuropathy:
—  Optimal metabolic control of diabetes, with par-
ticular attention to avoiding hypoglycemia;
—  Blood pressure and lipid control, smoking cessa-
tion, avoiding alcohol use;
—  Drug therapy: alpha-lipoic acid, benfotiamine, 
ACEI.
 2.  Symptomatic treatment of somatic diabetic neuropa-
thy:
—  Pregabalin;
—  Gabapentin;
—  Carbamazepine;
—  Tricyclic antidepressants (amitryptiline);
—  Serotonin and norepinephrine reuptake inhibitors: 
duloxetine, venlafaxine;
—  Tramadol and opioid analgesics;
—  Topical agents: capsaicin, nitroglycerin;
— Non-steroidal anti-inflammatory drugs and acet-
aminophen;
—  Non-drug treatments: physical therapy, acupuncture.
 3.  Symptomatic treatment of autonomic diabetic neu-
ropathy:
—  Cardiovascular system:
• Cardiac arrhythmia — controlled graded exer-
cise, ACEI, beta-blockers (without intrinsic sym-
pathomimetic activity),
• Orthostatic hypotension — compression cloth-
ing to increase venous return (e.g. compression 
stockings), mineralocorticoids (fludrocortisone);
—  Gastrointestinal system:
• Gastroparesis — diet modification (frequent 
small meals, semiliquid or liquid diet in severe 
dysfunction), prokinetic drugs (domperidone, 
cisapride, erythromycin), acid reducers (H2 re-
ceptor antagonists, proton pump inhibitors), 
antiemetics, nasoduodenal tube, surgical treat-
ment, gastric electrical stimulation therapy,
• Intestinal dysfunction — diet modifications 
(consider gluten- or lactose-free diet), chole-
styramine, clonidine, octreotide, antidiarrheals 
(loperamide), pancreatic enzymes, antibiotics;
—  Genitourinary system:
• Bladder dysfunction — avoiding urinary reten-
tion, regular micturition, anticholinergic drugs 
(bethanechol), external bladder massage be-
fore micturition, bladder catheterization (tem-
porary or permanent);
• Erectile dysfunction — phosphodiesterase type 5 
inhibitors (sildenafil, vardenafil, tadalafil), 
central erection stimulants (apomorphine), 
vacuum penile pump devices, intracavernosal 
prostaglandin E1 injections, penile prostheses,
• Female sexual dysfunction — mechanical stimu-
lating devices, topic moisturizers;
—  Dysfunctional perspiration:
• Botulinum toxin, vasodilators, moisturizing 
creams.
21. Diagnosis and management of diabetic foot syndrome
Multidisciplinary (reference) diabetes foot clinics 
should be created in regional (voivodship, university) dia-
betologic centers, and basic diabetes foot clinics should 
be created at diabetology clinics to continue care initia-
ted in a multidisciplinary clinic.
Organizational structure and responsibilities in accor-
dance with the Diabetes Foot Outpatient Treatment Sup-
port Program by the Ministry of Health (http://www.
mz.gov.pl/zdrowie-i-profilaktyka/programy-zdrowotne/
wykaz-programow/program-wsparcia-ambulatoryjnego-
-leczenia-zespolu-stopy-cukrzycowej/).
I.		 	 Definition. Diabetic foot is a foot infection and/or 
ulceration and/or deep tissue (e.g., bone) destruc-
tion caused by a varying degree of damage to pe-
ripheral nerves and/or pedal vessels. Implied in the 
definition is further categorization of this condition 
into neuropathic, vascular, and mixed diabetic foot.
Investigations in the diabetic foot syndrome in-
clude evaluation for peripheral polyneuropathy, leg isch-
emia, deformations, and other risk factors for foot dam-
age. It is recommended that physicians directly inspect 
patients’ feet during each visit.
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II. Risk factors for diabetic foot syndrome:
— Peripheral neuropathy and/or vascular ischemic 
changes within lower limbs;
— Low patient knowledge;
— Long-lasting, poorly controlled diabetes;
— Inappropriate foot hygiene;
— Inappropriate footwear;
— Presence of corns and calluses;
— Foot deformations;
— Increased sole pressure.
Factors contributing to disease recurrences:
— Previous amputations;
— History of ulcerations;
— Neuropathic arthropathy (Charcot foot).
III.	Clinical	classification	of	diabetic	foot	syndrome
The Perfusion, Extent, Depth, Infection, Sensation 
classification (PEDIS) is recommended, taking into ac-
count both infections and the ischemic factor (Table 
21.1).
IV. Prevention:
— Systematic foot examination; yearly evaluation for 
abnormal sensation (physical examination) and 
ischemia [assessment of dorsalis pedis and poste-
rior tibial artery pulses; consider measurement of 
the ankle-brachial index (ABI)] in all patients;
— Regular podiatric care (removal of calluses and 
hyperkeratosis);
— Use of recommended footwear, orthopedic in-
soles, and socks;
— Systematic patient education regarding foot hy-
giene and consequences of absent protective pain 
sensation;
— Education and systematic treatment of other risk 
factors such as smoking, overweight, hyperten-
sion, and dyslipidemia, along with good metabolic 
control of diabetes;
— Early identification and treatment of limb isch-
emia.
V. Infections in the course of diabetic foot
 1.  The diagnosis is mostly based on the clinical picture 
(the presence of at least two typical symptoms and 
signs of infection) and not only microbiological test-
ing results.
 2.  Evaluation of the severity of infection (see the PEDIS 
classification).
 3.  Microbiological testing (including antibiotic suscepti-
bility) and its interpretation (colonization, contamina-
tion, infection):
—  It is recommended to collect tissue samples, as-
pirate, or scrapings for culture following wound 
debridement;
—  Testing is recommended if a clinically infected 
wound is present;
—  When evaluating infection, interpretation of the 
culture result is difficult, and it is recommended 
that this evaluation is primarily based on the clini-
cal picture;
—  Blood culture is recommended only in case of 
systemic evidence of an infection (grade 4 by the 
PEDIS classification);
—  If there is no or mild clinical wound infection, and 
no antibiotics were used previously, it is accept-
able not to perform culture.
 4.  Evaluation for osteomyelitis (should be performed in all 
cases of an infected ulceration, particularly if chronic):
Table	21.1.	The	PEDIS	classification
                           Degree of severity
1 2 3 4
Perfusion Normal: palpable pedal pulses 
or ABI > 0.9
Clinical evidence of impaired 
perfusion: intermittent claudi-
cation, ABI < 0.9,  
TcpO2 30–60 mm Hg
Critical ischemia: resting 
pain, ABI < 0.4,  
TcpO2 < 30 mm Hg
Extent Ulceration size in square centimeters
Depth Superficial ulceration within 
the dermis
Ulceration may involve all soft 
tissues
Penetration to bone: 
osteo lysis in X-ray or posi-
tive probe-to-bone test
Increase of 
infection
No clinical evidence  
of infection
Infection involving the skin and 
subcutaneous tissue, inflam-
mation within 2 cm from the 
margin of the ulceration
Locally severe inflamma-
tion, beyond 2 cm from 
the margin of the ulcer-
ation, but no evidence of 
a systemic infection
Evidence of a systemic  
infection: fever > 38°C,  
heart rate > 90 bpm,  
breath rate > 20/min,  
leukocyte count > 12,000/mm3 
or < 4000/mm3
Sensation No evidence of sensory  
neuro pathy in basic tests  
(using a monofilament and 
tuning forks or Neurotip)
Sensory neuropathy present
ABI — ankle-brachial index; TcpO2 — transcutaneous oxygen pressure
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—  Probe-to-bone test;
— Foot radiography (every 3–6 weeks);
— Magnetic resonance imaging (indicated);
— Bone biopsy or bone sample culture (indicated);
— Laboratory tests — erythrocyte sedimentation rate 
> 70 mm at one hour indicates an increased likeli-
hood of osteomyelitis, and lower rates indicate 
a lower risk. Evaluation of C-reactive protein 
(CRP) level and leukocyte count may also be use-
ful. A possibility of bone inflammation cannot be 
definitely excluded based on normal laboratory 
test results.
 5.  The nature of the wound (dry or exudative) is the 
primary criterion for the choice of dressing.
A.  Approach to antibiotic therapy
—  Use only for a confirmed infection (do not use 
prophylactically);
—  Do not delay therapy.
—  Initially, use an antibiotic covering the most com-
mon causative bacterial flora (staphylocci and 
streptococci);
—  In grade 4 infections by the PEDIS classification, 
provide coverage also for Gram-negative bacteria 
and anaerobes;
—  Duration of antibiotic therapy — until resolution of 
the infection and not just healing of the ulceration:
• Grade 2 infection by the PEDIS classification — 
1–2 weeks, in some cases longer (in particular 
in immunocompromised patients and those 
with limb ischemia);
• Grade 3–4 infection by the PEDIS classification 
— 2–4 weeks; 
— Route of administration:
• Intravenous — grade 4 infection by the PEDIS clas-
sification, some cases of grade 3 infection (MRSA, 
P. aeruginosa), intolerance of oral antibiotics;
• Oral — grade 2–3 infection by the PEDIS classifica-
tion, improved grade 4 infections;
• Topical — collagen sponge with gentamycin; use 
of garamycin sponge may be considered;
• Intraarterial — not recommended.
B.   Choice of antibiotics
— Severe infections:
• Intravenous therapy — ciprofloxacin + 
clindamycin, amoxicillin-clavulanate or piper-
acillin-tazobactam, or carbapenem + vancomy-
cin until a MRSA infection is excluded,
• Oral continuation — amoxicillin-clavulanate 
and cotrimoxazole (doubled dose) or cipro-
floxacin 750 mg twice daily or moxifloxacin + 
linezolid,
• MRSA infection: linezolin, vancomycin;
— Less severe infections:
• Usually oral therapy, using similar antibiotics as 
in severe infections, e.g.:
• Gram-positive bacteria: semisynthetic peni-
cillins/first-generation cephalosporins;
• Recent antibiotic therapy, Gram-positive or 
Gram negative bacteria: fluorochinolones, 
beta-lactams or if allergy to beta-lactams: 
clindamycin, flurochinolones, cotrimoxazole;
— Management of osteomyelitis (no consensus treat-
ment approach):
• Surgical removal of the affected bone (small 
amputation);
• Antibiotic therapy as in severe infections;
• Monitoring of the treatment effectiveness: lab-
oratory tests (erythrocyte sedimentation rate, 
CRP), foot radiographs.
VI.   Multidisciplinary management of the diabetic 
foot syndrome
Effective treatment of the diabetic foot syndrome 
may only be provided within multidisciplinary clinics. This 
concept encompasses an organizational structure that 
allows patient access to the required specialists knowl-
edgeable and experienced in the treatment of diabetic 
foot syndrome who form a therapeutic team and com-
municate with each other.
The management of the diabetic foot syndrome in-
cludes:
— Metabolic control of diabetes: insulin therapy 
(intensive insulin therapy is preferred), treatment 
with oral antidiabetic agents is acceptable in some 
cases if it allows appropriate metabolic control of 
diabetes and insulin treatment is not required;
— Foot off-loading: appropriate off-loading device 
for the affected foot (temporary footwear to off-
load the forefoot or hindfoot), compensatory 
footwear for the healthy foot, therapeutic insoles, 
crutches, wheelchair, plaster cast, specialized foot-
wear, bedrest. The gold standard for foot off-
loading is total contact cast;
— Antibiotic therapy (oral or intravenous), see above;
— Surgical treatment — removal of necrotic tissues, 
drainage, incisions;
— Intravascular and vascular surgical procedures, hy-
brid procedures (diabetic foot with a predominant 
ischemic etiology — patients with low ABI and/or 
a history of intermittent claudication should be 
referred for further vascular investigations and to 
a vascular surgeon or angiology specialist; of note, 
limb ischemia may not manifest with typical 
pain symptoms in many diabetic patients);
— Podiatric treatment (regular wound care, conven-
tional dressings, and wound moisturizing therapy);
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— Other — skin transplantation; growth factors; hu-
man skin preparations (in selected cases); hyper-
baric chamber, negative-pressure wound therapy; 
medications to improve perfusion (ischemic or 
predominantly vascular etiology); low-molecular-
weight heparins (acute ischemia, critical limb isch-
emia); acetylsalicylic acid; walking training. Sulo-
dexide treatment may be considered.
Each patient with the diabetic foot syndrome should 
receive education regarding ulcer prevention.
Neuropathic osteoarthropathy (Charcot foot)
—  Evaluation:
• Clinical picture when other causes have been 
excluded, radiograph (initially in the acute 
phase, followed by repeated studies), consider 
magnetic resonance imaging;
—  Management:
• Acute condition — off-loading for 24 hours 
a day (total contact cast, other forms of off-
loading), bisphosphonate therapy with vitamin 
D and calcium administration may be considered 
(long-term treatment, not always effective);
• Chronic condition — education, foot hygiene, 
special orthopedic footwear with corrective in-
soles, surgical and orthopedic procedures to cor-
rect deformations (exostectomy, arthrodesis).
Multidisciplinary team management is recommended.
VII. Indications for hospital admission
Acute admissions:
—  Grade 4 infection by the PEDIS classification;
—  Grade 3 infection by the PEDIS classification if 
intravenous antibiotic therapy is needed;
—  Need for negative-pressure wound therapy;
—  All cases of critical limb ischemia.
Elective admissions:
—  No improvement despite 2 months of outpatient 
treatment;
—  Preparation before planned surgery (small am-
putation, skin transplantation, revascularization 
procedures).
VIII. Amputation
—  Large amputation (above the ankle) should be 
considered in case of:
• A life-threatening condition due to inflamma-
tion, extensive necrosis (an absolute indica-
tion),
• Debilitating, treatment-resistant pain, particu-
larly due to ischemia (a relative indication),
• Loss of the support function of the foot (a rela-
tive indication);
—  Small amputation (below the ankle) should be 
considered in case of:
• Liquefactive necrosis,
• Osteomyelitis involving distal phalanges of the 
foot (avoidance of chronic antibiotic therapy, 
faster healing),
• In dry necrosis, awaiting until autoamputation 
is recommended.
The choice of the level of amputation depends on 
tissue perfusion, and reconstruction and rehabilitation 
possibilities.
Amputation should always spare as much limb as 
possible.
22. Diabetes in children and adolescents
The following chapter deals with variations from the 
general recommendations related to specific pediatric issues.
I. Diabetes types in the pediatric population
 1.  Autoimmune diabetes type 1 is the most common 
form.
 2.  In obese subjects, impaired fasting glucose and/or 
impaired glucose tolerance may develop, followed 
by diabetes type 2. OGTT (with insulin level testing) 
is recommended every two years in children above 
10 years of age (or earlier, if the puberty has already 
commenced) with BMI > 95th percentile.
 3.  Of note, monogenic diabetes is the second most 
common form of diabetes in the pediatric population 
in Poland. Investigations for monogenic diabetes are 
indicated in case of:
—  Development of diabetes during the first 9 months 
of life;
—  Mild hyperglycemia without the need for drug 
treatment;
—  Absence of anti-GAD, ICA, IA2, IAA, ZnT8 antibo-
dies;
—  Concomitant additional structural or developmental 
abnormalities affecting the kidneys, liver, pancreas, 
brain, or presence of concomitant conditions typi-
cal for genetic syndromes associated with diabetes;
—  Presence of diabetes and/or concomitant condi-
tions typical for genetic syndromes associated 
with diabetes in a first-degree relative;
—  Presence of diabetes or concomitant conditions 
typical for genetic syndromes associated with dia-
betes in a first-degree relative.
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 4.  The number of children with cystic fibrosis and dys-
glycemia or diabetes is increasing. Diabetes in these 
patients is usually asymptomatic. Annual OGTT with 
blood glucose measurements at 30, 60, 90 and 120 
minutes should be performed in children > 10 years 
of age.
 5.  Primary diagnostic work-up for hyperglycemia or re-
vision of the diagnosis always includes testing for 
anti-GAD65 antibodies along with 1–2 from the fol-
lowing: ICA, IA2, IAA, ZnT8 (testing should always be 
performed in a reference laboratory).
 6.  The possibility of a mixed diabetes etiology should 
always be borne in mind.
II. Therapeutic targets
 1.  Achieving and maintaining normal, harmonious phys-
ical development including body height, weight, and 
composition (as evaluated using percentile growth 
charts), and the course of puberty that is appropriate 
for age and gender, and providing an appropriate 
quality of life of the patient and his/her family.
 2.  Prevention of acute and chronic diabetes complica-
tions.
 3.  Therapeutic targets for cardiovascular risk reduction:
—  HbA1c ≤ 6.5% with stable blood glucose levels and 
minimized hypoglycemia episodes;
—  LDL cholesterol < 100 mg/dL (< 2.6 mmol/L), HDL 
cholesterol > 40 mg/dL (1.1 mmol/L), triglycerides 
< 100 mg/dL (1.1 mmol/L);
—  Blood pressure < 90th percentile for age, gender, 
and height (> 16 years of age: < 130/85 mm Hg);
—  BMI < 85th percentile for age and gender;
—  Moderate physical activity > 1 hour per day;
—  Sedentary activities < 2 hours per day.
III. Management of diabetes
 1.  Drug therapy
Diabetes type 1 — insulin therapy:
— The approach to insulin therapy should be ad-
justed to individual patient needs and accepted by 
the patient and his/her caregivers;
— Intensive insulin therapy is the treatment of choice, 
either as:
• Multiple daily injections using insulin pen nee-
dles with the length of ≤ 6 mm,
• Continuous subcutaneous insulin infusion (CSII) 
using a personal insulin pump;
— Indications for and contraindications to CSII — see 
respective Chapter;
— Initiation of CSII therapy at the disease onset is 
recommended in children < 10 years of age;
— Bolus calculator function use from the beginning 
of the therapy is advised, as it increases the stabi-
lity of blood glucose values and reduces the risk of 
hypoglycemia; it is necessary to verify and modify 
bolus calculator settings;
— The choice of rapid-acting and long-acting insulin 
analogs should be individualized based on pa-
tient’s needs, taking into account pharmacologi-
cal differences between various preparations and 
their licensed indications;
— In pediatric patients, daily insulin requirement is 
characterized by a large variability and increases 
significantly in the pubertal period;
— During intensive insulin therapy: the magnitude 
of the basal dose (20–50% of the daily dose) and 
its profile depend on the age of the child and the 
type of insulin pump; 
— Rapid-acting insulin analog/short-acting insulin is 
best administered 15–20 or 30–45 minutes be-
fore a meal, respectively; consider dose splitting 
and administering half of the dose before a meal 
and the other half during or after a meal, and in 
exceptional cases administering the whole dose 
after a meal;
— In appropriately educated patients, use of the 
bolus calculator function of the personal insulin 
pump increases stability of blood glucose levels 
and decreases the risk of hypoglycemia.
Diabetes type 2 — metformin and/or insulin is the 
treatment of choice.
In case of:
— Absent symptoms, HbA1c < 9%, and no acidosis, 
drug treatment may be started with metformin;
— Present symptoms and/or HbA1c ≥ 9% and no 
acidosis, initial drug treatment includes metformin 
and basal insulin;
— Ketoacidosis — initial treatment as in diabetes 
type 1.
Monogenic diabetes and diabetes in genetic syn-
dromes — treatment depends on the type of disease (use 
of sulphonylureas is off-label).
Diabetes in cystic fibrosis — an insulin-dependent 
condition, and insulin therapy is the treatment of choice.
2.   Nutrition in diabetic children and adolescents
Basic principles of healthy nutrition in diabetic chil-
dren are the same as in their non-diabetic peers.
 It is recommended to maintain normal energy bal-
ance and gradually reduce absorbable carbohydrate in-
take, maximally to 45–50% of the daily calorie require-
ment. Reduction of simple sugar intake to 10% of the 
daily calorie requirement is recommended, particularly in 
adolescents.
3.   Self-monitoring:
— Measurements of blood glucose, glucosuria and 
ketonemia/ketonuria and interpretation of these 
readings are the basis for pediatric diabetes care. 
Blood glucose monitoring may be undertaken by 
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blood glucose self-monitoring and/or real-time 
continuous glucose monitoring (CGM) generating 
messages and sound alerts without user input;
— Frequency of blood glucose measurements should 
be individualized but not less than 6 (usually 8–12) 
times per day;
Blood glucose should be measured in fasting condi-
tions and before meals, 1–2 hours after the meal, before 
bedtime, and before, during and after exercise. Periodic 
evaluation of night-time blood glucose profile is recom-
mended. Patients should be instructed to measure blood 
glucose immediately if feeling unwell.
If CGM is used, blood glucose levels should be measu-
red using a glucose meter when making therapeutic de-
cision or to verify the reading in case of hypoglycemia or 
high blood glucose values, and when clinical symptoms 
are inconsistent with the readings. Use of CGM requi-
res structured diabetes education regarding appropriate 
expectations towards this system, proper sensor calibra-
tion, appropriate choice and programming of messages 
and alarm limits, and proper interpretation of current 
readings and blood glucose trends.
The CGM system allows more effective adjustment 
of insulin doses to blood glucose trends, resulting in 
more stable blood glucose values, a reduced number of 
hypoglycemia episodes, better metabolic control, and 
improved quality of life of patients and their caregivers. 
It is particularly indicated in children with hypoglycemia 
unawareness, frequent nocturnal hypoglycemia, and in 
patients < 10 years of age. In these patient groups, it 
is recommended to use insulin pumps integrated with 
CGM, with a function of automatic temporary cessation 
of insulin administration in case of low blood glucose 
values or a risk of hypoglycemia. Use of CGM requires 
structured diabetes education. Only frequent use of CGM 
is effective therapeutically.
Criteria of appropriate metabolic control of diabetes 
based on blood glucose self-measurements: mean blood 
glucose level < 140 mg/dL, standard deviation < 50 mg/dL.
Betahydroxybutyrate testing by a test strip is a more 
sensitive marker of ketonemia than testing for ketones 
in urine.
4.   Therapeutic education 
— Education is a key element of diabetes manage-
ment; it should always be targeted at the patient 
and his/her caregivers;
— Patient and his/her parents/caregivers need initial 
education and regular educational reinforcements 
at least once in 1–2 years;
— Educational methods and programs should be var-
ied and adjusted to the patient’s age, intellectual 
capabilities, and educational tasks of the parents;
— In adolescents and young adults, particular at-
tention should be paid to prevention of chronic 
diabetes complications, contraception, and addic-
tions.
— The process of developing self-monitoring skills 
should be gradual; too early or too late place-
ment of this responsibility on children and ado-
lescents with diabetes is associated with treat-
ment failures;
— Workshops and camps for children, adolescents 
and young adults with diabetes are a useful and 
effective educational tool;
— Initiating and continuing diabetes education is 
a responsibility of the whole therapeutic team, 
with a particular role of a diabetes educator.
 5.  Psychological care
— Continuous psychological care of children, ado-
lescents and young adults with diabetes and their 
families is required since the disease onset;
— Common problems include subclinical and clinical 
depressive syndromes, eating disorders including 
anorexia nervosa (particularly in adolescent girls), 
and other non-specific conditions (eating disor-
ders not otherwise specified, ED-NOS);
— Care should be provided by an experienced psy-
chologist who is well versed with the problems of 
pediatric and adolescent diabetes.
— Screening for depressive disorders should be per-
formed in all patients every 1–2 years, and addi-
tionally in all patients with poor metabolic control 
of the disease.
 6.  Additional remarks
— The whole patient family should be involved in 
the process of treating diabetes in children and 
adolescents, with joint discussions on therapeutic 
targets;
— Patients should be encouraged to be independent 
and take responsibility for their treatment to a de-
gree that is appropriate for their age, intellectual 
development, and emotional maturity;
— Children > 10 years of age should be able to me-
asure blood glucose using a glucose meter and 
CGM, inject insulin using a pen, and change in-
fusion sets in personal insulin pumps and CGM 
sensors.
IV. Concomitant conditions in patients with diabetes 
type 1
— The most common conditions are autoimmune 
thyroiditis and celiac disease;
— Their course is usually oligo- or asymptomatic 
(e.g., increased blood glucose excursions, im-
paired growth).
V. Acute and chronic diabetes complications (see also 
respective chapters)
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1. Acute complications:
— Hypoglycemia in children should be diagnosed 
when blood glucose falls below 70 mg/dL (3.9 
mmol/L) or typical clinical symptoms occur; in case 
of hypoglycemia, glucose should be administered 
at about 0.3 g/kg body weight (dose depends 
on blood glucose values and active insulin), and 
blood glucose measurement should be repeated 
after 10–15 minutes;
— Severe hypoglycemia in children is diagnosed in 
case of altered consciousness and/or seizures;
— Diagnostic criteria for ketoacidosis and hypergly-
cemic hyperosmolar state in children are the same 
as in adults;
— Management of diabetic ketoacidosis in children is 
summarized in Figure 22.1;
— Management of hyperglycemic hyperosmolar 
state:
• Fluid therapy: rapid initial infusion ≥ 20 mL/ 
/kg body weight of 0.9% saline, with next doses 
administered until restoration of peripheral tis-
sue perfusion, followed by fluid replacement 
during 24–48 hours using 0.45% saline. The 
optimal rate of serum sodium reduction is 0.5 
mmol/L per hour, and of blood glucose is 50–70 
mg/dL per hour and no more than 90 mg/dL 
per hour. If blood glucose decreases by > 90 
mg/dL per hour, addition of 2.5–5% dextrose 
should be considered after a few initial hours 
of hydration therapy;
• Insulin therapy: insulin should be added if 
blood glucose does not decrease by at least 50 
mg/dL per hour during appropriate fluid thera-
py only; initial insulin dose is 0.025–0.05 unit/ 
/kg/hour, with further adjustment to achieve 
blood glucose reduction at the rate of 50–70 
mg/dL per hour;
• Electrolytes: potassium, phosphorus, and 
magnesium deficit is higher than in diabetic 
ketoacidosis; potassium supplementation shou-
ld be started as soon as renal function and diu-
resis is stabilized; intravenous administration of 
potassium phosphate and potassium chloride 
(1:1) allows adequate phosphate supplemen-
tation; phosphate administration may result in 
hypocalcemia; magnesium supplementation 
should be considered in hypomagnesemia.
 2.  Chronic complications:
— Regular follow-up evaluations are needed to pre-
vent complications (Table 22.1);
— If any chronic complication is diagnosed, screening 
for other abnormalities (e.g., nephropathy, retinopa-
thy, neuropathy, and macroangiopathy) is necessary;
— With persistent albuminuria, when albumin lev-
el is above the upper limit values, ACEI or ARB 
treatment is indicated to reduce its progression. 
Treatment effectiveness should be monitored with 
follow-up testing for albuminuria;
— ACE or ARB treatment is recommended to normal-
ize blood pressure; treatment effectiveness should 
be constantly monitored, and obtaining noctur-
nal blood pressure reduction is indicated, as con-
firmed by ambulatory blood pressure monitoring;
— Management of dyslipidemia:
• LDL cholesterol levels > 100 mg/dL (2,6 mmol/L) 
require improvement of blood glucose control 
and lifestyle modifications;
• In children > 10 years of age, if previous at-
tempts at making lifestyle modifications did 
not result in beneficial changes in serum lipids 
or other risk factors for atherosclerosis are pres-
ent, genetic testing for LDL cholesterol receptor 
gene mutations and possibly statin treatment 
should be considered if LDL cholesterol level is 
> 159 mg/dL (4.1 mmol/L).
VI. Perioperative management (see respective chapter)
VII. Recommendations regarding diabetes care in chil-
dren and adolescents (Table 22.1)
 1.  General recommendations
—  Every child with new-onset diabetes should be ad-
mitted to a specialist pediatric diabetes unit, and 
later remain under regular specialist care in a pediat-
ric and adolescent diabetes clinic until transition to 
adult diabetes care (for transition see Appendix 1);
—  A 24-hour access to diabetes information for pa-
tients and their caregivers should be provided;
—  Admission to a diabetes unit should be always 
considered with disease decompensation (HbA1c 
> 7.0% or blood glucose excursions above 1 stan-
dard deviation, recurrent hypoglycemia).
 2.  Therapeutic team
—  Inpatient care — per 10 pediatric diabetes beds: 
physicians (specialist in pediatric diabetes, spe-
cialist in pediatric diabetes and endocrinology, if 
unavailable: pediatrician/endocrinologist with an 
experience in diabetology confirmed by the voivod-
ship diabetes consultant in diabetology or pedia-
tric endocrinology or diabetology) — two full-time 
posts; nursing personnel devoted exclusively to 
diabetes education or diabetes educators — two 
full-time posts; dietitian (full post), psychologist 
(full post), and a social worker (1/4 post);
—  Outpatient care — per a therapeutic team caring 
for 300 patients: specialist in pediatric diabetes 
(if unavailable: pediatrician), specialist in pedi-
atric diabetes and endocrinology, if unavailable: 
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Figure 22.1. Management of diabetic ketoacidosis in children; ECG — electrocardiogram; i.v. — intravenous
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pediatrician/endocrinologist with an experience in 
diabetology confirmed by the voivodship diabetes 
consultant) — one full-time post; nursing person-
nel with duties limited to diabetes care or diabetes 
educators — 1–2 full-time posts; dietician — 1/2 
post; and psychologist — 1/2 post.
 3.  Outpatient visits
—  Unlimited frequency of diabetes visits, recom-
mended frequency every 6–8 weeks, at least 4 
times a year;
—  Recommended mean duration of a visit: 20–30 
minutes for a specialist visit and 30–40 minutes for 
a procedural and diagnostic visit (treatment with 
a personal insulin pump);
—  Educational visits do not always constitute a part 
of a physician consultation and may also be con-
veyed using electronic means;
—  Additional tasks of the therapeutic team include 
organization of care for diabetic children in edu-
cational facilities, organization of educational 
camps/workshops, and preparation of educational 
materials.
 4.  Outpatient clinic and hospital unit equipment
—  Equipment: automatic syringes, personal insulin 
pumps, glucose meters, CGM systems, ambulatory 
blood pressure monitors, ophthalmoscope, mono-
filaments, food scales, computer equipment to 
retrieve and print data from therapeutic systems;
—  Space and necessary teaching equipment for edu-
cation;
—  Hospital units: ≥ 1 intensive metabolic care bed 
per 10 regular diabetes beds, equipped with pulse 
oximetry and ECG monitor, oxygen source, USG 
machine with vascular flow measurement option.
VIII. A child with diabetes in an educational facility
 1.  Cooperation between the therapeutic diabetes team, 
pedagogical personnel, school nurse, and the patient 
Table 22.1. Recommendations regarding diabetes care in children and adolescents
Therapeutic education targeted at the 
patient and his/her caregivers
At the diagnosis and afterwards as required, at the discretion of the treating physician or 
education nurse
Nutritional education targeted at the 
patient and his/her caregivers 
At the diagnosis and afterwards as required, at the discretion of the treating physician or 
education nurse
Psychological care of the patient and his/ 
/her caregivers
At the diagnosis and afterwards as required, at the discretion of the treating physician or 
education nurse
Anti-GAD antibodies and 2 of the  
following: ICA, IA2, IAA1, ZnT8
At the diagnosis and revision of the diagnosis
HbA1c 3–4 times a years, more frequently as required
Serum total cholesterol, HDL cholesterol, 
LDL cholesterol, triglycerides
If positive family history — monitor annually since the diagnosis
If negative family history — assess at the diagnosis, then monitor every 5 years if LDL  
cholesterol > 100 mg/dL (2.6 mmol/L), annually if LDL cholesterol > 100 mg/dL  
(2.6 mmol/L)
If family history unavailable — assess at the diagnosis, then monitor every 1–2 years if LDL 
cholesterol > 100 mg/dL (2.6 mmol/L), every 2 years if LDL cholesterol > 100 mg/dL (2.6 
mmol/L)
Serum creatinine Calculation of eGFR using the Schwartz formula every 1–2 years, at the discretion of the 
treating physician
Albuminuria Every 1–2 years, at the discretion of the treating physician. An abnormal albuminuria  
testing result should by confirmed by its determination in 2 of 3 subsequent urine tests
Urinalysis (sediment, proteinuria) Every 1–2 years, at the discretion of the treating physician
Blood pressure During each visit, at least twice a year in children < 7 years of age, 24-hour ambulatory 
monitoring in children > 10 years of age
Ophthalmologic examination Every 1–2 years, at the discretion of the ophthalmologist
Body weight and growth monitoring At each visit using percentile charts for age and gender
Monitoring of pubertal development  
using the Tanner scale
At the discretion of the physician, at least annually
Monitoring of menstrual bleeding Menstrual bleeding diary
Investigations for celiac disease According to the respective ESPGNH guidelines, screening every 1–2 years for the first 10 
years of the disease duration if no clinical symptoms
Evaluation of thyroid function/ 
/investigations for thyroid disease
At the onset of the disease: TSH, FT4, anti-TPO and anti-TG (USG in case of positive  
antibody testing and/or thyroid dysfunction), followed by TSH, anti-TPO and anti-TG every  
1–2 years (at the discretion of the treating physician)
Specialist consultations According to general pediatric indication and at revision of the diagnosis
1Only at the diagnosis, within first 5 days of insulin therapy
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family is needed to ensure child safety at school and 
prevent diabetic patient stigmatization:
—  Following the diagnosis of diabetes, the peda-
gogical personnel should be provided with written 
information about the disease and necessary help 
in life-threatening situations, along with contact 
telephone numbers of the parents, treating physi-
cian, and education nurse;
— Appropriate training of the pedagogical personnel 
regarding diabetes self-management;
— Training of the school nurse regarding the use of 
a glucose meter, insulin pen, or insulin pump;
—  The educational facility should be adequately pro-
vided with glucose and glucagon by the patient’s 
caregivers;
—  Diabetes is not an indication for an individualized 
education plan or exemption from any activities 
(e.g., sport activities or school trips).
 2.  Duties of the pedagogical personnel:
—  Comprehensive help allowing rapid and safe pa-
tient return to the educational facility and full 
integration with peers;
—  Basic knowledge of diabetes self-management;
—  Allowing on-site diabetes self-monitoring in the 
educational facilities by patients of all age groups, 
with supervision by the school staff in younger 
children;
—  Strict cooperation with the therapeutic diabetes 
team and the patient’s caregivers;
—  Providing immediate help in life-threatening con-
ditions associated with diabetes.
Guidelines for teachers are available online at: http://
www.mz.gov.pl/__data/assets/pdf_file/0003/6096/cukrzy-
ca.pdf.
IX. Travel
— Responsibilities of the patient and his/her care-
givers include informing the organizer about the 
disease, its management, nutrition, and help in 
acute situations, and providing contact telephone 
numbers of the members of the therapeutic dia-
betes team;
—  An appropriate certificate in English informing 
about the disease should be prepared before an 
international travel;
—  Insulin, glucagon, glucose, glucose meter with 
reagent strips, equipment for insulin pumps, and 
insulin pens should be appropriately stored and 
placed in the hand-luggage.
X. Choice of future profession
—  Particular attention should be paid to education 
of diabetic patients, and providing them with as 
good education as possible;
—  A task of the therapeutic diabetes team is to help 
the patient with the choice of future profession by 
evaluating his/her health status, presence of com-
plications, and intellectual and mental capabilities.
23. Diabetes and pregnancy
Pregnancy planning in all women with diabetes has 
a major effect on the course of the disease, reducing 
adverse maternal and fetal/neonatal outcomes.
Diabetes in pregnancy includes:
 1.  Pregestational diabetes mellitus (PGDM) — diabetes 
preexisting in a woman who becomes pregnant (re-
gardless of the diabetes type).
 2.  Hyperglycemia first detected at any time during preg-
nancy.
I. Contraception
Diabetic women may use barrier methods or oral 
contraception.
 1.  Barrier methods [intrauterine devices (IUD), condoms] 
may be used with the same limitations as in non-
diabetic women.
 2.  Hormonal contraception is possible in diabetic women:
—  Who do not smoke;
—  With BMI < 30 kg/m2;
—  With well-controlled diabetes.
If vascular complications are present, the physician 
must assess the risk-to-benefit ratio before prescribing 
hormonal contraception.
Combined oral contraceptives containing less than 
35 µg of ethinylestradiol are recommended due to their 
minimal effect on carbohydrate and lipid metabolism. 
Preferred progestins include levonorgestrel and norethis-
terone.
A progestin-releasing IUD is recommended as a con-
traceptive method in obese women > 35 years of age, 
patients with diabetes type 2, and in those with concomi-
tant vascular complications.
II. Model of care for pregnant diabetic women
 1.  During pregnancy planning, pregnancy, and the post-
partum period, all diabetic women should remain 
under care of an experienced team of diabetologists 
and obstetricians.
 2.  Management aims include:
—  Optimization of diabetes treatment;
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—  Evaluation and treatment of diabetic complica-
tions;
—  Diabetes education, including nutritional advice;
—  Evaluation of thyroid function (to exclude hypo-
thyroidism): the upper limit of the reference range 
for thyroid-stimulating hormone (TSH) should be 
defined as 2.5 µIU/mL in the first trimester and up 
to 3.0 µIU/mL in the second and third trimester;
—  During pregnancy, visits related to diabetes should 
occur at least once a month, and in some cases 
every 2–3 weeks. This is due to, among others, 
changing insulin requirements and the need to 
monitor body weight, renal function, eyesight, 
and blood pressure;
—  In diabetic women with chronic hypertension, tar-
get systolic blood pressure is 110–129 mm Hg and 
target diastolic blood pressure is 65–79 mm Hg 
(methyldopa is the first-choice drug during preg-
nancy);
—  In case of gestational hypertension at blood pres-
sure values exceeding 140/90 mm Hg treatment 
should be resumed.
 3.  Pregnancy is not recommended in women with dia-
betes complicated by:
— Severe nephropathy with GFR < 40 mL/min;
—  Uncontrolled, treatment-resistant hypertension;
—  Severe, treatment-resistant proliferative retinopa-
thy;
—  Active, advanced ischemic heart disease or a his-
tory of myocardial infarction;
—  Autonomic neuropathy involving the cardiac con-
duction system or the gastrointestinal system.
Ultimately, decisions regarding procreation are to be 
made by the patient herself, but the patient must be in-
formed about the health risks of pregnancy in such cases.
Pregnancy does not seem to be associated with a risk 
of post-partum worsening of chronic diabetes complica-
tions. Unless the above listed complications are present, 
women with diabetes are free to plan any number of 
children they wish.
III.	Diagnostic	criteria	and	classification	of	hyperglyce-
mia	first	detected	during	pregnancy
All pregnant women should be evaluated for dys-
glycemia. Initial fasting blood glucose measurement to 
detect gestational hyperglycemia should be ordered early 
during pregnancy, at the time of the first visit to a gy-
necologist. In pregnant women at risk (see Table 23.1), 
a diagnostic test (OGTT with 75 g of glucose) should 
be ordered already at the time of the first visit during 
pregnancy (see Chapter 1). If blood glucose is normal 
(see Figure 23.1), the diagnostic test should be repeat-
ed between 24 and 28 weeks of gestation or in case 
of symptoms suggesting diabetes. Between 24 and 28 
weeks of gestation, single-step diagnostic investigation 
is performed using OGTT with 75 g of glucose. 
Hyperglycemia first detected at any time during preg-
nancy should be diagnosed and categorized using the 
2013 WHO classification:
— Diabetes mellitus in pregnancy — if general condi-
tions for the diagnosis of diabetes are met, i.e.;
• Fasting blood glucose ≥ 7.0 mmol/L (126 mg/ 
/dL), or
• Blood glucose at 2 hours of OGTT with 75 g of 
glucose ≥ 11.1 mmol/L (200 mg/dL), or
• Random blood glucose ≥ 11.1 mmol/L (200 mg/dL) 
associated with clinical symptoms of hypergly-
cemia;
— Gestational diabetes mellitus (GDM) — if at least 
one of the criteria in Table 23.2 is met.
In the postpartum period, blood glucose normalizes 
in most women but all women should be evaluated for 
dysglycemia, as diabetes in pregnancy is a risk factor 
for overt diabetes during later life. An OGTT with 75 g 
of glucose is recommended at 6–12 weeks postpartum, 
followed by fasting blood glucose measurements every 
year. An OGTT with 75 g of glucose should be performed 
before the next planned pregnancy.
IV. Multidisciplinary, integrated approach to the man-
agement of pregestational diabetes mellitus and 
hyperglycemia during pregnancy
Hyperglycemia during pregnancy increases the risk of 
complications in the pregnant woman and the develop-
ing fetus, and also affects further child development. 
Thus, blood glucose values seen in healthy pregnant 
Table 23.1. Risk factors for hyperglycemia during pregnancy
— pregnancy beyond 35 years of age
— history of macrosomia (birth weight > 4000 g)
— previous delivery of a neonate with a congenital anomaly
— history of intrauterine fetal demise
— hypertension
— overweight or obesity
— family history of diabetes type 2
— gestational diabetes during previous pregnancies
— multiparity
— polycystic ovary syndrome
Table 23.2. Diagnostic criteria for gestational diabetes ba-
sed on an oral glucose tolerance test with 75 g of glucose 
according to IADPSG (2010) and WHO (2013)
Measurement Plasma glucose
[mg/dL] [mmol/L]
Fasting 92–125 5,1–6,9
60 minutes ≥ 180 ≥ 10,0
120 minutes 153–199 8,5–11,0
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Figure 23.1. Detection of diabetes during pregnancy. An oral glucose tolerance test (OGTT) with 75 g of glucose is recommen-
ded (one step approach). Note: randomly measured fasting blood glucose in the first trimester > 92 mg/dL but > 125 mg/dL 
may not be used to diagnose diabetes during pregnancy; OGGT is required following appropriate patient preparation
women should be aimed for regardless of the type of 
pregnancy (PGDM or hyperglycemia during pregnancy). 
Currently, the following target self-measured blood glu-
cose values are recommended:
—  Fasting and before meals: 70–90 mg/dL (3.9–5.0 
mmol/L);
—  Maximum blood glucose level at one hour after 
a meal: < 140 mg/dL (< 7.8 mmol/L);
—  Before 2 and 4 AM: 70–90 mg/dL (3.9–5.0 mmol/L).
Pregnant women should perform SBGM after an ap-
propriate training by a nurse experienced in caring for di-
abetic patients. The number and timing of SBGM should 
depend on the severity of dysglycemia and the treatment 
used. CGM may be helpful in women treated with CSII.
HbA1c level in women with PGDM should be mea-
sured every 6 weeks, and values < 6.5% in the first tri-
mester, < 6.0% in the second and third trimester should 
be aimed for. No evidence supports the usefulness of 
HbA1c measurements as a tool to monitor metabolic con-
trol in GDM.
 1.  Nutritional therapy:
— Carbohydrates — 40–50% of the daily calorie in-
take (approximately 180 g carbohydrates/day); 
low glycemic index carbohydrates are preferred;
— Protein — 30% of the daily calorie intake (1.3 g/kg 
body weight) per day;
— Fats — 20–30% of fats the daily calorie intake 
(saturated < 10%);
— Daily calorie intake depending on body weight, 
height, physical activity and age — the mean dai-
ly calorie requirement is about 35 kcal/kg body 
weight or 1500–2400 kcal;
— Low calorie diet is recommended in overweight 
patients;
— Excessive body weight in pregnant woman is asso-
ciated with increased risks of large for gestational 
age;
— The diet should allow normal body weight increase 
during pregnancy, i.e. on average by 8–12 kg de-
pending on baseline body weight (ranging from 
about 7 kg for BMI > 29.0 kg/m2 to 18 kg for BMI 
< 19.8 kg/m2);
— Use of artificial sweeteners is allowed, except for 
saccharin which crosses the placenta and its effect 
on the developing fetus is not entirely clear (see 
Appendix 5);
— Use of multivitamin preparations available on the 
market in Poland is recommended, similarly to all 
pregnant women.
 2.  Physical exercise:
— Aerobic activity of moderate intensity is recom-
mended unless contraindicated.
 3.  Insulin therapy in PGDM:
— Human insulins have been long used for the treat-
ment of diabetes during pregnancy and their safe-
ty has been established. Safety of insulin analogs 
lispro and glargine has been shown in a number 
of observational studies, and that of aspart and 
determir also in randomized studies;
— Intensive insulin therapy with multiple insulin in-
jections (see Chapter 11);
— Insulin therapy with CSII — rapid-acting insu-
lin analogs are recommended. Patient selection 
for personal insulin pump therapy and manag-
ing PGDM patients using this approach should 
be undertaken in diabetes units experienced in 
CSII therapy. Treatment should be preferably initi-
ated while planning pregnancy or during early 
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pregnancy (before 12 weeks of gestations), and 
only exceptionally later in those patients in whom 
adequate metabolic control cannot be achieved 
during treatment with multiple insulin injections.
 4.  Insulin therapy in hyperglycemia first detected during 
pregnancy:
— The recommended approach is intensive insulin 
therapy with multiple insulin injections;
— Insulin requirement is sharply reduced postpartum 
and insulin therapy may be withdrawn in most 
patients with GDM.
 5.  Oral antidiabetic agents are currently not recom-
mended for the treatment of diabetes during preg-
nancy due to the fact that they pass through the pla-
centa and no data are available regarding their long-
term effects in the offspring. In women treated with 
oral antidiabetic agents, initiation of insulin therapy 
while planning pregnancy or as early as possible after 
the diagnosis of pregnancy is recommended.
 6.  Educational system:
— Clinical issues — instruction provided by a physi-
cian, nurse, or dietitian knowledgeable in personal 
insulin pump therapy;
— Technical issues regarding the use of a personal insu-
lin pump — instruction provided by a nurse or physi-
cian certified as a technical instructor or an employee 
of the company producing personal insulin pumps;
— Education program is undertaken according to the 
training card which serves to document the course 
of treatment;
— Education program may be undertaken in outpa-
tient and/or inpatient settings;
— Treatment initiation is possible when the patient 
absorbs basic clinical and technical knowledge re-
garding CSII (understanding the therapeutic prin-
ciples and technical details of using main insulin 
pump functions).
 7.  Breastfeeding should be widely promoted and rec-
ommended in women with PGDM and DGM unless 
contraindicated for other reasons.
24. Diabetes in the elderly
I.   The prevalence of diabetes in the elderly (subjects 
> 65 years of age) may be as much as 25–30%.
II.   Symptoms of hyperglycemia in patients > 65 
years of age may be less evident than in younger 
subjects, leading to a delayed diagnosis.
III.   Expected survival time is much reduced in diabet-
ic patients at an advanced age, and thus it should 
be remembered while planning the therapy that 
preventing complications that develop after sev-
eral years of the disease becomes less important 
than in younger subjects.
IV.   Management goals in diabetic patients > 65 
years of age:
—  The major management goal in the elderly diabet-
ic patients is to improve or at least preserve their 
previous quality of life. Avoiding hypoglycemia 
while reducing the symptoms of hyperglycemia is 
of key importance;
—  If the expected survival time of a diabetic patients 
is longer than 10 years, diabetes control should be 
gradually instituted with the target HbA1c level of 
≤ 7%;
—  In patients at an advanced age with long-standing 
diabetes and significant macroangiopathic compli-
cations (previous myocardial infarction or stroke), 
the target HbA1c level is ≤ 8.0%;
—  Investigating for diabetic complications, prevent-
ing their progression, and recommending appro-
priate therapy;
—  Management of concomitant conditions to reduce 
functional impairment and improve the quality of 
life.
V.   Physical exercise — following initial determination 
of the individual risk and patient’s exercise tolerance, 
outdoor exercise characterized by gradual onset and 
termination should be recommended, with avoid-
ance of straining and breath-holding exercises and 
due attention to the risk of trauma, in particular the 
risk of developing diabetes foot syndrome.
VI.   Nutritional recommendations — general recom-
mendations apply; no age-specific recommenda-
tions; diet modifications are of little effectiveness 
due to long-lasting dietary habits.
VII.   Oral antihyperglycemic agents:
—  Metformin — see Chapter 10, section II (stage 1 
treatment of diabetes type 2); consider concomi-
tant conditions and an increasing risk of metabolic 
acidosis; particular attention is required in patients 
with estimated GFR < 60 mL/min/1.73 m2 (see 
Table 18.3);
—  Sulphonylureas — treatment should be initiated 
with low doses due to a risk of hypoglycemia;
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—  DPP-4 inhibitors, GLP-1 receptor agonists, alpha-
glucosidase inhibitor, PPAR-g agonist, SGLT-2 in-
hibitors — no specific contraindications exist to 
the use of these agents in patients > 65 years of 
age; these agents may be particularly useful in this 
age group due to a minimal risk of hypoglycemia. 
Do not use the PPAR-g agonist in patients with 
even mild heart failure.
VIII. Insulin therapy:
—  No specific indications and contraindications exist 
regarding insulin therapy in the elderly;
—  If indicated, insulin therapy should not be delayed;
—  Insulin preparations characterized by the lowest 
risk of hypoglycemia should be selected when ini-
tiating or modifying insulin therapy;
—  Age > 65 years is not a contraindication to inten-
sive insulin therapy;
—  In some very elderly patients (> 80 years of age), it 
may be effective to use low doses of a short-acting 
insulin or rapid acting analogous of insulin before 
main meals without basal long-acting insulin;
—  If meal size is unpredictable (e.g. patients with 
poor appetite or advanced dementia), rapid-act-
ing insulin analogs administered directly after the 
meal in a dose adjusted to the meal size may be 
indicated.
IX. Diabetes education — should be targeted to both 
patients and their caregivers.
X. Antihypertensive therapy:
—  Age is not a criterion when selecting antihyperten-
sive drug classes;
—  Benefits of antihypertensive therapy in patients 
> 65 years of age are similar compared to those 
in younger subjects.
XI.  Lipid-lowering therapy:
—  Although direct evidence are lacking, it may be 
concluded that benefits of lipid-lowering therapy 
seen in both primary and secondary prevention in 
younger subjects may also be extended to patients 
> 65 years of age;
— Recommended doses of statins, depending on the 
risk of cardiovascular disease and age of the pa-
tient, are showed in Table 13.1.
25. Preparing a diabetic patient for a surgical procedure
General remarks:
—  In hospital, the patient should be consulted by 
a diabetologist before a surgery;
—  Investigations to assess the degree of diabetes 
control and the presence of diabetes complica-
tions should be performed;
—  Appropriate metabolic control is required in dia-
betic patients before the planned surgery;
—  Insulin therapy must not be interrupted in patients 
previously treated with insulin.
I. Investigations necessary before the planned surgi-
cal procedure:
—  24-hour blood glucose profile (7 measurements 
during 24 hours, with an additional measurement 
at 3 AM in insulin-treated patients);
—  HbA1c level;
—  Complete blood count;
—  Serum creatinine, electrolytes (Na+, K+), amino-
transferases (AST, ALT);
—  International normalized ratio (INR), bleeding 
time, activated partial thromboplastin time (APTT);
—  Acid-base balance (blood gases);
—  Urinalysis;
—  Fundoscopy;
—  Resting ECG (see Remark 1);
—  Chest radiograph.
Remark 1: Complete non-invasive diagnostic work-
up (exercise testing, echocardiography, ECG Holter moni-
toring) should be performed in patients with several 
risk factors for ischemic heart disease, angina pectoris, 
previous myocardial infarction, heart failure, and those 
scheduled for an extensive procedure (e.g. abdominal or 
iliac vascular surgery).
Remark 2: One-day surgery may be planned only in 
patients with good metabolic control during intensive 
insulin therapy. Patients with diabetes type 2 who are ef-
fectively treated with diet only or with diet and metformin 
[blood glucose < 140 mg/dL (7.8 mmol/L), HbA1c ≤ 6.5%] 
may also undergo one-day surgery as perioperative insulin 
therapy is not required in these patients. However, it is 
necessary to withhold metformin by at least 24 hours be-
fore the planned surgery. Other diabetic patients, regard-
less of the diabetes type and previous treatment, should 
receive insulin therapy in the perioperative period.
II. Preoperative management
 1.  Diabetic patients requiring intermittent insulin ther-
apy should be admitted 2–3 days before the planned 
surgery.
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 2.  Elective surgery should be delayed in patients with in-
adequate metabolic control [persisting blood glucose 
values > 250 mg/dL (13.9 mmol/L), HbA1c > 9% and/ 
/or the presence of glucosuria with acetonuria].
 3.  Oral antidiabetic agents should be withdrawn 2 days 
before the surgery.
 4.  Insulin therapy with multiple injections should be 
initiated:
—  Daily insulin dose — 0.3–0.7 unit/kg body weight 
(see Remark 2);
• 50–60% of the daily dose — a short-acting 
insulin or rapid-acting insulin analog admin-
istered 15–30 minutes before main meals ac-
cording to the following regimen: 50–20–30% 
of the daily dose of short-acting insulin/rapid-
acting insulin analog;
• 40–50% of the daily dose — a long-acting insu-
lin (NPH) administered in two doses — at 7–8 
AM (40%) and 10–11 PM (60%), or a long-ac-
ting analog given once daily, most commonly in 
the evening. A well-trained diabetic patient 
with good metabolic control is able to self-
adjust insulin doses to his/her current needs 
and thus this practice should be allowed to 
be continued in the hospital instead of ini-
tiating	 treatment	with	fixed,	 unmodifiable	
insulin doses.
Individuals using personal insulin pump should ma-
intain the current treatment by the day of the surgery.
 5.  If preparation for the surgery requires a nil-by-mouth 
regimen during the day(s) before the surgery, intrave-
nous infusion of 10% dextrose with 12 units of rapid-
-acting insulin and 10 mmol of KCl is recommended 
instead of meal.
 6.  Blood glucose control: in the perioperative period, 
blood glucose levels should be kept within the safe 
range of 100–180 mg/dL (5.6–10.0 mmol/L).
 7.  The surgical and anesthetic team should be informed 
about complications that increase the operative risk 
(cardiac and renal disease, neuropathy, proliferative 
retinopathy).
Remark 3: Temporary intensive insulin therapy is not 
required in patients undergoing minor procedures (tooth 
extraction, abscess incision, small amputation performed 
in the outpatient settings, cataract surgery) but only if 
preparation for the surgery does not require any change 
in nutrition. If 1 or 2 meals need to be omitted due to 
the surgery, intravenous glucose, insulin, and potassium 
infusion is recommended (500 ml of 10% dextrose with 
12 units of a short-acting insulin and 10 mmol KCl), ad-
ministered at the rate of 100–150 ml/hour. Insulin and 
potassium doses may need to be modified according to 
blood glucose and serum potassium levels.
III. Management on the day of the surgery
 1.  Use intravenous glucose, insulin, and potassium infu-
sion with blood glucose monitoring:
—  Algorithm 1: In patients with absolute insulin 
deficiency, separate continuous intravenous in-
fusions of insulin (1 unit of short-acting human 
insulin in 1 mL 0.9% saline) and dextrose (5– 
–10%) using infusion pumps are recommended. 
For each 1 g of exogenous dextrose, 0.2–0.3 unit 
of insulin is needed (Table 25.1). If blood glu-
cose during the procedure increases by 30–50 
mg/dL over 180 mg/dL, the rate of insulin infu-
sion should be increased by 1–2 units/hour. If 
blood glucose increases above 250 mg/dL (13.9 
mmol/L), dextrose infusion should be stopped 
and resumed only after blood glucose decreases 
below 180 mg/dL (10 mmol/L). At the same time, 
it is also recommended to increase the rate of 
insulin infusion. This treatment should be contin-
ued until resumption of oral feeding. During in-
travenous insulin infusion, blood glucose should 
be monitored every 1 hour, followed by every 
2 hours after blood glucose is stabilized in three 
subsequent readings;
—  Algorithm 2: In patients with diabetes type 2 and 
preserved insulin secretion, an optional approach 
is to administer glucose, insulin, and potassium 
(500 mL 10% dextrose with 8–16 units of short-
acting insulin and 10–20 mmoL of KCl).
• A larger insulin dose (≥ 16 units) should be 
considered in obese patients, with severe infec-
tion, during cardiac or lung surgery, in patients 
operated under hypothermia, and if baseline 
blood glucose is > 180 mg/dL (10.0 mmol/L),
• A smaller insulin dose (12 units) should be con-
sidered in lean patients and in those receiving 
Table 25.1. Dosing of 10% and 5% dextrose and insulin infusion in relation to blood glucose levels
Blood glucose 10% dextrose  
[mL\hour]
5%	dextrose*	 
[mL\hour]
Insulin  
[units\hour]
< 90 mg/dL (< 5.0 mmol/L) 50 100 Stop infusion for 15–30 minutes 
90–120 mg/dL (5.0–6.7 mmol/L) 50 100 0.5–2 
120–180 mg/dL (6.7–10 mmol/L) 50 100 2–3 
*5% dextrose is preferred with greater fluid deficit and/or higher plasma osmolality
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small insulin doses or oral antidiabetic agents 
before the surgery.
 2.  Intravenous glucose, insulin, and potassium infusion 
should be initiated at 8 AM and continued at the rate 
of 80 mL/hour until resumption of normal oral feed-
ing.
 3.  During intravenous glucose, insulin, and potassium 
infusion, blood glucose should be kept at 100–180 
mg/dL (5.6–10.0 mmol/L):
—  If plasma glucose level decreases or is close to the 
lower limit of the recommended range, insulin 
dose should be reduced by 2–4 units;
—  It is recommended to increase the insulin dose 
by 2 units per each 30 mg/dL (1.6 mmol/L) rise 
of plasma glucose level over > 180 mg/dL (> 10 
mmol/L).
 4.  If continued surveillance over the operated patient is 
possible, the algorithm 1 should be preferred.
IV. Postoperative management
 1.  Insulin treatment with multiple subcutaneous insulin 
injections or using a personal insulin pump should 
be initiated upon resumption of oral nutrition and 
continued (in case of temporary insulin therapy) until 
surgical wound healing. Depending on blood glucose 
levels, insulin should be administered subcutaneously 
1–3 hours before termination of the intravenous infu-
sion.
 2.  If good metabolic control of diabetes was present 
before the surgery, resumption of previous treatment 
is possible upon surgical wound healing.
Remark 4: In diabetic patients previously treated 
with insulin, operated due to an acute or chronic inflam-
matory condition, a possibility of a reduction of daily 
insulin requirement should be taken into consideration.
Remark 5: In patients with diabetes type 2 previ-
ously treated with oral antidiabetic agents, in whom daily 
insulin requirement is less than 30 units, previous oral 
treatment may be resumed in case of good metabolic 
control of diabetes.
V. Perioperative management in children — Table 25.2
Insulin dosing algorithm in case of major procedures 
and those requiring intravenous insulin therapy (Tab-
le 25.2).
In case of non-major procedures (< 2 hours) under 
general anesthesia or conscious sedation, patients with 
good metabolic control may be admitted in the morning 
on the day of the procedure or in the afternoon on the 
preceding day. Subcutaneous insulin therapy may be 
continued, or the algorithm for major procedures may 
be used (Table 25.3).
VI. Urgent surgery
Diabetic patients may sometimes require an urgent 
surgery.
In these cases, it is necessary to exclude ketoacidosis 
associated with poor metabolic control of diabetes as 
the cause of peritonism. Thus, if an acute abdomen is 
thought to be present in a patient with diabetic acidosis 
(acetonuria and metabolic acidosis as indicated by blood 
gases), correction of acid-base abnormalities should be 
attempted immediately.
 1.  Ketoacidosis (base excess < –12; pH < 7.3) and hy-
perglycemic hyperosmolar state should be corrected 
according to the general management principles.
 2.  If acute diabetes complications are nor present and 
the patient took his/her morning insulin dose, intra-
venous insulin infusion should be administered dur-
ing the procedure, as described above.
Table 25.2. Perioperative management in children. An algorithm for intravenous insulin dosing in relation to blood  
glucose levels
Infusion of a 1 unit of insulin/1 mL solution  
(add 50 units of insulin to 50 mL 0.9% saline) using a syringe pump
Blood glucose [mg/dL]/[mmol/L] Insulin infusion rate Hydration
< 90/5.0 Stop infusion for 10–15 minutes Type	of	fluid:
90–109/5–6.1 0.02 mL/kg/hour • blood glucose > 250 mg/dL: 0.9% saline
110–126/6.1–7.0 0.025 mL/kg/hour (basal infusion rate) • blood glucose < 250 mg/dL: 10% dextrose
127–143/7.0–8.0 0.035 mL/kg/hour Rate:
144–216/8.0–12.1 0.05 mL/kg/hour • 4 mL/kg/hour (for body weight up to 10 kg)
217–271/12.1–15.1 0.075 mL/kg/hour • add 2 mL/hour per each kg of body weight  
between 11–20 kg
> 271/> 15.1 0.1 mL/kg/hour • add 1 mL/hour per each kg of body weight > 20 kg
Maximum rate 2000–2500 mL/day
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Every child with diabetes should undergo all currently 
recommended vaccinations. According to the 2015 im-
munization schedule for Poland, compulsory immuniza-
tion includes vaccination against Streptococcus pneu-
moniae at 2–5 years of age (using 10- or 13-valent pneu-
mococcal vaccine), and 13-valent pneumococcal vaccine 
is recommended from 6 years of age until the elderly age. 
Annual influenza vaccination is recommended in children 
> 6 years of age and adults. Chickenpox (varicella) vac-
cinations should be encouraged as the disease may result 
in serious decompensation of diabetes.
Since 1996, all infants are vaccinated against hepatitis 
B virus, and since 2000 this vaccination is also offered to 
14-year-olds. Vaccination is recommended in all patients. 
Unvaccinated subjects at any age should be actively iden-
tified and offered vaccination according to the 0, 1, 6 
months regimen. If the anti-HBs antibody titer in previ-
ously vaccinated subjects is < 10 IU/L, revaccination using 
1–3 doses is recommended. If a protective antibody titer is 
not achieved after 3 vaccine doses (at 4–12 weeks after the 
last dose), further vaccination is not attempted. Each vac-
cination should be preceded by a physician examination.
Table 25.3. Subcutaneous insulin therapy in case of non-major procedures under general anesthesia or conscious  
sedation
Basal–bolus  
therapy
Basal insulin: NPH insulin — 50% of the morning dose, long-acting insulin analog — 100% of the morning 
dose
Initiate intravenous fluids; in patients with normal blood glucose levels, non-glucose-containing fluids may 
be used initially, followed by 5% or 10% dextrose in amounts appropriate to prevent hypoglycemia.
Morning procedure:
Bolus — only as a correction dose
Initiate intravenous fluids
Afternoon procedure:
Bolus — if the child is allowed to have a breakfast — the usual dose of a rapid-acting insulin analog or 50% 
of the usual dose of a short-acting insulin; a correction dose may be added
Initiate intravenous fluids 2 hours before the procedure or no later than at noon
Therapy using  
personal insulin 
pump
It may be continued only if the anesthesiologist accepts this form of therapy and is able to manage it
Continue insulin therapy using a previosly programmed basal dose for a given period during the day  
(modification of the basal dose is usually not required)
Hypoglycemia: withhold basal dose administration (for up to 30 minutes)
Hyperglycemia: a correction bolus
Initiate intravenous fluids 2 hours before the procedure
26. Vaccinations in diabetic patients
27. Recommendations regarding professional activity of diabetic patients
Developed in cooperation with Dr. Andrzej Marcinkiewicz 
and Prof. Jolanta Walusiak-Skorupa from the Institute 
of Occupational Medicine in Łódź
 1.  The sole fact of suffering from diabetes should never 
be a basis for discrimination or unequal treatment. 
Any professional limitations should be imposed after 
a careful analysis of the individual patient status and 
health condition.
 2.  In addition to providing effective therapy, the role of 
diabetologist in maintaining professional activity of 
diabetic patients includes:
—  Health education targeted at the development of 
health awareness and understanding of limita-
tions arising from potential diabetes complica-
tions;
—  Help with producing an objective opinion regard-
ing patient’s health predispositions to professional 
activity by presenting information to the physician 
authorized for medical review and opining.
 3.  The patient’s attitude should be the key factor taken 
into account when evaluating the health status for the 
purpose of professional activities. Each diabetic patient, 
regardless of the diabetes type and the management 
approach, must actively participate in the treatment.
 4.  Patient’s health predispositions to professional activi-
ties or driving are evaluated and opined by a physi-
cian authorized to perform preventive health exami-
nations or medically certify drivers. Due to an inci-
dental nature of contacts with patients (often dur-
ing a single consultation) leading to opining on the 
individual health status, it is advisable that a diabetic 
patient produce an opinion of the treating physician.
 5.  During the consultation for the purpose of medical 
review and opining, a diabetes specialist should:
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—  Evaluate patient knowledge regarding the disease, 
its treatment, and possible complications, rating it 
as extensive, satisfactory, or not satisfactory;
—  Evaluate blood glucose self-management ability, 
rating it as high, acceptable, or low;
—  Evaluate hypoglycemia awareness and the pa-
tient’s ability to prevent and counteract hypogly-
cemia, rating it as good or not satisfactory;
—  Confirm the presence or absence of hypoglycemia 
prodromes;
—  Categorize the risk of hypoglycemia as low, ac-
ceptable, or high;
—  Determine the presence of chronic diabetes com-
plications involving the eye, nervous system, and 
cardiovascular system;
—  Provide additional comments regarding chronic 
diabetes complications and the health condition 
of the patient which are important for the assess-
ment of the risk for public safety.
 6.  Justification of professional activity limitations in dia-
betic patients is twofold and results from:
—  A risk of a hypoglycemic episode and associated 
impaired consciousness;
—  A risk of late diabetes complications which reduce the 
ability to engage in specific professional activities.
Contraindications to driving for holders of various 
categories of driving license and contraindications to 
work at specific workplaces are given in Appendix 2 
 7.  Patients with advanced chronic diabetes complica-
tions should not engage in professional activities in 
which organ damage resulting from diabetes might 
affect work safety. However, this should not refrain 
them from undertaking other activities for which 
a given diabetes complication is not an issue. At 
the same time, the nature of professional activities 
and related nuisances should not hinder metabolic 
control of diabetes, and thus patient protection from 
the development and acceleration of chronic diabetes 
complications.
 8.  A diabetes consultation for the purpose of examin-
ing drivers and workers should conclude with issuing 
a clear opinion on a standardized diabetes consultation 
card, using a template provided in the Appendix 2.
 9.  Health requirements for diabetic patients should be 
divided into two categories depending on patient’s 
professional activities or workplace.
 10. The first (higher) category includes professional activi-
ties and workplaces requiring unaffected psychomotor 
skills and related to exposure to adverse psychosocial 
factors, when performing professional duties might 
have an effect on the safety of the worker and his/her 
environment (collaborators and other persons who 
are not directly involved in these professional activities 
but are present in the immediate vicinity or are poten-
tially affected by these activities, e.g. road traffic par-
ticipants, big-box store clients, etc.). More restrictive 
health requirements should be viewed in the context 
of the risk of impaired consciousness, which may be an 
effect of severe hypoglycemia in diabetic patients. 
 11. Professions requiring a higher category health re-
quirements, and thus particularly requiring consider-
ation of the fact that a worker suffers from diabetes, 
are those related to public safety, including:
—  Professional driving (passenger transport drivers, 
truck drivers, train and underground drivers, taxi 
drivers);
—  Uniformed and emergency services: armed forces 
(army, navy, airforce), police, fire services, munici-
pal police, paramedic services, shipping, peniten-
tiary service, security guards;
—  Civil aviation: pilots and aviation engineers, flight 
deck personnel, air traffic controllers;
—  Other professions associated with particular 
dangers (working at a height, operating moving 
equipment, work at furnaces, in high ambient 
temperatures, incineration plants, ironworks, min-
ing, places with high traffic and other places with 
high risk of accidents).
 12. The second (lower) category of health requirements 
involves professional activities and workplaces with 
noxious factors and nuisances which may have 
a negative effect on the course of diabetes. In case 
of this lower category of health requirements, some 
professions and workplaces should be viewed as not 
recommended rather than absolutely contraindicat-
ed. Thus, addition attention should be paid to, and 
individual evaluation of health predispositions of 
a diabetic patient is required when making a decision 
regarding initiation or continuation of work at the 
following workplaces:
—  requiring increased physical effort, particularly of 
a static nature (e.g. miner, ironworker);
—  involving shift or night work;
—  involving exposure to carbon disulfide and pes-
ticides — 2-chlorophenoxyacetic acid derivatives 
(e.g. dichlorprop, mecoprop).
13. Diabetologist should serve as an advisor to young 
patients, in whom particular attention should be paid 
to the choice of profession. In these cases, the natural 
history of diabetes should be taken into consideration 
in addition to the current health status, as future 
health limitations may prevent not only vocational 
training but also, in the longer term, work itself.
14. Appendix 3 includes the Charter of Employer and Em-
ployee Rights and Duties, serving to increase patient 
responsibility and their position as employees on one 
hand, and on the other hand to counteract exclusion 
of the diabetic patients from the labor market.
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28. Diabetes care in penitentiary institutions
The penitentiary institution personnel should be in-
formed about the diagnosis of diabetes in a detained 
subject, and should be trained how to recognize hyper- 
and hypoglycemia and intervene in such situations as 
well as in other emergencies.
Subjects detained in penitentiary institutions (prisons, 
remand centers, juvenile detention centers) should be of-
fered access to the same level of medical care, including 
diabetes care, as in the general population.
29. Metabolic surgery
Metabolic surgery is an effective approach to man-
age obesity and concomitant conditions, in particular 
diabetes type 2. Multidisciplinary approach allows proper 
patient selection for metabolic surgery and choice of an 
appropriate surgical technique.
I. Patient selection for metabolic surgery
 1.  Metabolic surgery should be considered in all patients 
with diabetes type 2 and BMI > 35 kg/m2, especially 
if concomitant conditions are present, such as hyper-
tension and lipid disorders. In particular, metabolic 
surgery should be considered if drug treatment and 
lifestyle modifications do not allow adequate control 
of diabetes type 2 and obesity.
 2.  Referral for metabolic surgery is recommended in all 
patients with diabetes type 2 and BMI > 40 kg/m2.
 3.  Metabolic surgery is indicated in patients with diabe-
tes type 2 between 18 and 65 years of age. The upper 
age limit may be in some cases extended to 70 years 
if the individually assessed operative risk is lower than 
the potential benefits of surgery.
 4.  Patient selection for bariatric surgery should be per-
formed by a physician team that at least comprises 
a diabetologist and a surgeon with a large experience 
in metabolic surgery. It is also recommended that the 
multidisciplinary team involved in patient selection 
include a cardiologist, respiratory medicine special-
ist, psychologist or psychiatrist, anesthesiologist, and 
dietician.
II. Types of surgical procedures
 1.  It is recommended that patients be referred for mini-
mally invasive (laparoscopic) surgery.
 2.  Based on the available study results, patients with 
diabetes type 2 should be primarily referred for 
laparoscopic Roux-en-Y gastric bypass, laparoscopic 
sleeve gastrectomy, or laparoscopic biliopancreatic 
diversion.
 3.  The decision regarding the type of surgery should 
be made after a surgical consultation and individual 
consideration of the advantages and disadvantages 
of all surgical techniques listed above.
 4.  Before making the decision regarding metabolic sur-
gery, patients are recommended to become acquaint-
ed with the informed consent forms prepared by the 
Metabolic and Bariatric Surgery Section of the Polish 
Society of Surgeons.
III.  Complications of surgical treatment of diabetes 
type 2
Thirty-day mortality after metabolic surgery has been 
estimated at 0.1–0.3%, which is identical with the mor-
tality risk associated with laparoscopic cholecystectomy 
and may be categorized as low risk. The most common 
complications of metabolic surgery include suture line 
dehiscence (3.1%), surgical suite infection (2.3%), pulmo-
nary complications (2.3%), and gastrointestinal bleeding 
(1.7%).
IV.   Evaluating outcomes of surgical treatment of dia-
betes type 2
Diabetes type 2 resolves in 40–95% of patients, de-
pending on its duration, severity of obesity, and the type 
of surgical procedure.
The following approach to evaluating outcomes of 
surgical treatment of diabetes type 2 is recommended:
 1.  Resolution of diabetes and concomitant conditions
The disease may be considered resolved if after cessa-
tion of drug therapy:
—  HbA1c level is < 6.5%;
—  No hypoglycemia episodes occur in the patient;
—  Total cholesterol is < 4 mmol/L, and LDL choles-
terol is < 2 mmol/L;
—  Triglyceride level is < 2.2 mmol/L;
—  Blood pressure is < 140/90 mm Hg;
—  Body weight decreased by > 15% compared to 
baseline, i.e. preoperative body weight.
 2.  Clinical improvement
The disease may be considered improved following 
metabolic surgery if after reduction of drug treatment 
used before the surgery:
—  HbA1c level decreased by > 20%;
—  LDL cholesterol is < 100 mg/dL (< 2.6 mmol/L);
—  Blood pressure is < 140/90 mm Hg.
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V.   Recommendations following surgical treatment 
of diabetes type 2
 1.  Each patient after surgical treatment of diabetes 
should remain under the care of a diabetologist and 
a general surgeon.
 2.  Continued vitamin and mineral supplementation is 
needed to prevent their deficiencies.
VI. Pregnancy and metabolic surgery
 1.  Pregnancy is allowed (i.e., becomes not contraindi-
cated) 24 months after metabolic surgery.
 2.  Continued contact with the treating diabetologist is 
recommended before conception and throughout 
the pregnancy.
VII.  Contraindications to metabolic surgery in patients 
with diabetes type 2
 1.  No patient acceptance for surgical treatment of dia-
betes type 2.
 2.  Alcohol or drug dependence.
 3.  Mental conditions that cannot be controlled with 
drugs.
 4.  High cardiovascular risk associated with the proce-
dure.
30. Selected special situations in diabetic patients
I. Shift work
Shift work may be associated with both an increased 
risk of diabetes and its worse control. Hours of admini-
stration of oral hypoglycemic drugs or insulin may need 
to be modified.
 1. Intensive self-monitoring is required in patients wor-
king in shifts, particularly during working hours.
 2. Antidiabetic drugs associated with low risk of hypo-
glycemia and allowing greater dosing flexibility (both 
oral and injected, including insulin) are preferred in 
patients working in shifts.
 3. Patients treated with insulin, particularly those with 
diabetes type 1, should be able to modify insulin do-
ses during intensive insulin therapy.
II. Time zone change
Travel is not contraindicated in diabetes. Diabetic 
patients, particularly those with diabetes type 1 or 2 
treated with insulin, should prepare for the travel, taking 
into account such factors as travel duration, means of 
transportation, time zone change (the direction of travel 
should also be considered, i.e., eastbound or westbound) 
and the climate of the destination country. Particular 
problems may be posed by a rapid change of the time 
zone (airplane travel).
 1. Diabetic patients treated with insulin, particularly 
those with diabetes type 1, should be particularly 
alert during the period of adaptation to the new time 
zone (its duration in days equals the time difference 
in hours). Frequent blood glucose monitoring is ne-
cessary during this period.
 2. Patients treated with basal-bolus insulin therapy fly-
ing westbound (i.e., with prolongation of the day) 
should administer a previously used long-acting in-
sulin dose in the evening (new time). Possible hy-
perglycemia resulting from, e.g., meals consumed 
onboard, may be corrected with additional doses 
of a short-acting insulin/rapid-acting insulin analog. 
When travelling eastbound (i.e., with shortening of 
the day), it may be necessary to reduce the evening 
dose of long-acting insulin.
 3. Patients treated with personal insulin pump do not 
need to adjust the pump clock or modify insulin 
doses when the time zone change does not exceed 
2 hours. With a greater change of the time zone and 
a longer planned duration of stay in the new time 
zone, it is recommended to gradually shift basal in-
sulin infusion by 2 hours per day.
III. Glucocorticosteroid therapy
 Multiple drugs have a diabetogenic effect. One par-
ticularly important class of diabetogenic drugs are glu-
cocorticosteroids, both due to the magnitude of their 
diabetogenic effect and the frequency of their use. Glu-
cocorticosteroids mostly increase postprandial glycemia.
 1. Substitution doses of glucocorticosteroids (hydrocorti-
sone up to 20 mg/day) and inhaled glucocorticosteroids 
have no significant effect on carbohydrate metabolism.
 2. An increased risk of steroid-induced diabetes is af-
fected by the following factors: older age, obesity, 
impaired glucose tolerance, use of a high glucocorti-
costeroid dose, and simultaneous use of other diabe-
togenic medications.
 3. The preferred approach to the treatment of gluco-
corticosteroid-induced diabetes is intensive insulin 
therapy (or only administration of short-/rapid-acting 
insulin preparations before meals, if fasting and pre-
prandial glycemia is acceptable). No superiority of 
any insulin or insulin analog preparation over the 
others has been shown in steroid-induced diabetes.
 4. In patients with diabetes type 2 treated with oral 
hypoglycemic drugs who require temporary glucocor-
ticosteroid use, particularly in high doses, intensive 
insulin therapy is recommended.
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 5. In patients with diabetes type 2 receiving combined 
therapy with basal insulin (NPH insulin or a long-
-acting insulin analog), it is usually necessary to add 
short-acting insulin before meals.
 6. In diabetic patients treated with insulin, glucocorti-
costeroid use is associated with an increased insulin 
requirement, particularly during the day.
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Appendix 1
Recommendations regarding transition of patients with diabetes type 1 
from pediatric to adult diabetes care
Transition from pediatric to adult diabetes care is 
a special period in the life of a young patient with diabetes 
type 1. The basic principle of this transition should be to 
provide continuity of care without any significant gap 
between termination of pediatric care and initiation of 
adult care. To make the transition smooth, the following 
recommendations should be adhered to:
 1.  The moment of transition from pediatric to adult 
diabetes care should be set individually so as not to 
interfere with the therapeutic process. Depending on 
the emotional development, family and educational 
situation, and other factors, the optimal age for tran-
sition of care is 16–21 years.
 2.  The patient should be prepared for the transition by 
his/her pediatrician over the period of at least one 
year.
 3.  At the last visit in the pediatric diabetes clinic, which 
should take place at least 6 months before the tran-
sition, the patient should be referred to an adult 
diabetes clinic in a coordinated effort, which should 
include in particular:
— setting the date of first visit in the adult clinic by 
contacting in advance the clinic, its coordinator, or 
optimally the future treating physician;
— providing the patient with the pediatric care dis-
charge summary (see an attached template on 
page A57) which includes all relevant information 
regarding previous pediatric diabetic care;
— sending (by conventional or electronic mail) com-
plete information (including sensitive data regard-
ing, e.g., management problems, difficult family 
situation, etc.) to the adult clinic;
— informing the adult clinic (e.g., by e-mail) about 
termination of pediatric care and patient referral 
to the adult care.
 4.  Adult care should begin within 6 months after termi-
nation of the pediatric care.
 5.  It is recommended to create regional networks of 
cooperating pediatric and adult clinics that would 
develop the policy of continuous contact and patient 
transfer. This cooperation should include:
— preparing, a year in advance, lists of patients to 
be discharged from pediatric care and regularly 
transferring these lists to adult care.
— developing and accepting common medical record for-
mats, including pediatric care discharge summary;
— setting reliable communication channels, includ-
ing by electronic means.
 6.  If the transition of care involves a large number of 
patients, it is recommended to appoint, both in pe-
diatric and adult clinics, transition care coordinators 
who would manage the process of patient referral 
and care transition by scheduling visits, providing ef-
ficient flow of information, etc.
 7.  Devoting separate days for new arrivals of transitioned 
pediatric patients to adult clinics is not necessary but 
may be helpful in terms of organizing care, as these 
visits are much more time-consuming, particularly in 
patients treated with personal insulin pumps.
Developed by:   
Leszek Czupryniak, Przemysława Jarosz-Chrobot, Tomasz 
Klupa, Małgorzata Myśliwiec, Agnieszka Szadkowska, 
Bogna Wierusz-Wysocka, and Bogumił Wolnik
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1.	Patient	data*
Name and surname
Age      PESEL
Address:               City/town                   Postal code
Street   House/apartment number  
Pediatric care discharge summary
2. Duration of diabetes  Years
3. Acidosis at the disease onset: Yes     No  
4. Family history of diabetes: Yes     No  
5. Antibody presence/titer: ICA    IA-2A    GADA    IAA    Not investigated  
6. Peptide C level at the diagnosis: Fasting     ng/mL     Following stimulation     ng/mL       
    Not investigated   
7. Duration of remission: No remission    Remission     Months
8. Treatment – conventional insulin therapy (mixed insulins)
    — Duration  Years 
    — Basal-bolus treatment  
    • Fixed doses   Years
    • Intensive insulin therapy (pen)   Years
    • Intensive insulin therapy (pump)   Years
9. Comments regarding current therapy:
10. Number of hospitalizations due to diabetes since the diagnosis  
11. Reasons for hospitalization (state how many times): Acidosis    Significant metabolic disturbances  
        Labile diabetes  Severe hypoglycemia  
12. Episodes of severe hypoglycemia (state how many times)
13. Retinopathy: No     Yes     Severity  
14. Nephropathy: No     Yes     Severity  
15. Neuropathy: Peripheral: No    Yes   
      Autonomic: No     Yes     
16. Hypertension: No     Yes  /  mm Hg (current blood pressure values) 
      Treatment
17. Concomitant conditions
18. HbA1c level: Current  % Highest  %  Lowest  %
19. Physical activity: High    Participation in sport – specify which   Average    Low  
20. Cigarette smoking: No    Yes    Former smoking    
21. Alcohol: Yes    Frequency    Type of beverage    No    
22. Drugs: Yes  Frequency  Type  No  Occasionally  
23. Eating disorders: Anorexia     Bulimia     
24. Cooperation with the therapeutic team: Good    Poor    Variable
25. Family problems (rapport with parents): Good    Poor    Dysfunctional family    
26. School problems (ability to read, calculate)
27. Current schooling
      Physical job    Mental job     Does not attend any school     Does not work  
28. Additional remarks
                   Date                Treating physician
*Mark or fill in as appropriate.
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Appendix 2
Medical review and opining in drivers  
and workers with dysglycemia or diabetes
I.   Medical review and opining in drivers
 1. Medical review and opining in drivers with dysglyce-
mia or diabetes is regulated by the Appendix No. 6 
to the ordinance of the Minister of Health of July 17, 
2014 on medical examinations of driving license ap-
plicants and drivers (Journal of Laws 2014, item 949), 
entitled “Detailed conditions of the medical examina-
tions related to diabetes”.
 2. Based on the results of a medical examination, labora-
tory tests, and specialist consultations, a physician au-
thorized to medically certify drivers evaluates the risk 
for traffic safety and includes it in the medical opinion.
 3. According to the section 4 of the above mentioned Ap-
pendix to the ordinance of the Minister of Health, an 
opinion of a diabetes specialist or another physi-
cian engaged in treating diabetes, including a state-
ment of no other medical contraindications to driving 
related to diabetes, is obligatory in subjects:
— Applying for or holding a category C1, C1+E, C, 
C+E, D1, D1+E, D, D+E driving license, or a tram 
driving permit;
— Working as road transport drivers; 
— Working as drivers of emergency vehicles or ar-
mored transportation service vehicles;
— Driving license instructors and examiners.
 4. In case of diagnostic or medical opining uncertainties, 
a physician authorized to examine drivers may also 
order a diabetes consultation if:
— The patient has inadequate knowledge regarding 
diabetes, its, treatment, and possible complica-
tions;
— The patient does not adhere to medical recom-
mendations, in particular does not undertake blood 
glucose self-monitoring or does not take the pre-
scribed drug therapy;
— During documented blood glucose self-monitoring, 
more than 10% of flood glucose readings are below 
70 mg/dL;
— Metabolic control of the disease is poor (HbA1c level 
> 8%).
 5. To be considered by a physician authorized to medi-
cally certify drivers, a diabetes consultation for the 
purpose of medical review and opining in drivers 
must conclude with issuing a diabetes consulta-
tion card using a template provided in the Appendix 
No. 6 to the above mentioned ordinance of the Min-
ister of Health of July 17, 2014 (see page A67).
 6. The consulting diabetes specialist should also assess 
the patient’s ability to drive, using the respective space 
provided in the consultation card. Issues related to 
dysglycemia may have the following effect of the final 
medical opinion:
— No medical contraindications for driving:
• Without time constraints resulting from the 
investigations for dysglycemia,
• With time constraints resulting from the iden-
tified dysglycemia (consistent with a low or in-
creased risk for traffic safety);
— Medical contraindications for driving resulting from 
the identified dysglycemia:
• Relative, with indication of a 6-month period after 
which the patient may undergo a repeated medi-
cal assessment (consistent with a high risk for traf-
fic safety, and an option of reassessment),
• Absolute medical contraindications for driving 
(consistent with a high risk for traffic safety and 
no indication of the timing of a repeated medi-
cal assessment).
 7. Absolute contraindications for driving are as follows:
— In holders of a category AM, A1, A2, B1, B, B+E, or 
T driving license:
• Recurrent severe hypoglycemia (at least two epi-
sodes of severe hypoglycemia during the last 12 
months),
• Hypoglycemia unawareness;
— In holders of a category C1, C1+E, C, C+E, D1, 
D1+E, D, D+E driving license, or tram driving per-
mit, road transport drivers, emergency vehicle or 
armored transportation service drivers, and driving 
license instructors and examiners:
• Any history of severe hypoglycemia,
• Hypoglycemia unawareness,
• Other diabetes-related complications that pre-
clude driving.
Developed in collaboration with Andrzej Marcinkiewicz, MD, and Prof. Jolanta Walusiak-Skorupa from the  
Institute of Occupational Medicine in Łódź
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 8. The consultation card is handed by the diabetes 
specialist to the patient who presents it to the 
physician authorized to medically certify drivers. 
In case of a negative opinion regarding the ability to 
drive, it is recommended that the opining physician 
who referred a patient for a diabetes consultation is 
informed directly by the diabetes specialist.
 9. Diabetes consultation should be performed by 
a	physician	certified	in	diabetology	or	a	physician	
with	other	board	certification	who	manages	diabe-
tes in the consulted patient.
II.   Medical review and opining in workers
 1. Medical review and opining in workers and persons 
taking up work is regulated by the ordinance of the 
Minister of Health of May 30, 1996 on medical ex-
aminations of workers, the extent of preventive care 
for workers, and issuing medical opinions for the pur-
poses provided for in the Labour Code (Journal of Laws 
1996 No. 69, item 332 with amendments). 
 2. A physician performing a preventive examination may 
extend it with a diabetes consultation and additional 
tests if these are considered necessary for proper eval-
uation of the health status of a worker or a person 
taking up work. 
 3. To serve as a useful opinion allowing an objective 
decision to be made based on individual patient as-
sessment, diabetes consultation for the purpose of 
preventive examination should include key infor-
mation for the evaluation of health predispositions 
to	work	 in	 specific	 conditions	 and	 in	 accordance	
with	specific	requirements. For this purpose, it is rec-
ommended to use a diabetes consultation card based 
on the template provided (see page A68). 
 4. Based on the results of a medical examination, labo-
ratory tests, and specialist consultations, a physician 
authorized to perform preventive examinations and 
medically certify workers issues a medical opinion re-
garding the absence or presence of medical contra-
indications to perform or take up work at a specific 
workplace. 
 5. Absolute contraindications to perform work at 
workplaces associated with higher health require-
ments include: 
— Recurrent severe hypoglycemia or even a single 
previous episode of medically unexplained severe 
hypoglycemia (a fall in blood glucose level leading 
to impaired consciousness and the need for medical 
intervention); 
— Hypoglycemia unawareness without prospects for 
an improvement, resulting from a chronic diabetes 
complication of vegetative neuropathy which im-
pairs patient’s ability to detect an increasing sever-
ity of hypoglycemia, and thus is not associated with 
an appropriate patient response to decreased blood 
glucose levels; 
— Advanced eye complications, mostly diabetic reti-
nopathy or cataract with vision impairment; 
— Other advanced chronic diabetes complications; 
— An opinion of a diabetologist or a treating primary 
care physician which states a high risk of hypogly-
cemia and/or unawareness of hypoglycemia pro-
dromes. 
 6. Relative contraindications to perform work at 
workplaces associated with higher health require-
ments exist in conditions with a potential to im-
prove, including: 
— Lack of metabolic control of the disease (HbA1c  ≥ 8%); 
— Lacking or low blood glucose self-management 
ability; 
— Inadequate patient knowledge regarding diabetes, 
hypoglycemia, and the approaches to prevent hypo-
glycemia; 
— Non-compliance to physician recommendations. 
7. In such cases, reassessment should be scheduled 
within 1–3 months.
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 Diabetes consultation card for examining  
 driving license applicants and drivers
 (Appendix No. 6 to the ordinance of the Minister of Health  
 of July 17, 2014 on medical examinations of driving license  
 applicants and drivers — Journal of Laws 2014, item 949)
Patient data
Name and surname
 
PESEL      Personal identity card details and   
      number in non-PESEL holders
Adress:             City/town                 Postal code
 
Street             House/apartment number
  Driving license applicant  Driver   
Diabetes:    Date          Type  Treating  
     of diagnosis    physician:
Entity performing     Diabetes clinic  
medical activities
Patient knowledge regarding the disease,   Extensive      Satisfactory            Not satisfactory    
its treatment, and complications:
Blood glucose self-management ability:  High      Acceptable             Low
Hypoglycemia awareness, ability to prevent:   Good       Not satisfactory  
and counteract hypoglycemia
Occurrence of hypoglycemia prodromes:    Yes      No
Risk of hypoglycemia:    Low      Acceptable                        High
       Presence of chronic diabetes complications   No chronic diabetes complications
      Eye              Nervous system                 Cardiovascular system
Comments regarding other diabetes complications:
.........................................................................................................................................................................................................
.........................................................................................................................................................................................................
Assessment of the ability to drive:
.........................................................................................................................................................................................................
.........................................................................................................................................................................................................
.........................................................................................................................................................................................................
Other remarks:
.........................................................................................................................................................................................................
.........................................................................................................................................................................................................
      Date      Signature and stamp of the diabetes specialist   
                      or another physician engaged in treating diabetes
Stamp of the healthcare unit or physician’s practice
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Workplace 
Noxious factors   
and nuisances
Diabetes:    Date          Type  Treating      Primary care            Diabetes clinic   
     of diagnosis    physician:
Patient knowledge regarding the disease,   Extensive      Satisfactory            Not satisfactory    
its treatment, and complications:
Blood glucose self-management ability:  High      Acceptable             Low
Hypoglycemia awareness, ability to prevent:   Good       Not satisfactory  
and counteract hypoglycemia
Occurrence of hypoglycemia prodromes:    Yes      No
Risk of hypoglycemia:    Low      Acceptable                        High
       Presence of chronic diabetes complications   No chronic diabetes complications
      Eye              Nervous system                 Cardiovascular system
Comments regarding other diabetes complications:
.........................................................................................................................................................................................................
.........................................................................................................................................................................................................
Other remarks:
.........................................................................................................................................................................................................
.........................................................................................................................................................................................................  
...............................................................................................................................................................................................................  
...............................................................................................................................................................................................................
      Date      Signature and stamp of the diabetes specialist   
                      or another physician engaged in treating diabetes
Diabetes consultation card for preventive examinations 
— documentation of diabetes control by the treating physician for 
the purpose of evaluation of patient’s health predispositions to pro-
fessional activity(developed by A. Marcinkiewicz and D. Szosland)
Patient data
Name and surname
 
PESEL      Personal identity card details and   
      number in non-PESEL holders
Adress:             City/town                 Postal code
 
Street             House/apartment number
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Appendix 3
Charter of Employer and Employee Rights and Duties
Diabetes is a chronic metabolic disease that affects an 
increasing number of patients. It has been estimated that 
the number of subjects with diabetes in Poland is about 
2.6 million people, and the disease has been identified and 
treated in 60% of them. The current scope of this problem 
and an increasing incidence of both diabetes type 1 and 
type 2 have very significant medical and socioeconomic 
consequences, and issues related to the prevention and 
effective treatment of diabetes and its complications are 
beyond the responsibility of the medical community and 
patients themselves.
According to the World Bank estimates, the economic 
burden of diabetes is second only to that of ischemic heart 
disease. This economic toll results not only from the costs 
of diagnosing and treating diabetes but also from the 
costs of premature termination of professional activity, 
including inability to work and related social benefits, as 
well as unemployment which is a particular problem in 
diabetic subjects.
Due to the fact that:
• unemployment rates among diabetic subjects are 
more than twice increased compared to the healthy 
population, and the resulting worse economic status 
may hinder appropriate diabetes control;
• the place of work is an important link in the pro-
cess of preventing civilization disorders;
and also due to our belief that:
• drugs currently used in the treatment of dia-
betes, along with increasing patient awareness 
regarding self-management, lead to a longer 
and more effective preservation of a good heal-
th condition and the ability to remain professio-
nally active;
• the sole fact of having diabetes does not automa-
tically make the employee inferior;
Building on numerous European initiatives target-
ed at the prevention, early detection, and appropriate 
treatment of diabetes, and improvement of the qual-
ity of life of diabetic patients, including the European 
Parliament resolution of March 13, 2012 on addressing 
the diabetes epidemic in the European Union and the 
Copenhagen roadmap developed during the European 
Diabetes Leadership Forum on April 25-26, 2012;
On the eve of the 2012 World Diabetes Day, the 
signatories of the present document, representing the 
medical community, diabetes patient community, and 
the employers’ community, postulate to write down 
the rights and duties of diabetic patients and their 
potential employers to increase patient responsibility 
and their position as employees on one hand, and on 
the other hand to counteract exclusion of the diabetic 
patients from the labor market.
Rights and duties of an employee suffering 
from diabetes
1. Each diabetic patient should be aware of the fact 
that effective diabetes control must take place both 
at home and at work.
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2. At work, an employee suffering from diabetes 
should conform to the same principles of diabe-
tes control as at home, i.e. periodic blood glucose 
monitoring, taking medications as prescribed by 
a physician, and adhering to the recommended meal 
timing and diet.
3. An employee suffering from diabetes should inform 
the employer about the disease and if possible, in-
dividually adjust the nature and timing of the work 
to allow disease control.
4. Diabetic patients should be aware of the contrain-
dications to engage in some professions (e.g., pi-
lot, public transport driver, working at height, work 
requiring extremely strenuous exercise) and should 
inform their employers if their professional respon-
sibilities entail such activities.
5. An employee suffering from diabetes should inform 
his/her closest collaborators about the disease so as 
they are able to provide appropriate help in case of 
an episode of hyper- or hypoglycemia, and main-
tain continuity of work.
Rights and duties of an employer
1. Each employer should be aware that diabetes does 
not disqualify subjects with this disease from un-
dertaking professional activities, and any employee 
discrimination due to incident or prevalent diabetes 
On behalf of the signatories
Prof. Leszek Czupryniak
President of Diabetes Poland
Warsaw, November 13, 2012
is unacceptable. Acquirement of the basic knowl-
edge about the disease by the employer is the key 
to understand the situation of a diabetic patient.
2. Carrying out employer’s duties, including the ob-
ligation to create safe and hygienic work environ-
ment, requires that the employer has the right to 
and should know which of his/her employees suffer 
from diabetes.
3. The employer should allow the employee suffering 
from diabetes to conform to the principles of con-
trolling the disease at work and motivate him/her to 
a responsible behavior that guarantees the safety of 
the patient him-/herself and his/her collaborators.
4. If possible, the employer should provide the em-
ployee suffering from diabetes with a workplace 
that allows optimal disease control (e.g., option to 
discontinue shift work, short breaks for additional 
meals).
5. If possible, the employer should allow transfer of 
an employee with newly diagnosed diabetes to an-
other/equivalent workplace if continuing work at 
the previous workplace might be associated with 
work safety hazards or would make controlling the 
disease difficult for the employee.
6. If possible, the employer should promote the 
healthy lifestyle at work by encouraging employees 
to engage in physical activity, adhere to a balanced 
nutrition, and undergo preventive examinations.
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Appendix 4
Recommendations of the Polish Endocrine Society  
and Diabetes Poland  
on screening for thyroid dysfunction  
in diabetes type 1 and 2
Diabetes type 1
1.  During each patient visit to a diabetes specialist, it is 
necessary to perform clinical examination targeted at 
thyroid disease. If thyroid dysfunction is suspected, 
thyroid-stimulating hormone (TSH) level should be 
measured.
2.  It is recommended to determine TSH level and thyroid 
peroxidase autoantibody (TPOAb) titer in all patients 
with newly diagnosed diabetes type 1 and in patients 
with established diabetes type 1 in whom thyroid 
function was not evaluated previously.
3.   In patients with anti-TPO antibody titer above the re-
ference range and TSH level ≥ 2 mIU/L, free thyroxine 
(fT4) should be measured and TSH level measurement 
should be repeated annually.
4.   In patients with anti-TPO antibody titer within the refe-
rence range and TSH level ≥ 2 mIU/L, TSH level should 
be measured every 2 years.
5.  In patients with TPOAb titer within the reference range 
and TSH level < 2.0 mIU/L, TSH level should be deter-
mined every 5 years.
6.  In patients with a positive family history of hypothy-
roidism due to chronic autoimmune thyroiditis, TSH 
level should be determined annually.
7.  TSH level should be determined in diabetic patients 
with uncontrolled lipid parameters.
8.  TSH level and TPOAb titer should be determined in 
any patient planning pregnancy (particularly with an 
adverse obstetric history).
9.  TSH level and TPOAb titer should be determined in all 
patients at 4–8 weeks of gestation (initial obstetric 
visit).
10. In all patients with a history of Graves disease, TSH 
level and thyrotropin receptor antibody (TRAb) titer 
should be determined at 4-8 weeks of gestation (initial 
obstetric visit). In addition, TRAb titer should reevalu-
ated at the end of the second trimester (before 22 
weeks of gestation).
Diabetes type 2
1.  During each patient visit to a diabetes specialist, it is 
necessary to perform clinical examination targeted at 
thyroid disease. If thyroid examination is abnormal, 
TSH level should be measured.
2.  It is recommended to determine TSH level in all pa-
tients with newly diagnosed diabetes type 2 and in 
patients with established diabetes type 2 in whom 
thyroid function was not evaluated previously.
3.  TPOAb titer should be determined in patients with TSH 
level ≥ 2.0 mIU/L.
4.  If TPOAb titer is above the reference range, the dia-
betes type should be verified, primarily by measuring 
anti-glutamic acid decarboxylase (anti-GAD) autoanti-
bodies.
5.  In patients with TPOAb titer above the reference range 
and TSH level ≥ 2.0 mIU/L, fT4 level should be mea-
sured, and TSH level should be determined annually.
6.  In patients with TPOAb titer within the reference range 
and TSH level ≥ 2.0 mIU/L, and TSH level should be 
determined every 2 years.
7.  In patients with TPOAb titer within the reference range 
and TSH level <2.0 mIU/L, TSH level should be deter-
mined every 5 years.
8.  TSH level should be determined in diabetic patients 
with uncontrolled lipid parameters.
9.  TSH level should be determined in any patient plan-
ning pregnancy.
10. TSH level and TPOAb titer should be determined in all 
patients at 4–8 weeks of gestation (initial obstetric 
visit).
11. In all patients with a history of Graves disease, TSH 
level and thyrotropin receptor antibody (TRAb) titer 
should be determined at 4-8 weeks of gestation (initial 
obstetric visit). In addition, TRAb titer should reevalu-
ated at the end of the second trimester (before 22 
weeks of gestation).
Source: Sowiński J, Czupryniak L, Milewicz A, Hu-
balewska-Dydejczyk A, Szelachowska M, Ruchała M, 
Lewiński A, Górska M, Siewko K, Wender-Ożegowska 
E, Zozulińska-Ziółkiewicz D, Junik R, Sawicka N, Gutaj P. 
Recommendations of the Polish Endocrine Society and Diabe-
tes Poland for the diagnosis and management of thyroid 
dysfunction in diabetes type 1 and 2
www.dk.viamedica.plA72
Clinical Diabetology 2017, Vol. 6, Suppl. A
Appendix 5
Position of the Polish Society of Obesity Research and Diabetes Poland  
on the use of low-calorie sweeteners
An increasing prevalence of overweight and obesity 
along with their complications, primarily diabetes type 2 
and cardiovascular disease, is one of the major challenges 
of modern medicine. Obesity has been considered a 21st 
century epidemic by the World Health Organization. The 
epidemic of obesity is caused by lifestyle changes such 
as lack of physical activity and excessive consumption 
of highly processed high-energy-dense foods, leading to 
a positive energy balance.
Effective prevention and treatment of overweight and 
obesity together with their complications requires perma-
nent lifestyle changes which are difficult due to numer-
ous intrinsic and extrinsic factors that tend to decrease 
the motivation of a person forced to stop consuming 
favorite foods. A reduction of the energy density of the 
available foods by changing their production technol-
ogy and composition is an important component of 
prevention efforts at the societal level. However, intro-
duction of such changes requires consumer acceptance 
regarding the choice of low-calorie products, which in 
turn requires preservation of an attractive taste by the 
food industry. In humans, sweet taste preferences develop 
already in childhood, as human milk contains lactose and 
has a mildly sweet taste. To satisfy consumer preference 
for sweet taste and at the same time reduce the calorie 
content of foods and beverages, low-calorie sweeteners 
are used by the food industry.
Low-calorie sweeteners are substances with a sweet 
taste and the energy content of zero to few calories. As 
their sweet taste is very intensive, they may be added to 
foods in very low quantities. Currently, sweeteners are 
used in the production of non-alcoholic beverages, sweets, 
frozen desserts, yoghurts and puddings, as well as many 
medications.
A natural low-calorie sweetener, stevia, may be used 
for baking and cooking, as it is resistant to temperatures 
up to 200°C.
Based on safety studies and positive opinions of the 
European Food Safety Authority and the Panel on Food 
Additives and Nutrient Sources Added to Food, eleven low- 
-calorie sweeteners are approved for use in the European 
Union: acesulfame K (E950), aspartame (E951), aspartame-
acesulfame salt (E962), cyclamate (E952), neohesperidine 
dihydrochalcone (DC) (E959), saccharin (E954), sucra-
lose (E955), thaumatin (E957), neotame (E961), eryth-
ritol (E968), and steviol glycosides (E960). According to 
the Regulation (EC) No. 1333/2008 on food additives, 
food products containing these substances should be la-
belled accordingly. In addition, the Regulation (EC) No. 
1333/2008 specifies the maximum content of specific low- 
-calorie sweeteners for different food product categories.
During the process of approving low-calorie sweeten-
ers, the acceptable daily intake (ADI) in mg/kg body weight 
per day is also determined, defined as the amount of the 
substance which may be safely taken daily on a long-term 
basis (throughout life) without any harmful effects on the 
health. ADI values for specific low-calorie sweeteners are 
shown in Table 1.
The remaining approved substances are very rarely 
used by the food industry and therefore respective ADI 
values have not been determined.
European studies indicate that the intake of all low- 
-calorie sweeteners is lower then their ADI.
Regarding reports of a purportedly increased risk 
of some neoplasms in experimental animals given sac-
charine, aspartame, and cyclamate, it should be em-
phasized that the results of recent human studies did 
not	confirm	these	suggestions.
Based on these data, the Polish Society of Obesity 
Research	 and	Diabetes	 Poland	 confirm	 the	 safety	 of	
Table	1.	Acceptable	daily	intake	(ADI)	of	specific	low-calorie	sweeteners
Substance Code ADI [mg/kg body weight/day]
Acesulfame K E950 0–15
Aspartame E951 0–40
Cyclamate E952 0–7
Saccharin E954 0–5
Sucralose E955 0–15
Neotame E961 0–2
Steviol glycosides E960 0–4
www.dk.viamedica.pl A73
2017 Guidelines on the management of diabetic patients
low-calorie sweetener use in food products and rec-
ommend substituting these substances for saccharose 
by overweight and obese subjects, particularly if dys-
glycemia (impaired fasting glucose, impaired glucose 
tolerance, or diabetes type 2) is also present.
Of note, a beneficial effect of low-calorie sweeteners 
on body weight in children and adolescents has been re-
cently confirmed in randomized studies published in the 
New England Journal of Medicine.
A separate issue is the use of low-calorie sweeteners 
during pregnancy. While saccharine crosses the placenta 
and should not be used during pregnancy due to its un-
clear effects on the fetus, other low-calorie sweeteners are 
allowed during pregnancy.
The Polish Society of Obesity Research and the Diabe-
tes Poland would like to draw attention of patients and 
physicians to the need to evaluate the energy value of 
the products in which low-calorie sweeteners have been 
substituted for sugar and which are marketed as safe 
for diabetic patients due to the fact that they have no 
significant effect on postprandial glucose and insulin 
levels. Despite this modification, some of these products 
may still be characterized by a high energy value due 
to their fat content and may contribute to an increase 
in body weight, thus worsening blood glucose control. 
The best way to make sure that a product in which low-ca- 
lorie sweeteners were substituted for sugar is actually 
a low-calorie product is to compare its energy value 
with the energy value of a similar sugar-containing 
product, and to note its fat content.
The Polish Society of Obesity Research and Dia-
betes Poland emphasize that consumption of food 
products with a reduced energy value due to their 
low-calorie sweetener content may not be the sole 
lifestyle change introduced. This is only an approach 
to satisfy the need for sweet taste without consuming 
mono- and disaccharides, which may facilitate adher-
ence to the nutritional recommendations and blood 
glucose control. However, another factor that plays 
an important role in the development of overweight 
and obesity along with their complications is fat intake 
which also needs to be reduced. It should also be em-
phasized that decreasing food energy value alone leads 
to a reduction of not only adipose tissue mass but also 
muscle mass. Thus, regular physical activity is required 
to prevent muscle mass loss (30 minutes of aerobic 
exercises at least 5 times a week, e.g. walking, cycling, 
swimming).
Magdalena Olszanecka-Glinianowicz
President of the Polish Society of Obesity Research
Leszek Czupryniak
President of the Diabetes Poland
A74
Clinical Diabetology 2017, Vol. 6, Suppl. A
I.   Requirements for centers providing the service re-
imbursed by the National Health Fund which inclu-
des patient education regarding continuous sub-
cutaneous insulin infusion, providing the patient 
with an insulin pump, and offering consultation 
services.
 1.  Initial training should include technical aspects of 
insulin pump handling and discussion of the fol-
lowing issues: principles of basal rate programming 
and modification, temporary changes of a basal rate, 
use of simple, extended, and complex boluses, use of 
bolus calculator function, principles of setting up an 
infusion set (including choice of the puncture site). If 
a pump with continuous glucose monitoring option is 
needed, the training should also include the principles 
of system functioning, its calibration, interpretation 
of messages and alerts, and placing a sensor. Training 
should continue until the patient is well versed with 
practical aspects of personal insulin pump use.
 2.  Particular attention should be paid to the following 
issues: what to do in case of an insulin pump failure 
– return to treatment using insulin pens, management 
of initial symptoms of ketoacidosis, principles of wit-
hholding insulin infusion in special situations (e.g., 
following sport activities).
 3.  Organizational requirements: minimum duration of 
training 9 hours, split into minimum 3 sessions. Trai-
ning should be performed in groups not larger than 
6–8 persons. Parents or legal guardians should parti-
cipate in training of children and adolescents. Patients 
should be offered an opportunity to practice with 
infusion sets using phantoms. It is also recommended 
to practice subcutaneous insertion of an infusion set in 
the period before initiating treatment with continuous 
subcutaneous insulin infusion.
The center providing reimbursement bears respon-
sibility for appropriate training and initial insulin pump 
settings. These settings should also include initiation of 
the bolus calculator function.
In case of insulin pumps with continuous glucose mo-
nitoring option, alarm presetting is recommended, taking 
into account the current level of metabolic control and 
patient capabilities. Patient knowledge should be verified 
using a diabetes knowledge test developed by the Polish 
Appendix 6
Recommendations on personal insulin pump treatment reimbursed  
by the National Health Fund in diabetic children, adolescents,  
and young adults below 26 years of age
Developed in cooperation with Andrzej Gawrecki, MD
Diabetes Society (PTD).
Regular use of the software for insulin pump and glu-
cose meter data retrieval is required.
II.   Indications for reimbursement by the National He-
alth Fund of personal insulin pump purchase in 
diabetic children, adolescents and adults below 26 
years of age.
1. Early morning hyperglycemia in patients with diabetes 
type 1 following the end of a remission period*.
2. Frequent hypoglycemia episodes in patients with dia-
betes type 1 following the end of a remission period*:
—  Severe hypoglycemia episodes more frequently 
than once a year;
— Hypoglycemia £ 70 mg/dL without the need for 
help of another person ≥ 4 times a week;
—  Inability to achieve target hemoglobin A1c (HbA1c) 
level without frequent hypoglycemia episodes, i.e. 
≥ 4 times a week;
— Impaired awareness of typical hypoglycemia 
symptoms.
3. Persistently elevated HbA1c level > 6.5% but < 9.0% de-
spite treatment intensification in a patient who is well 
educated regarding the principles of intensive insulin 
therapy, cooperates with the diabetes treatment team, 
and adheres to blood glucose self-monitoring recom-
mendations (≥ 6 blood glucose measurements per day).
4. Subjects engaged in shift work, with irregular school or 
professional activity, or traveling frequently to other 
time zones, with HbA1c level < 9.0%.
5. Subjects engaged in competitive sport or undertaking re-
gular intensive physical activity, with HbA1c level < 9.0%.
6. Children below 10 years of age with diabetes type 1.
7. Continuation of previous treatment with personal insu-
lin pump if no contraindications exist (e.g., personal 
insulin pump failure)**.
In selected cases, the decision on insulin pump 
purchase reimbursement may be made by the 
voivodship diabetes consultant after reviewing the 
patient’s medical records and obtaining an opinion 
of the treating diabetes specialist (including such 
issues as concomitant conditions and corticosteroid 
treatment). 
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III.  Contraindications for reimbursement of personal 
insulin pump purchase in diabetic children, adole-
scents and adults below 26 years of age.
 1. HbA1c level ≥ 9.0% — an average value during the last 
year.
 2.  Mental disorders — psychosis and severe depression, 
also those affecting the parents of children below 10 
years of age.
 3.  Intellectual disorders, also those affecting the parents 
of children below 10 years of age, which prevent un-
derstanding the principles of intensive insulin therapy 
and personal insulin pump handling.
 4.  Eating disorders.
 5.  Addiction, also those affecting the parents of children 
below 10 years of age.
 6.  Unexplained missing visits to a diabetes clinic (atten-
dance at only one visit or no visits during a year).
 7.  Non-adherence to or non-comprehension of the prin-
ciples of intensive insulin therapy (no adequate blood 
glucose self-monitoring, failure to test for ketone bo-
dies in cases of prolonged hyperglycemia, imprecise 
estimation of prandial insulin doses).
 8.  More than one episode of ketoacidosis during a year.
 9.  Severe, rapidly progressing proliferative retinopathy 
before or during laser therapy.
10.  No disease acceptance despite full diabetes care and 
psychologic support (a written opinion of psychologist 
experienced in diabetes care).
11.  Poor personal hygiene.
12.  Regular exposure to strong magnetic fields.
IV.  Contraindications to continuation of treatment 
with a personal insulin pump and equipment reim-
bursement***	in	diabetic	children,	adolescents	and	
adults below 26 years of age
 1.  No improvement or worse metabolic control of dia-
betes after one year of treatment using a personal 
insulin pump.
 2.  More than one episode of diabetic ketoacidosis during 
a year.
 3.  More episodes of severe hypoglycemia compared to 
during treatment with insulin pen devices.
 4.  Non-adherence to the principles of intensive insulin 
therapy (< 70% of correct answers in the test to 
check diabetes knowledge developed by Diabetes 
Poland).
 5.  Severe skin reactions at the site of infusion set implan-
tation despite an attempt to change the type of the 
infusion set.
 6.  Irregular exchanges of infusion sets (less frequently 
than every 3 days).
 7.  Unexplained missing visits to a diabetes clinic (atten-
dance at only one visit or no visits during a year).
 8.  Persisting HbA1c level ≥ 9.0% (two subsequent readings).
A diabetes specialist applies for reimbursement of 
personal insulin pump purchase for the patient to a cen-
ter providing this service.
The patient presenting to a center offering the reimbursed 
service submits:
 • A reimbursement application filled in by the treating 
diabetes specialist;
 • A glucose meter report covering the last 4 weeks — at 
least 6 measurements per day are required (glucose 
meter may be read in the clinic);
 • In some patients with inadequate metabolic control, 
providing additional information regarding the amount 
of consumed carbohydrate equivalents and insulin doses 
is indicated before considering CSII therapy. This infor-
mation may be provided using a self-control diary or 
appropriate application (electronic data).
*Remission criteria according to Schölin A et al. Diabet Med. 2011; 28: 156: normoglycemia in blood glucose profile with insulin requirement < 0.3 unit/kg 
body weight per day and peptide C level > 0.5 ng/mL.
**Patients previously treated with a personal insulin pump which failed or reached its end of service life date undergo the same selection process as new 
patients. Previous treatment with a personal insulin pump does not automatically lead to reimbursement of a new device.
***An order for personal insulin pump supplies may be issued only by a physician working in a diabetes clinic or a hospital unit.
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Appendix 1
Requirements for the computer software for pump memory data retrieval:
—  Current basal rates (all available at single data retrieval, with data on graphs or in tables, exact doses and time with 
accuracy of insulin administration at a given basal rate);
—  Used correction factors with time periods set in bolus calculators;
—  History of boluses (precise information on bolus type, dose, and timing of administration);
—  History of infusion set primings;
—  Daily graphs showing:
• Basal rate on a given day,
• Temporary changes of the basal rate,
• Timing of pump switching on and off,
• All administered boluses, with information on their types and timing of administration, included that of extended 
boluses,
• Blood glucose readings transmitted from a compatible glucose meter;
—  History of alarms;
—  Free provision of the software to the patients upon request;
—  Data retrieval software should also be able to retrieve data from a glucose meter and integrate both types of infor-
mation.
Appendix 2
Required information available on the webpage:
—  Telephone number of a 24-hour helpline providing information to insulin pump users in case of technical problems 
associated with pump use;
—  Telephone numbers of local representatives with their working hours;
—  Data on pump supplies (types of needles, syringes, batteries along with their pricing etc.).
RECOMMENDED ADDITIONAL OPTIONS
 1.  Integration with a glucose meter: wireless communication with at least one type of a glucose meter, possibility to 
activate and deactivate the option of data transmission from the glucose meter to the pump, possibility of recording 
blood glucose values with the bolus calculator function switched on or off.
 2.  Insulin pumps that have a dedicated glucose meter should be distributed together with that glucose meter.
 3.  Alarms to remind about boluses or blood glucose measurements at times set by the user.
 4.  Price of infusion sets not exceeding the monthly reimbursement limit in persons <26 years of age and 30% of that limit 
in persons > 26 years of age.
For a separate package for children/adults with recurrent hypoglycemia: personal insulin pump and a CGM 
system:
—  At least 1 transmitter for 5/10 pumps and 2 sensors for each transmitter.
ADDITIONAL NOTES
The ordering party may determine additional parameters in accordance with the needs of specific patient 
groups. In addition, the offer should include accessories necessary for therapy initiation and educations: ser-
ters, various types of infusion sets, insulin containers, batteries for the pump, protective cases.
When evaluating a pump during a tender, the pump price should count for 60%, and additional functions for 40% 
of the overall assessment.
